Design and synthesis of novel PPAR agonists for the treatment of the metabolic syndrome and diabetes type II by Bhurruth, Anju Hina Yushma & Bhurruth, Anju Hina Yushma
Design and Synthesis of Novel 
PPAR Agonists for the Treatment of 
the Metabolic Syndrome and 
Diabetes Type II 
Anju Hina Yushma Bhurruth 
Imperial College London 
A thesis submitted for the degree of 
Doctor of Philosophy of the University of London 
and for the 
Diploma of Membership of Imperial College London 
October 2007 
Declaration 
I hereby declare that the work described here is entirely my own, except where 
specifically acknowledged in the text. 
Anju Hina Yushma Bhurruth 
October 2007 
2 
Acknowledgements 
First of all, I am grateful to Professor Andrew Miller for allowing me to start this new 
medicinal chemistry project in his group. Thank you for trusting me and for allowing 
me to be independent in my research project. I wish to acknowledge both the GTC 
and IC-VEC Ltd. for funding my project and for my bursary. 
Next, I want to thank Dr Michael Jorgensen for his constant support and guidance. 
Thank you so much for being present and for all your help, you've always been there 
when I needed you. I have learnt a lot from you, thank you also for being a good 
friend, for taking us out for drinks and for some delicious barbecues! 
I wish to express my gratitude towards Professors Christopher Schofield and William 
Motherwell for accepting to be my examiners. 
I am really grateful to Therese Rost, Dr Jon Skorve and Professor Rolf Berge from 
the Institute of Medicine, Bergen and Thia Medica AS, Norway, for the biology 
testing. Big thanks to Therese for looking after me in Bergen and for replying to all my 
questions and emails about the assay! 
I would like to extend some special acknowledgements towards the following people 
for technical support: John Barton for HRMS, Stephen Boyer for elemental analysis, 
Andrew White for x-ray crystallography, Pete Haycock for NOE experiments, the 
chemistry research technicians without whom the lab would not function and 
chemistry stores. 
This manuscript would not be what it is today if it had not been for Mike J, Steve, 
Mike W and last but not least, Damien, whom I wish to acknowledge for proof 
reading. Your efforts and comments were strongly appreciated. Thank you for your 
time! 
Some especial acknowledgements to Professor Charles Rees and Dr Alan Spivey for 
a few stimulating discussions about heterocyclic chemistry. Thank you for your 
kindness and for being attentive to my questions. Thank you to Alan for having 
accepted to be my examiner for my transfer and for keeping in touch since then. 
The past three years would not have been the same without the support of the group, 
in particular Nic, Arnaud, Mike W, Wayne, Jim, Ben, Top, Mike K, Nazila and Steve. I 
3 
will always remember Nic who showed me around the lab and who made me 
discover the Thai Square! Arnaud, thanks for looking after me during my first week 
and for being so friendly and caring. Mike W, thank you so much for your help with 
POs and computer problems... But most important of all, thanks for being a good 
friend and for your constant support. Wayne, you've taught me so much, can I really 
write everything here? We've had so many good times in the lab and I really enjoyed 
sharing my cooking recipes with you while doing columns! Thanks for being such a 
good friend and for your jokes, I miss them so much! Nazila, we started our PhDs on 
the same day and we've been through so much together, hang on, you are nearly 
there too! Top, you're joking! Steve, you were only here for a couple of months, but it 
was really good fun and "chilaxing". Thanks for being so supportive and so helpful, I 
really appreciate it. Peerada, Soumia and Taka, you've only been here over the past 
year, but it's been great to have you around. Thank you for being so caring and 
supportive. 
Of course, I have some very especial thoughts for my family, in particular my 
grandmother and my parents. I've been away from you for so long, it is always hard 
for me not to have you around. My heart is always with you and I would not be here if 
it was not for your love and support. Yash, it's been great to have you in London for 
the past year, sorry for not being present all the time, but you know how much I love 
you. Nana, I miss you too, I am sure you would have been happy to share this 
moment with me. Warm thanks to Damien's family for being caring and thoughtful. 
Finally, Damien, what would I be today had it not been for you? No words could ever 
be enough to say how much I am grateful for having you by my side everyday and 
how happy I am with you. I can't wait for us to start a new chapter of our life in 
Paris... 
4 
To Mum and Dad 
This thesis is for you. 
May your love and support guide me throughout my life, as always. 
"All religions, arts and sciences are branches of the same tree. All these aspirations 
are directed toward ennobling man's life, lifting it from the sphere of mere physical 
existence and leading the individual towards freedom." 
- Albert Einstein 
5 
Abstract 
The metabolic syndrome and diabetes type II are a major public health problem 
throughout the world. One current class of pharmaceutical drugs is the 
thiazolidinediones, which are peroxisome proliferator-activated receptor (PPAR)7 
agonists. However, their side-effects include weight gain, oedema and liver toxicity. 
New effective drugs with an improved side-effect profile are needed. 
PPARs are transcription factors which control gene expression by binding to specific 
response elements within promoters; there are three subtypes a, y,  and 8. Both 
PPARa and PPAR8 have been shown to be regulators of fatty acid /3-oxidation while 
PPART has been implicated with adipocyte differentiation, triglyceride synthesis and 
fatty acid p-oxidation. Given the critical physiological role of all the PPAR subtypes as 
lipid sensors and regulators of lipid metabolism, the aim of this project is to 
synthesise novel dual or pan PPAR agonists as potential drugs for the treatment of 
metabolic disorders. 
The first part of the project consisted of the synthesis of lipid analogues in 
collaboration with Thia Medica AS, Norway. Tetradecylthioacetic acid (TTA), a fatty 
acid analogue, developed by Thia Medica AS, was found to be a potent pan PPAR 
agonist. Although it is presently in clinical studies, TTA suffers from poor absorption, 
distribution, metabolism and elimination (ADME) characteristics. I have synthesised 
new lipid analogues of TTA as natural prodrugs in order to improve its bioavailability. 
Preliminary biological analyses with the new TTA analogues have shown better 
results in vitro and in vivo than with TTA. 
Furthermore, two novel heterocyclic scaffolds were designed as dual PPARa/7 
agonists using proprietary software by an in silico screening company, Prosarix Ltd, 
UK. The synthesis of the indole scaffold was carried out using a variety of solution 
phase chemistry. The in vitro PPAR activation assay showed potency on both 
PPARa and PPARS. The synthesis of the second heterocyclic scaffold consisting of a 
pyrrolidine core, is also described. 
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Yushma BHURRUTH 	 Chapter 1 
1.1 Peroxisome proliferator-activated receptors 
1.1.1 Introduction to PPARs 
Peroxisome Proliferator-Activated Receptors (PPARs) are nuclear receptors 
belonging to the superfamily of ligand-activated transcription factors;1'" these include 
receptors for steroids, thyroid hormone, vitamin A- and D- derived hormones and 
some fatty acids.4 Structurally, they share common features. Nuclear receptors 
generally bind to DNA in the form of dimers, either homodimers or more often 
heterodimers with the receptor for 9-cis retinoic acid known as retinoid receptor X 
(RXR).5 
The first cloning of PPARs occurred while searching for the molecular target of 
hepatic peroxisome proliferating agents in rodents in 1990.6 Peroxisome proliferators, 
located in the nuclei of cells, influence both the size and number of peroxisomes. 
Peroxisomes, so-called because of the production of hydrogen peroxide during fatty 
acid oxidation, contain various fatty acid oxidising enzymes such as acyl-CoA 
oxidase.7 These organelles, bounded by a single membrane, perform various 
metabolic functions within the cell, including peroxide-derived respiration, beta 
oxidation of fatty acids and cholesterol metabolism. Peroxisomes are also an 
intracellular site of expression for the hydrogen peroxide-destroying enzyme, 
catalase. 
PPARs are transcription factors which play an important role during cell signalling 
when activated by specific ligands. There are three subtypes of PPARs: PPARa, 
PPARy and PPARS. Over the past years, it has been shown that PPARs play a 
critical physiological role as lipid sensors and regulators of lipid metabolism and they 
have become an important target for the treatment of diabetes type II amongst other 
diseases in the pharmaceutical industry!" Therefore, a significant understanding of 
the molecular and physiological characteristics of these receptors has become 
extremely important. Lately, many research teams have published research 
connecting PPARs to various medical indications such as inflammation, cancer and 
diseases of the central nervous system.10,11,12,7,13,14,15  
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1.1.2 Receptor structure 
The protein domain structure of PPARs is similar to that of the other members of the 
nuclear receptor gene family. This consists of (Figure 1):16 
a variable N-terminal domain which contains the ligand-independent 
transcriptional activation function 1 domain (AF-1); 
- a highly conserved central DNA binding domain (DBD), which consists of two 
zinc fingers. One is responsible for specific recognition of the response 
element and the other is involved in dimerisation; 
- a hinge region, D; 
- a ligand binding domain (LBD) in the COOH- terminal region which has been 
shown by crystallographic studies to be composed of 13 a-helices and a small 
4-stranded /3-sheet (Figure 2). Within the LBD lies a C-terminal region which 
contains the ligand-dependent transcriptional activation function 2 domain 
(AF-2). The ligand binding pocket of PPARs, which is much larger than that of 
other nuclear receptors with a volume of —1300A3, is occupied to 30-40% by 
its ligand.17'18.19 The LBD contains some conserved amino acids, critical for 
the role of the receptor in signal transduction. However, there is also a 
significant sequence variation in the residues that line the ligand-binding 
pocket, which is reflected in the pharmacological distinction of each receptor 
subtype.2° The main differences between the three PPAR LBDs are that the 
PPARS pocket is narrower in the region adjacent to the AF-2 helix, and that a 
histidine is present at the carboxylate-binding residue in PPARy rather than a 
tyrosine as in PPARa. Most PPAR agonists share a common binding mode, in 
which the acidic head group of the ligand forms a network of hydrogen bonds 
within the ligand binding pocket. These interactions stabilise a charge clamp 
between AF-2 and a highly conserved lysine residue on the surface of the 
receptor, through which coactivator proteins are recruited to the receptor.21 In 
addition to ligand binding, the LBD is essential for receptor dimerisation; and 
- a domain of unknown function F. 
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Figure 1 Structure of PPAR receptors 
Representation of the PPARs' x-ray crystal structures: PPARa (red worm), PPARy (yellow worm) and PPAR(5(green 
worm). Each PPAR is complexed to a high-affinity ligand (not shown). PPARa and PPARy are complexed to the co- 
activator which consists of LXXLL (X = any amino acid) peptides represented by purple worms. The white surface 
represents the solvent-accessible ligand binding domain. 
Figure 2 The x-ray crystal structures of PPARa, PPARy and PPARS 19 
1.1.3 Mechanism of action of PPARs 
PPARs control gene expression by binding to specific peroxisome proliferator 
response elements (PPREs) within promoters.22 This results in activation or 
suppression of a target gene. PPREs have been identified in the regulatory regions of 
a large number of genes, including many that encode proteins involved in lipid 
metabolism and energy balance, such as aP2,23 phosphoenylpyruvate carboxykinase 
(PEPCK),24 acyl-CoA synthetase, and lipoprotein lipase (LPL).2526 All natural PPREs 
consist of a direct repeat of two more-or-less conserved AGGTCA hexamers 
separated by a single base pair. 
Dimerisation is essential for the function of PPARs. Before binding to the PPREs 
occurs, PPARs form heterodimers with the 9-cis retinoic acid receptor (RXR) which 
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stimulate gene activity.27 Upon binding an agonist, the conformation of a PPAR is 
altered and stabilised such that a binding cleft is created and recruitment of 
transcriptional coactivators occurs. This results in gene transcription. A 'mouse trap' 
model of receptor activation has been proposed, in which the AF-2 helix closes on 
the ligand-binding site in response to the ligand and establishes a transcriptionally 
active form of the receptor.28,29 
The coactivators or cofactor proteins mediate the ability of nuclear receptors to 
initiate or suppress the transcription process.3° These coactivators interact with 
nuclear receptors in an agonist-independent manner through a conserved LXXLL 
motif where X is any amino acid. One example of a coactivator of PPARy is 3-
phosphoinositide-dependent protein kinase-1 (PDK1).31 The coactivators allow 
further contacts to be made with the PPRE, which lead to an enhancement of 
transcription of the target gene. Ligand binding leads to preferential recruitment of 
chromatin-decondensing coactivator complexes and favours dismissal of the 
corepressor complex. 
In the absence of a PPAR ligand. the heterodimer forms high-affinity complexes with 
nuclear co-repressor proteins. This prevents transcription activation by sequestration 
of the receptor complex from the promoter. Dissociation of corepressors occurs as a 
consequence of a ligand-induced conformational change, and the activated 
heterodimer can subsequently bind to the PPRE. 
Figure 3 shows the binding of the heterodimer PPAR-RXR to the corresponding 
PPRE.32 
25 
Cis-RA 0 A 
Co-repressors 
L 
Co-activators 
	 T 	 
------- Nucleus 
Absence 
of ligand PPAR 
ligand 
PPRE 
gene 
5' 3' 
AGGTCA A AGGTCA 
TCCAGT TCCAGT 
Yushma BHURRUTH 
	
Chapter 1 
Cytoplasm 
Upon activation by a ligand, the PPAR receptor forms a heterodimer with the RXR receptor, itself complexed to its 
ligand cis-retinoic acid (cis-RA). Coactivator proteins are recruited and the PPAR-RXR heterodimer binds to the 
PPRE in the promoter region of specific genes. In the absence of a PPAR ligand, the heterodimer binds to 
corepressor proteins which block transcription. 
Figure 3 Binding of PPAR-RXR heterodimer to PPRE 
1.1.4 The three PPAR isoforms PPARa, PPARy and PPARS 
Three PPAR isoforms, encoded by different genes, have been identified so far: 
PPARa, PPARyand PPAR6.33 Their main characteristics are summarised in Table 1. 
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PPARa PPARy PPA RS 
Primary sites of 
expression 
Liver, heart, kidney Adipose tissue 
Adipose tissue, skin, 
brain 
Cellular 
processes 
involved 
Fatty acid /3-oxidation, 
lipoprotein synthesis, 
amino acid catabolism 
Adipocyte 
differentiation, 
triglyceride synthesis 
Fatty acid )3- 
oxidation 
Physiological 
function 
Coordination of metabolic 
response to fasting 
Differentiation of 
adipocytes, fatty acid 
trapping 
Currently being 
investigated 
Key target genes 
Carnitine palmitoyl 
transferase I, HMG CoA 
synthase 2, 
apoA-I 
Fatty acid-binding 
protein 4, lipoprotein 
lipase, adiponectin 
Acyl-CoA oxidase 
Metabolic 
phenotype of 
knockout mice 
Fasting hypoglycaemia, 
hypothermia, 
hypoketonaemia and 
hepatic steatosis 
-I- Lethal, -1+ more 
insulin sensitive at 
baseline 
Reduced base-line 
adiposity; increased 
obesity on high-fat 
feeding 
Table 1 The three PPAR isoforms34 
PPARa 
PPARa is abundantly expressed in catabolically active tissues such as the liver, 
heart, kidneys, skeletal muscle and brown fat. It is also present in monocytic, 
vascular endothelial and vascular smooth muscle cells. 
It is important in the oxidation of fatty acids in various organelles such as 
mitochondria, peroxisomes and microsomes. It stimulates the uptake of fatty acids 
and has an important role in lipoprotein metabolism. PPARa has mainly been studied 
in the liver where it is highly expressed. In the liver, PPARa's target genes participate 
in many aspects of lipid catabolism, such as intracellular binding by fatty acid binding 
proteins, activation by the acyl-CoA synthase, as well as catabolism by p-oxidation in 
the peroxisomes and mitochondria, and co-oxidation in the microsomes.35 Research 
conducted by Wahli et al. has shown that PPARa regulates amino acid metabolism 
by regulating genes that lead to a decrease in amino acid degradation.3613 Oxidation 
of amino acids contributes largely to energy production in several organs, including 
the liver and gut. Finally, recent evidence also implicates PPARa in the regulation of 
carbohydrate metabolism and in gluconeogenesis. Indeed, PPARa activation has 
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been shown to cause triglyceride lowering.37 As a result, PPARa acts as a global 
regulator of energy metabolism in the liver thereby coordinating the rates of utilisation 
of the different energy substrates with respect to food availability. 
A new interesting development is that PPARa has been demonstrated to play an 
important role in the control of inflammation.38,39  The influence of PPARa inhibitors on 
plasma cytokine levels as well as on acute-phase proteins was subsequently 
determined by Staels et .9/.49'11 Furthermore, it has been reported that PPARa 
agonists reduce microglial activation."2 
PPAR7 
PPARywas first cloned in 1992.43 It exists in two different isoforms: 71 is expressed in 
a broad range of metabolically active tissues such as skeletal muscle, kidneys and 
intestine and predominantly in adipose tissue while 22 is exclusively expressed in 
adipose tissue. PPARy2 has 30 additional amino acids, encoded by a single exon, at 
its N-terminus.44'45 This confers a 5- to 6-fold increase in transcription-stimulating 
activity of the ligand-independent activating function AF-1.23 
PPARy has a significant role in fat cell differentiation as it controls the expression of 
genes encoding proteins involved in lipid metabolism and fat-derived hormones. It 
promotes fatty acid storage in fat depots through fatty acid transport protein' and 
regulates the expression of adipocyte-secreted hormones that impact on glucose 
homeostasis.46'47'48 PPARy enhances lipoprotein triglyceride hydrolysis by endothelial 
lipoprotein lipase (LPL) and modifies triglycerides synthesis starting with free fatty 
acids' esterification by acyl CoA synthase. PPARy stimulates the binding and 
activation of fatty acids in the cytosol, events that are required for the synthesis of 
triglycerides. Direct target genes of PPARy in lipid metabolism include those that 
code for the adipocyte fatty acid binding protein aP2,23 lipoprotein lipase,25 acyl-CoA 
synthase35 and fatty acid transport protein.49 Moreover, PPARy regulates genes that 
control cellular energy homeostasis.' 
One particular gene to which PPARy has been associated is tumour necrosis factor 
TNF-a, a pro-inflammatory cytokine that is expressed by adipocytes. This gene has 
been linked to insulin resistance and diminished insulin signal transduction. The 
inhibitory effects of PPARy on TNF-a action have led research groups to investigate 
the anti-inflammatory properties of PPARy agonists. PPARy agonists were shown to 
28 
Yushma BHURRUTH 	 Chapter 1 
inhibit TNF-a and interleukins expression in monocytes,5° as well as inducible nitric 
oxide synthase (iNOS) in macrophages.51'52 Some recent studies have shown anti-
proliferative and pre-apoptotic effects of PPARy ligands on T cells, whose activation 
has been shown to be crucial for the initiation and clinical progression of 
demyelinating diseases, such as multiple sclerosis.53'54 Moreover, activation of 
PPARy exerts anti-inflammatory effects in brain glial cells and neurons, with 
decreased expression of pro-inflammatory cytokines.5558 
PPARS 
PPARy, also first cloned in 1992, is expressed in a wide range of tissues and cells, 
with relatively higher levels of expression in the brain, adipose and skin.43 
It is involved in the regulation of lipid metabolism and cholesterol efflux.13'57 There are 
three major types of blood cholesterol combined with protein: high-density lipoprotein 
(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and very low-density 
lipoprotein (VLDL) cholesterol. Each type contains a specific combination of 
cholesterol, protein and triglyceride and a blood fat. HDL, known as "good" 
cholesterol, consists of very small amounts of cholesterol and triglycerides, coated 
with an especial protein that distinguishes it from VLDL. It plays a protective role 
through the process of reverse cholesterol transport whereby cholesterol is removed 
from peripheral cells, including macrophage-derived foam cells, and returned to the 
liver.58 Small dense LDL particles are prone to accumulate in the arterial wall leading 
to the formation of atherosclerotic cholesterol-laden foam cells.59 VLDL cholesterol 
contains the highest amount of triglyceride and is considered as "bad" cholesterol, 
like LDL. Elevated levels of VLDL lead to an increased risk of coronary artery 
disease. Agents that raise the levels of HDL through reverse cholesterol transport 
could be potential drugs for the prevention of atherosclerotic cardiovascular disease. 
Oliver et al. reported that the potent and selective PPAR8 agonist GW-501516 
(Figure 3) could induce a substantial increase in HDL-cholesterol levels as well as a 
reduction in triglyceride levels in obese Rhesus monkeys.6°  
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CF3 
GW-501516 
Figure 4 Structure of GW-501516, a selective PPARoagonist 
PPARS has been suggested to mediate lipid accumulation in macrophages in 
response to VLDL61  and has been shown to limit inflammation.62 Some studies in 
mice suggest a role for PPARS in myelination, neuronal signalling and lipid 
metabolism in the central nervous system.63,64,65,66 
So far, PPARS remains the most elusive out of the three subtypes. It is quite difficult 
to foresee a specific function for this receptor due to its broad tissue distribution. 
1.1.5 Natural and synthetic ligands 
PPARa can be activated by a wide variety of saturated and unsaturated fatty acids, 
including palmitic acid 2, oleic acid 3, linoleic acid 4 and arachidonic acid 5 (Figure 
5).67 
Figure 5 PPARa fatty acid ligands 
Its synthetic ligands include amphiphatic carboxylic acids and fibrates (Figure 6). 
Fibrates are a type of cholesterol-reducing drug that lower the levels of fats (lipids) in 
the blood, including cholesterol and triglycerides." 
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Figure 6 PPARafibrate ligands 
Various fatty acids such as linoleic acid, linolenic acid 9, arachidonic acid and 
eicosapentaenoic acid 10 and eicosanoid derivates bind and activate PPARy at 
micromolar concentrations (Figure 7).69 An example of synthetic ligands are the 
thiazolidinediones which are a class of anti-diabetic agents.7°  
H3CH2C 	 (CH2)7COOH 	HOOC(H2C)3 
alpha-linolenic acid 	 eicosapentanoic acid 
9 
	 10 
Figure 7 PPARy natural ligands 
Some non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin 11, 
fenoprofen 12 and ibuprofen 13 are dual PPARa/yagonists (Figure 8).71'9 
CH2COOH 
CI 
13 
Figure 8 PPARa/ydual agonists 
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PPARS also binds to saturated and unsaturated fatty acids such as dihomo-8-
linolenic acid, eicosapentaenoic acid, arachidonic acid, palmitic acid and to some 
eicosanoids.72 Some synthetic ligands include L165.041 14 (Figure 9) and GW-
501516 1 (Figure 4).73'6° 
Figure 9 Structure of L165.041, a PPARgagonist 
Given the implication of PPARs in lipid and carbohydrate metabolism, PPAR agonists 
could be potential drugs for the treatment of the metabolic syndrome and diabetes 
type II. On the other hand, PPAR agonists could also be used in the treatment of 
neurological inflammatory diseases such as Alzheimer's disease and multiple 
sclerosis since they have anti-proliferative and anti-inflammatory effects in brain glial 
cells, T-cells and macrophages.14.74'78 
1.2 The Metabolic syndrome and diabetes type ll 
1.2.1 The metabolic syndrome 
The metabolic syndrome is a complex set of disorders that significantly increases the 
risk of heart disease (Figure 10).78'77 The clustering of the atherosclerotic risk factors 
that identify the metabolic syndrome was first recognised in 1983.78 It was in 1988 
that Professor Gerald Reaven named this cluster of disorders syndrome X, now 
termed as the metabolic syndrome by the World Health Organisation.79'8°  
Dysglycaemia 	 Obesity 
Coronary heart 
disease 
Dyslipidaemia 
Blood pressure elevation 	 Insulin resistance 
Figure 10 The metabolic syndrome 
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Features of the metabolic syndrome81 
Blood pressure elevation is an arterial disease which consists of chronic high blood 
pressure. It is a risk factor for stroke and heart disease. Coronary heart disease 
occurs as a result of fat build up in the coronary arteries. Dysglycaemia is 
characterised by an abnormal blood glucose level, without defining a threshold 
whereas dyslipidaemia is characterised by high levels of triglycerides and low levels 
of high-density lipoproteins in the blood, leading to build-up of plaque in blood vessel 
walls. Excess abdominal obesity is associated with a potentially atherogenic 
lipoprotein profile: increased proportion of small, dense LDL particles and reduced 
HDL cholesterol concentrations.82 
Insulin sensitivity is defined as the ability of insulin to lower blood glucose 
concentrations. This reduction is achieved by stimulating glucose uptake of muscle 
and adipose tissues (the two primary tissues affected by insulin resistance) and by 
suppressing hepatic glucose production. A central cause of the metabolic syndrome 
is insulin resistance, a condition of low insulin sensitivity.83 Therefore, patients 
suffering from the metabolic syndrome have an excess of glucose in the blood. Due 
to the compensatory hyperinsulinemia caused by insulin resistance, the sympathetic 
nervous system is stimulated, causing vasoconstriction, increased cardiac input and 
renal absorption of sodium, which in turn leads to elevated blood pressure. Several 
components of the metabolic syndrome have proatherogenic properties and have an 
adverse effect on the vascular endothelium, producing endothelial dysfunction. The 
latter is an underlying and inciting process that propagates athesclerosis because of 
the following combined effects of elevated concentration of free fatty acid circulation 
and all the effects associated with insulin resistance. 
The metabolic syndrome affects a quarter of the world's adults. People with the 
metabolic syndrome are twice as likely to die, and three times as likely to have a 
heart attack or stroke compared to people without the syndrome.84 Moreover, people 
with the metabolic syndrome have a five fold greater risk of developing diabetes type 
11. 85 The number of deaths from the metabolic syndrome and diabetes is a lot higher 
than from AIDS, yet the problem is being recognised very slowly.86  
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1.2.2 Insulin and its role in glucose level 
Insulin is a polypeptide hormone (6000 Daltons), of empirical formula 
C257H383N65077S6, that consists of two peptide chains A (21 amino acids) and B (30 
amino acids), linked together by two disulfide bonds. There is an additional disulfide 
in the A chain. Figure 11 shows the structure of this protein. 
Red: carbon, green: oxygen; blue: nitrogen; pink: sulfur. The blue/purple ribbons denote the skeleton [-N-C-C-b in the 
protein's amino acid sequence H+NH-CHR-CO-b-OH. 
Figure 11 Insulin's structure87 
Insulin is produced in the islets of Langerhans in the pancreas (Figure 12). In healthy 
individuals, the /3-cells secrete small amounts of insulin every 8-10 minutes in a 
continuous pulsatile, oscillating pattern, without regard to food. The human pancreas 
has two main functions: the production of pancreatic endocrine hormones (e.g. insulin 
and glucagon), which help regulate many aspects of our metabolism, and the 
production of pancreatic digestive enzymes. 
Insulin facilitates the entry of glucose into muscle, adipose tissue and several other 
tissues. It also stimulates the liver to store glucose in the form of glycogen. In lipid 
metabolism, insulin promotes the synthesis of fatty acids in the liver and inhibits the 
breakdown of fat in adipose tissue. In each case, insulin triggers these effects by 
binding to the insulin receptor. 
Glucagon secretion is stimulated by low, and inhibited by high, concentrations of 
glucose and fatty acids in blood plasma. Glucagon counterbalances the action of 
insulin, increasing the levels of blood glucose and stimulating protein breakdown in 
muscle. It is a major catabolic hormone which acts primarily on the liver to stimulate 
glycogenolysis (glycogen breakdown) and gluconeogenesis (synthesis of glucose 
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from non-carbohydrate sources), and inhibiting glycogenesis (glycogen synthesis) 
and glycolysis, increasing hepatic glucose output and ketone body formation. 
Figure 12 The pancreas and its /3-cells88 
The liver is a central fat metabolising organ that controls the levels of fats, amino 
acids and glucose in the blood. It coordinates the synthesis of free fatty acids, 
esterification of triacylglycerols (TAG) and their packaging into dense VLDL after 
ingestion of food. Upon absorption of excess cholesterol from tissues, HDL in the 
circulation becomes mature and returns to the liver. The liver recognises its 
lipoprotein coat and directs the cholesterol to the liver pool. HDL is capable of 
helping us maintain a good balance of cholesterol delivery and removal. The liver and 
the pancreas together regulate blood glucose levels in the body (Figure 13).89 
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Figure 13 Regulation of blood glucose levels by the pancreas and the liver89 
1.2.3 Diabetes type II and its treatment 
Diabetes is a major health problem throughout the world. It is defined as a group of 
metabolic diseases, characterised by hyperglycaemia (elevation of blood glucose), 
arising as a consequence of a relative or absolute deficiency of insulin secretion, 
resistance to insulin action or both.9° Hyperglycaemia desensitises fi-cells and 
reduces insulin secretion. Also, it directly increases insulin resistance in muscle 
tissue. The causes of diabetes can be genetic but obesity, a sedentary lifestyle and 
aging also contribute to its onset. The number of people with diabetes is expected to 
increase alarmingly in the coming decades. According to the World Health 
Organisation, the global figure of people with diabetes is expected to rise from the 
current figure of 194 million to 366 million in 2030. There are two types of diabetes: 
Type I 
It is characterised by a deficiency of insulin, usually due to an immune-mediated 
destruction of the insulin secreting cells, the pancreatic islet ,B-cells. Therefore, there 
is the need to replace insulin. 
Type II 
It is the more common type as it accounts for about 90-95% of all the cases of 
diabetes. Diabetes type II is usually due to resistance to insulin action by 
inappropriate response of the target tissues and to pancreatic /3-cell impairment.91  
Both factors have important roles to play in the onset of diabetes type 11.92.93 Diabetes 
type II arises in people who have a defect in insulin secretory capacity; thus 
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pancreatic insulin secretion fails to compensate for the insulin resistance. Patients 
suffering from diabetes type II have an increased pancreatic a-cell mass, an 
exaggerated response of glucagon to amino acids and an impaired suppression of 
glucagons secretion by hyperglycaemia. An important morphological feature is the 
amyloid deposition in the islets of the pancreas. 
Diabetes type II is a serious chronic disease that leads to the development of 
microvascular complications including retinopathy, neuropathy and nephropathy as 
well as macrovascular complications such as heart disease, stroke and peripheral 
vascular disease. As a consequence of these complications, it is a major cause of 
blindness, kidney failure, amputation and cardiovascular disease. It is estimated that 
200 million people will suffer from diabetes type II worldwide by the year 2010.94 
About 47 million people are affected by the metabolic syndrome in the United States 
today and more and more people in the developing world are being diagnosed 
everyday. Given these important figures, there is an urgent need to cure this 
metabolic disease. 
Current treatments for diabetes type II act by different mechanisms to attempt to 
regulate blood glucose levels and prevent the complications that affect the kidneys, 
cardiovascular, ophthalmic and nervous systems. Table 2 below shows the different 
classes of drugs and their targets while Table 3 compares the advantages and 
disadvantages of the different classes of drugs. These treatments include:95'96'97 
• diet and exercise; 
• insulin; 
Insulin was the first used therapeutic agent, however it is not suitable for most type II 
patients as it is not effective if the degree of insulin resistance is high. 
• 1st generation drug therapies: sulfonylureas (SUs), meglitinides, biguanides, 
acarbose and thiazolidinediones (TZDs). 
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Drug class 
Molecular 
target 
Site of 
action 
FDA administration 
status 
Effect 
Insulin 
Insulin 
receptor 
Liver, 
muscle, fat 
Combination with SUs, 
metformin, TZDs 
Suppresses glucose 
production 
Augments glucose 
utilisation 
(SUs) 
Sulfonylureas Pancreatic 
SU 
receptor/K
+ 
ATP channel 
/3-cell 
Monotherapy 
or combination with 
insulin, metformin, 
acarbose, TZDs 
Stimulate the 
pancreas to produce 
more insulin 
Meglitinides K+ channel 
Pancreatic 
,8-cell 
Monotherapy 
or combination with 
metformin, TZDs 
Stimulate the 
pancreas to produce 
more insulin 
Biguanides- 
metformin 
Unknown 
Liver 
(muscle) 
Monotherapy 
or combination with 
insulin, SUs, TZDs 
Suppress glucose 
production by the 
liver 
Increase the 
responsiveness of 
tissues to insulin 
(not proven) 
Acarbose 
a- 
Glucosidase 
Intestine 
Monotherapy 
or combination with 
SUs 
a-Glucosidase 
inhibitor which 
interferes with gut 
glucose absorption 
Thiazolidine- 
diones (TZDs) 
and glitazones 
PPARy 
Fat, 
muscle, 
liver 
Monotherapy 
or combination with 
insulin (pioglitazone 
only), SUs, metformin 
New class of 
compounds that 
enhance insulin 
activity in peripheral 
tissues, such as 
liver, fat cells and 
skeletal muscle 
Table 2 Current therapeutic targets for diabetes type II 
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Drug Class Advantages Disadvantages 
Insulin Endogenous hormone 
Hypoglycaemia 
Weight gain 
Sulfonylureas 
Well established 
Improve fasting and postprandial glucose 
Decrease microvascular risk 
Convenient once-daily dosing 
Hypoglycaemia 
Weight gain 
Associated with increased 
cardiovascular complications 
Adverse drug-drug interactions 
Diminished effectiveness over time 
Meglitinides Quick onset and short duration of action 
Hypoglycaemia 
Weight gain 
Biguanides- 
metformin 
Well established 
Weight loss 
No hypoglycaemia 
Decrease micro- and macro-vascular risk 
Nonglycemic benefits (decreased lipid 
levels and hyperinsulinemia) 
Convenient once- or twice-daily dosing 
Gastrointestinal side-effects Lactic 
acidosis 
Contraindicated in > 50% of patients 
with type II diabetes including the 
elderly and those with kidney, liver 
and respiratory problems 
Acarbose 
Targets postprandial glycaemia 
No hypoglycaemia 
Nonsystemic 
Gastrointestinal disturbances 
More complex dosing schedule 
No long-term data 
Thiazolidine- 
diones and 
glitazones 
Decreased hepatic glucose output 
No hypoglycaemia 
Improve insulin sensitivity 
Nonglycemic effects (decreased 
triglycerides levels and hyperinsulinemia, 
increased fibrinolysis and improved 
endothelial function) 
Increase adiponectin levels 
Possible /3-cell preservation 
Convenient once- or twice-daily dosing 
Weight gain 
Oedema 
Anaemia 
Possible liver dysfunction 
Slow onset of action 
No long-term data 
May be associated with colon 
tumours 
Adverse drug-drug interactions 
Table 3 Advantages and disadvantages of the current therapeutic classes for diabetes type II 
The sulfonylureas (SUs) were introduced in the 1950's and are still in use today, due 
in part to the advent of combination therapy, a new approach which involves an 
enhanced treatment through the use of two or more drugs for complex diseases. The 
major side-effects of SUs include hypoglycaemia and lack of efficacy in 10-20% 
patients. A small amount of the SU market loss was to repaglinide 16 (Figure 13) 
which belongs to the meglitinide class of drugs. 
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Figure 14 Structures of glimepiride and repaglinide 
Introduced in the late 1950's, the biguanide, metformin 17 (Figure 14) has 
maintained its strong footing in the market and remains the only biguanide in clinical 
use. It is particularly appropriate for use in obese patients because it does not cause 
weight gain. Phenformin 18 (Figure 15) was removed from the market in 1977 due to 
fatalities caused by lactic acidosis.98'9910° 
In contrast, the a-glucosidase inhibitor, acarbose 19 (Figure 16) which was 
introduced in the early 1990's, has been commercially less successful. This is largely 
attributed to the drug's adverse side effect profile which includes gastrointestinal side 
effects and hypoglycaemia when used in combination therapy. 
H3C 
HO 
OH 
OH 
Figure 16 Acarbose 
40 
Rosiglitazone 
20 
Pioglitazone 
21 
„......, N........„ zz... „........N ......................„. 0  ...„...... N..s.....s....z._...„.... o 
Troglitazone 
22 
Yushma BHURRUTH 	 Chapter 1 
The major new medicines in the oral antihyperglycaemic market are the new 
thiazolidinediones, or glitazones which are selective PPARy agonists (Figure 17). 
Both rosiglitazone 20 (GlaxoSmith-Kline's Avandia) and pioglitazone 21 
(Takeda/Lilly's Actos) were marketed in 1999.10170 
Figure 17 Structures of thiazolidinediones 
Thiazolidinediones (TZDs) appear to be the only oral anti-diabetic drugs that 
normalise pro-insulin levels, suggesting a reduction in pancreatic workload and 
preservation of g-cell function.102,103 Rosiglitazone 20, the most commonly used TZD, 
decreases the fasting and postprandial glucose concentrations, C peptide, insulin and 
non-esterified fatty acids in patients with diabetes type 11.104 However, the hepatic 
toxicity effects seen with the earlier compound, troglitazone 22, have caused some 
doubts about the safety of this class of drugs. Indeed, this compound was removed 
from the market after three years by its manufacturer, Warner-Lambert, due to liver 
toxicity side-effects. The main side-effects encountered with the TZDs include 
oedema, hemodilution and weight gain.105,106 Recently, there has been some concern 
about the safety of rosiglitazone in patients suffering from heart failure.107,108 Current 
data suggests that only patients with severe cardiovascular problems have to be 
cautious when taking the drug.109 
A new drug called Avandaryl, which combines two other diabetes drugs, Avandia and 
Amaryl, has reached the market in February 2006. This drug, marketed by 
GlaxoSmithKline, is the first fixed-dose tablet combining these two different classes of 
diabetes medications. Specifically, Avandia (rosiglitazone 20) is a PPARy agonist 
while Amaryl (glimepiride 15) is a sulfonylurea that lowers blood glucose. 
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1.2.4 New therapeutic approaches 
Considering the adverse effects of these treatments shown in Table 3, newer 
approaches that preserve normal endocrine responses to food intake are needed. 
The understanding of biochemical pathways related to the development of diabetes 
and the metabolic syndrome has expanded and the following new therapeutic 
approaches are now being considered.""6 
1.2.4.1 Reducing excessive hepatic glucose production 
The liver has a critical role in regulating endogenous glucose production from de 
novo synthesis (gluconeogenesis) or the catabolism of glycogen."' There are several 
drug targets in the liver that can offer ways of reducing hepatic glucose production.96 
Glucagon is a hormone that contributes to hyperglycaemia through the induction of 
both gluconeogic and glycogenolytic pathways. The glucagon receptor is one target 
for the development of small-molecule antagonists. Enzymes that regulate rate-
controlling steps in the gluconeogenic and glycogenolytic pathways are other 
potential targets. Increasing the activity of pyruvate dehydrogenase (PDH) by 
inhibiting the PDH kinase is expected to decrease blood glucose by increasing the 
glucose oxidation in peripheral tissues and by decreasing the supply of the 
gluconeogenic precursors, lactate and alanine to the liver. The potential liabilities to 
this approach include hypoglycaemia, accumulation of hepatic triglycerides and 
increased plasma lactate levels. 
1.2.4.2 Enhancing glucose-stimulated insulin secretion 
Researchers have been able to reduce insulin secretion in a glucose-dependent way 
by targeting two peptide hormones: glucagon-like-peptide (GLP-1) and gastric 
inhibitory peptide (Gip).112,113  Administration of these two hormones can induce 
insulin secretion. GLP-1 stimulates the release of insulin from pancreatic /3-cells as 
long as blood glucose levels are high. One promising GLP-1 analogue, approved in 
2005, is Exenatide. However, both GLP-1 and GIP are subject to rapid amino-
terminal degradation by dipeptidylpeptidase IV (DPP4). DPP4 inhibitors can thus 
represent an indirect therapeutic approach to stabilising endogenous GLP-1.114 GLP-
1 analogues and DPP4 inhibitors have the potential to overcome the hypoglycaemia, 
weight gain and other failures associated with the sulfonylureas. DPP4 inhibitors are 
expected to compete with oral drugs such as sulfonylureas and metformin. They 
could be recommended for early stage or prediabetes to help manage 
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hyperglycaemia. Sitagliptin, commercialised by Merck, was put on the market in 
2006. LAF-237 23, vildagliptin, is in clinical trials at the moment and may be marketed 
by Novartis in 2007 (Figure 18). The main drawback to GLP-1 therapy is nausea due 
to delayed gastric emptying. One important risk with DPP4 is that it is not a one-
substrate enzyme and it clips off the end of many proteins that have an alanine or 
proline at the 2-position.115 
Figure 18 Structure of LAF-237 
Another target is cortisol, an important glucocorticoid. This primary stress hormone is 
secreted by the adrenal glands when blood levels of amino acids, carbohydrates or 
fats fall below normal, or when there is inflammation from infection, injury, allergens 
or toxins. It is essential for life and regulates and supports a variety of important 
cardiovascular, metabolic, immunologic, and homeostatic functions. One of the ways 
cortisol functions is by stimulating gluconeogenesis in the liver: the conversion of fat 
and protein into intermediate metabolites that are ultimately converted into glucose. 
However, elevated levels of cortisol can disrupt blood sugar regulation. 11/3-
hydroxysteroid dehydrogenase type 1 activates inactive cortisone 24 to cortisol 25 as 
illustrated in Scheme 1. Research into 11/3-HSD1 inhibitors is now being investigated 
to uncover novel therapeutic options for the metabolic syndrome.116.117 
OH 	 OH 
Cortisone 	 Cortisol 
24 25 
Scheme 1 Interconversion of cortisone and cortisol as catalysed by 11/3-HSD types 1 and 2 
Analogues of amylin, a /3-cell hormone, are also being investigated. Amylin plays a 
complementary role to insulin by regulating the rate of glucose in the circulation 
43 
Yushma BHURRUTH 	 Chapter 1 
during the postprandial period. Its levels are low in people suffering from both 
diabetes types. Pramlintide was the first amylin analogue approved in 2005.18  
1.2.4.3 Targeting the insulin signalling pathway 
Insulin resistance can be caused by multiple defects in signal transduction such as 
impaired activation of insulin receptor-tyrosine kinase. Molecular targets that can 
enhance insulin-mediated signal transduction are now being investigated. An 
alternative approach to targeting the insulin receptor is to inhibit enzymes responsible 
for deactivation of the receptor or downstream targets in the signalling pathway. 
Protein tyrosine phosphatase 1B (PTP-1B) is an intracellular enzyme specifically 
implicated in the negative regulation of insulin signalling.119 
1.2.4.4 Targeting obesity, lipid metabolism and lipotoxicity 
Approaches to attenuate appetite and/or enhance energy expenditure will benefit the 
prevention and treatment of diabetes type II. One example is adiponectin, a protein 
that has recently been shown to produce beneficial metabolic effects in mice, 
including the ability to reduce glucose, triglycerides and free fatty acids. Another 
potential hormone could be leptin which can improve insulin resistance. Thus mimetic 
compounds could be envisaged as new therapeutic approaches. 
1.2.4.5 Peroxisome proliferator-activated receptors (PPAR) a/y dual agonists 
PPARs are a very promising area of research as they present multiple targets.9612° 
Thiazolidinediones (TZDs) previously discussed are selective PPARy activators. 
Given the importance of controlling both glucose and lipid levels in diabetes type II, it 
would be interesting to develop ligands that bind and activate both PPARa and 
PPARy. The dual agonism should produce additive and hopefully synergistic 
results.121,105 One such dual agonist, GW 409544 25 (Figure 19), currently in clinical 
trials, has indeed been shown to induce lowered serum insulin, triglycerides and non-
high density lipoprotein cholesterol.19 "Pan-agonists" (molecules that activate the 
three PPAR subtypes) could even be better in the treatment of diabetes. As 
described earlier, all three PPAR subtypes have important roles in the regulation of 
lipid and glucose metabolism. Activation of the three isoforms could potentially lead to 
increased positive effects though the targeting of multiple genes in complicated 
diseases such as the metabolic syndrome and diabetes type II. Table 4 shows how 
much PPAR agonists have attracted researchers in drug discovery. All the major 
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pharmaceutical companies have at least one PPAR agonist in their pipeline. The 
challenge lies in finding the PPAR agonists leading to the optimal activation of 
PPARa, PPARy and PPARS such that they are potent compounds for treating 
metabolic diseases and they balance the possible toxicity seen with some of the 
selective PPARy agonists. 
Figure 19 Structure of GW 409544, a dual PPARody agonist 
Company Drug Development status 
Activity on 
PPARs 
Indication 
targeted 
Sanofi-Aventis AVE-0847 Phase 2a a/yagonist Diabetes type II 
AstraZeneca AZD 6610 Phase 2 a/yagonist 
Metabolic 
disorder 
Roche R1439 Phase 2 a/yagonist Diabetes type II 
Wyeth/Plexxikon PLX204 Phase 1 pan agonist 
Metabolic 
disorder 
Bristol-Myers 
Squibb Co 
Muraglitazar Late stage clinical trials a/yagonist 
Metabolic 
disorder 
Eli Lilly & Co LY-465608 Phase 2 pan agonist Diabetes type II 
GlaxoSmithKline GW-2433 Research tool a/gagonist Hyperlipidaemia 
GlaxoSmithKline GSK-677954 Phase 2 pan agonist 
Obesity, diabetes 
type II 
Novartis LBM-642 Phase 1 a/yagonist 
Obesity, lipid 
metabolism and 
diabetes type II 
Table 4 PPAR agonist candidates in pipelines of pharmaceutical companies 
45 
Normal Alzheimer's 
Yushma BHURRUTH 	 Chapter 1 
1.3 Neurological diseases 
1.3.1 Alzheimer's disease (AD) 
1.3.1.1 Etiology 
Alzheimer's disease is a progressive neurodegenerative disorder which leads to 
irreversible brain damage.14,122 During the course of the disease, "plaques" and 
"tangles" are developed in the brain and these lead to the death of brain cells (Figure 
20).12' The plaques are due to the accumulation of beta amyloid in the brain while the 
neurofibrillary tangles consist of mainly the tau protein. This results in shrinkage of 
the brain cortex and enlargement of the ventricles (Figure 21).124 
Figure 20 Amyloid plaques and neurofibrillary tangles in Alzheimer's disease (left)123 
46 
Brain Cross-Sections 
Normal Alzheimer's 
Sulcus 
Gyrus  
Ventricle 
Language 
Memory 
Yushma BHURRUTH 	 Chapter 1 
Figure 21 Difference between a normal brain (left) and a brain affected by AD (right)124 
Progressive mental deterioration in old age had been recognised and described 
throughout history. However, it was not until the early part of the 20th century that a 
collection of brain cell abnormalities were specifically identified by Dr. Alois 
Alzheimer, a German physician, in 1906. He studied the brain of a woman who had 
died after years of experiencing severe memory problems. confusion, and difficulty 
understanding questions. The autopsy revealed the presence of dense deposits 
outside and around the nerve cells (neuritic plaques). Inside the nerve cells, he noted 
the presence of twisted bands of fibres (neurofibrillary tangles). Today, this 
degenerative brain disorder bears his name. The observation of the plaques and 
tangles at autopsy is still required to obtain a definitive diagnosis of Alzheimer's 
disease. The duration of the disease varies between 3 to 20 years and eventual 
extensive neuronal loss leads to death. The symptoms of the disease are as follows: 
disturbances in memory, attention, orientation and language difficulties. While there 
are some common symptoms of Alzheimer's disease, it is important to remember 
that everyone is unique. No two cases of AD are likely to be the same. People 
always experience illness in their own individual way. 
Some factors that are believed to cause the disease are age, genetic inheritance, 
environmental factors, diet and the overall general health. However, no one single 
factor has been identified as a cause.125 According to the World Health Organisation, 
24 million people suffer from dementia worldwide.126 Dementia affects 1 in 20 people 
over the age of 65 and 1 in 5 over the age of 80. By 2040 the number will have risen 
to 81 million. Alzheimer's disease makes up 55% of all cases of dementia. 
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1.3.1.2 Treatment of Alzheimer's disease 
At present, there is no cure for AD. The first few drugs are all cholinesterase 
inhibitors which can slow down the progression of the disease by maintaining the 
levels of acetylcholine. In 1993, the FDA approved the first drug to treat Alzheimer's 
disease: Cognex (Tacrine) increases the amount of the neurotransmitter 
acetylcholine in the brain and can slow cognitive decline. A number of other 
acetylcholinesterase inhibitors followed: Aricept (1996), Exelon (2000) and Razadyne 
(2001). In 1997, studies indicated that vitamin E and a drug normally used in the 
treatment of Parkinson's disease, Eldepryl (Selegiline), were helpful in slowing 
mental deterioration in patients with moderate Alzheimer's disease; however, further 
studies are necessary to corroborate these findings. In 2003, the FDA approved the 
first drug to treat moderate-to-severe Alzheimer's disease. Namenda is an N-methyl-
D-aspartate (NMDA) receptor antagonist, and appears to protect the brain's nerve 
cells against excess amounts of glutamate, a messenger chemical released in large 
amounts by cells damaged by this devastating neurological disease. 
1.3.2 Multiple Sclerosis (MS) 
1.3.2.1 Etiology 
Multiple sclerosis is a chronic, autoimmune, inflammatory disease of the central 
nervous system (CNS).14127 During the course of this disease, the myelin sheath 
insulating nerve cells is destroyed as illustrated in Figure 22.128 The symptoms of the 
disease include visual difficulties, emotional disturbances, speech disorders, 
convulsions, paralysis, bladder disturbances and muscular weakness. 
The exact causes of MS are unknown. Some potential factors are thought to be 
autoimmunity, exposure to pathogens and genetics. The National Multiple Sclerosis 
Society estimates about 2.5 million people are affected worldwide, out of which 
85,000 live in the UK. Diagnosis is usually between 20 and 40 years of age - rarely 
under 12 or over 55. Three women have MS for every two men.129 
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Figure 22 Difference between normal nerve cells (left) and those affected by MS (right)128 
1.3.2.2 Types of multiple sclerosis 
1. Relapsing/remitting multiple sclerosis 
It is the most common form of MS, affecting about 85% of people with the condition. 
Relapsing/remitting MS is characterised by sporadic attacks of degeneration 
(relapses) intermingled with remissions, periods of near-normal health that can last 
for months or years. Some people even go into permanent remission, but most 
experience a slow increase in permanent nerve damage. 
2. Secondary progressive multiple sclerosis 
This is a later stage of the relapsing/remitting form of MS where attack rate is 
reduced and the condition changes to a gradual but steady deterioration of body 
functions unrelated to acute attacks. Within 10 years, 50% of all patients with 
relapsing/remitting MS move into the secondary progressive type. 
3. Primary progressive multiple sclerosis 
After onset of symptoms, there is a gradual but steady deterioration of body functions 
without acute attacks in about 10% of sufferers. In the very worst cases, primary 
progressive MS can accelerate, leading to complete disability or death within just a 
few months. 
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4. Progressive/relapsing multiple sclerosis 
It is the most severe form of MS, affecting about 5% of people with the condition. 
Progressive/relapsing MS begins with a progressive course although these people 
also experience acute attacks. 
1.3.2.3 Treatment of multiple sclerosis 
There is no cure for this disease. There are now drugs that can modify its course for 
some patients and many symptoms can be successfully treated or managed. The 
different types of drugs on the market focus mainly on decreasing the rate and 
severity of relapse, reducing the number of MS lesions, delaying the progression of 
the disease, and providing symptomatic relief for the patient. The drug classes are as 
follows: 
Corticosteroids: these natural chemicals released by the body are frequently 
used for visual symptoms of MS and can prolong the onset of MS if used early 
in the disease course; 
• Interferons: substances produced by the body to regulate the immune system, 
mainly to combat viral infections. They decrease the worsening or relapse of 
MS. However, they do not stop the overall disease progression and they have 
significant side effects; 
• Glatiramer acetate: mixture of amino acids which decreases the relapse rates 
of MS by 30% and appears to also have an effect on the overall disability of 
MS. It is better tolerated than interferons and has fewer side effects; 
• Natalizumab (Tysabri): monoclonal antibody that binds to white blood cells 
and interferes with their movement from the bloodstream into the brain and 
spinal cord. White blood cells are thought to play a role in causing nervous 
system damage in MS. 
Several drugs that suppress the immune system and are used in the treatment of 
cancer have been used as well; however they make patients very ill. Four MS 
disease modifying drugs are licensed in the UK: Avonex and Rebif (both /3 interferon 
I a), Betaferon (,8 interferon 1 b) and Copaxone (glatiramer acetate). 
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However, the main drawback with these drugs is that they are only effective in about 
30% of the patients. New research and treatment methods are currently being 
investigated and are expected to offer some hope to people with MS. Some 
preclinical studies have shown that Pioglitazone 21 (Figure 17) delays the onset and 
reduces the severity of clinical symptoms in an animal model of multiple sclerosis. It 
was therefore tested in a patient with secondary MS by Feinstein et al. and an 
improvement in orientation, short-term memory and attention span was seen after 8 
months of the therapy.13° The possible neuroprotective effects of PPAR' agonists 
were reviewed by Feinstein.131  
1.3.3 Targeting the brain: brain glucose levels and the blood brain barrier 
Glucose is the main fuel of cerebral tissue. Because neurons cannot store glucose, 
they depend on the bloodstream to deliver a constant supply of this important fuel. 
Although the brain represents only 2% of the body weight, it receives 25% of total 
body glucose utilisation. Hexokinase metabolises glucose transported to the cerebral 
tissue to glucose-6-phosphate, a very important intermediate in the glucose 
catabolism system. Glucose-6-phosphate then enters a metabolic pathway where it is 
catabolised to generate high-energy phosphate compounds, such as ATP, through its 
linked phosphorylation reaction. 
Mental performance is strongly dependent on brain glucose utilisation whose rate is 
not uniform throughout the brain. Certain brain portions and cell types, such as 
astrocytes, have been found to be clearly insulin sensitive.132 Astrocytes are 
important communicating cells whose glucose utilisation is severely affected by 
diabetes as they can develop insulin resistance. So far, it is known that brain glucose 
utilisation is not altered in relation to diet, insulin treatment or diabetes. 
Memory loss and dementia generally develop with age. Not only does glucose 
utilisation in the brain decrease with age, but insulin-stimulated fuel utilisation in 
peripheral tissues, such as skeletal muscle, also declines with age, thereby leading to 
insulin resistance. This is often due to a reduced amplification of the insulin signalling 
process. As a consequence, insulin is less efficient in activating the normal insulin 
response. This suggests that insulin resistance in discrete brain areas and cell types 
may play a role in central glucose utilisation, resulting in reduced mental 
performance. However, glucose utilisation in the brain is under complex control and it 
cannot be predicted how significant the impact of insulin resistance on age-
decreased brain glucose utilisation is.133 
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Since neural tissue is entirely dependent on glucose for normal metabolic activity, 
metabolism in the brain is dependent upon adequate glucose delivery from the 
systemic circulation.134 Changes in endothelial glucose transport may have profound 
consequences on glucose delivery to these tissues and major implications in the 
development of two major diabetic complications, namely insulin-induced 
hypoglycaemia and diabetic retinopathy. 
The main issue with treating dementia by increasing brain glucose metabolism is that 
it is crucial to treat only brain glucose metabolism for patients with normal serum 
glucose. Accordingly, it is important to deliver agents for treating brain glucose 
metabolism to the cerebral tissue. Unfortunately, the blood brain barrier (BBB) is the 
major obstacle for delivering most medication to the central nervous system (Figure 
23).135 
Figure 23 The blood brain barrier136 
The BBB is formed by the tight apposition of endothelial cells lining blood vessels in 
the brain, forming a barrier between the circulation and the brain parenchyma (e.g. 
astrocytes, microglia). A thin basement membrane, comprising lamin, fibronectin and 
other proteins, surrounds the endothelial cells and associated pericytes, and provides 
both mechanical support and a barrier function. Brain capillaries, unlike all other 
capillaries in the body, have no gaps which allow permeation of substances into and 
out of the blood (Figure 24).137 Diffusion through the BBB depends mainly on the lipid 
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solubility of the solute as the cell membranes' main constituents are lipids. Water-
soluble molecules such as glucose and glutamate enter the brain almost exclusively 
by carrier-mediated transport. Blood-borne immune cells such as lymphocytes. 
monocytes and neutrophils cannot penetrate this barrier. 
Thus. the BBB is crucial for preventing infiltration of pathogens and restricting 
antibody-mediated immune responses in the central nervous system, as well as for 
preventing disorganisation of the fragile neural network. This, together with a 
generally muted immune environment within the brain itself, protects the fragile 
neuronal network from the risk of damage that could ensue from a full-blown immune 
response. 
Figure 24 Difference between a brain capillary and a capillary found 
anywhere else in the body137 
Some non-invasive methods for drug delivery into the central nervous system include 
the use of chimeric cell-penetrating peptides and the use of "prodrugs" such as 
lipophilic esters or amides of the molecule amongst others.138,139,140,141 Prodrugs are 
biologically inactive compounds that subsequently decompose to yield the active 
compound. Depending on the nature of the active compound, different modifications 
are possible in order to make a prodrug. One possibility includes converting an 
anionic group such as a sulfate or sulfonate into the corresponding ester. The 
prodrug, when administered to a patient, is either cleaved, enzymatically or 
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nonenzymatically, reductively or hydrolytically, to reveal the therapeutic target or is 
actively transported in vivo and is selectively taken up by target organs. It can be 
selected to allow specific targeting of the therapeutic moieties to the brain. 
Carrier molecules may also be used to transport active compounds to the brain. The 
carrier molecule, which can be natural or synthetic, may include a moiety capable of 
targeting the therapeutic compound to the brain by either active or passive transport 
such as a redox moiety.142,143,144 These carriers include lipids, proteins, peptides, fatty 
acids, inositol and 1,4-dihydropyridine. Some examples of useful protein carriers 
include antibodies specific for receptors within the brain, albumin, insulin, drugs, or 
growth factors. 
1.3.4 Targeting AD and MS via the effects of PPAR agonists 
1.3.4.1 Alzheimer's disease 
There are a number of abnormalities in brain glucose-sensing neurons, the 
transmitters and peptides that affect them, and the physiological responses to 
changes in glucose levels that occur in both obesity and diabetes. But there is no 
direct link yet between these defects and the pathophysiology of obesity and 
diabetes. Both animal models and studies with Type II diabetic elderly patients have 
shown that altered glucose regulation impairs learning and memory processes. 
People with type II diabetes have a 9% increased risk of developing dementia and 
Alzheimer's disease.133 Moreover, insulin degrading enzyme was found to inhibit the 
degradation of the beta amyloid produced in AD145 and to play a significant role in the 
regulation of the phosphorylation of the tau protein, the main component of the 
tangles.146 Insulin resistance and the resulting hyperinsulinemia appear to increase 
the risk of AD.147 As such a link exists, the next logical step would be to determine 
whether AD patients could benefit from treatments aimed at normalising blood 
glucose regulation and improving insulin sensitivity. 
In view of the fact that inflammatory responses are an important component in AD, 
and that glucose metabolism is perturbed in AD,148 PPARs could play an important 
role in the treatment of this disease.55,149,150,51,50,74,151  Studies with pioglitazone 21 
have shown that it significantly increases glucose consumption in astrocytes.152 
Studies with rosiglitazone 20 are currently being undertaken.153 
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1.3.4.2 Multiple Sclerosis 
MS lesions have been associated with increased levels of nitric oxide (NO) and pro-
inflammatory cytokines such as interleukin-1 /3 (IL-1#) and tumour necrosis factor 
(TN F- a). 154'155 
Nitric oxide transmits messages between nerve cells and is associated with the 
processes of learning, memory, sleeping, feeling pain, and, probably, depression. It is 
a mediator in inflammation and rheumatism. Scientists are currently investigating the 
participation of NO in brain cell damage that occurs in a variety of diseases. 
Interleukin-1# is a member of the interleukin-1 (IL-1) family. IL-1 is a cytokine that is 
secreted by macrophages, monocytes and dendritic cells and is an important part of 
the inflammatory response of the body against infection. It increases the expression 
of adhesion factors on endothelial cells to enable transmigration of leukocytes, the 
cells that fight pathogens, to sites of infection. It also re-sets the hypothalamus 
thermoregulatory center, leading to an increased body temperature, which expresses 
itself as fever. It is therefore called an endogenous pyrogen. The increased body 
temperature helps the body's immune system to fight infection. 
Tumor Necrosis Factor (TNF-a, cachexin or cachectin) is an important cytokine 
involved in systemic inflammation and the acute phase response: it can cause 
cytolysis of certain tumor cell lines; it is involved in the induction of cachexia; it is a 
potent pyrogen, causing fever by direct action or by stimulation of interleukin-1 
secretion; finally, it can stimulate cell proliferation and induce cell differentiation under 
certain conditions. 
An interesting study by Drew et al. has demonstrated that PPARa agonists inhibit 
microglia production of nitric oxide, IL-1# and TNF-a.156 Another study has shown that 
PPARa agonists inhibited IL-1# induction in astrocytes.157 Furthermore, Watanabe et 
al. have shown that PPAR7 activation increases neurite extension in brain cells.158 
With the findings that PPAR agonists could prevent anti-inflammatory activation of 
glial cells, reduce T cell activation and also regulate myelin gene expression,6s'159 
they could also become potential drugs for the treatment of multiple sclerosis.160,161,162 
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2.1 Objectives of the project 
In the first chapter, we discussed how peroxisome proliferator-activated receptors 
(PPARs) have been established as a prime target in drug discovery for the treatment 
of metabolic diseases because of their critical role in the regulation of lipid 
metabolism and fat cell differentiation. In particular, study into PPARy agonists have 
founded a class of drugs known as the thiazolidinediones (TZDs). The TZDs have the 
following beneficial effects: improved insulin sensitivity, decreased hepatic glucose 
output, nonglycemic effects (decreased triglycerides levels and hyperinsulinemia, 
increased fibrinolysis and improved endothelial function) and increased adiponectin 
levels.104 In addition, they are the only first generation drugs that have a possible 
potential to preserve the pancreatic 16-cells.102,103 Moreover, unlike insulin and 
sulfonylureas, they do not induce hypoglycaemia and they do not provoke gastric 
disturbances and lactic acidosis found with biguanide therapy. Their convenient once-
or twice-daily dosing makes them easier to use by patients. Nevertheless, they do 
have side effects such as weight gain, oedema, anaemia and possible liver 
dysfunction and care has to be taken in the case of patients suffering from severe 
cardiovascular complications.106.105 As a consequence of these side effects and given 
the complexity of the metabolic syndrome and diabetes, combination therapy is 
sometimes employed, for example, TZDs can be prescribed with metformin which 
does not induce any weight gain. 
We propose to design novel PPAR dual (i.e. an agonist of two of the three PPAR 
subtypes) or pan (i.e. an agonist of the three subtypes) agonists, which would 
hopefully lead to complementary and synergistic actions in improving lipid 
homeostasis, insulin sensitivity and inflammation control. PPARy is abundantly 
expressed in adipose tissue and has an important role in adipocyte differentiation and 
triglyceride synthesis. Selective PPARy agonists increase the diversion of fatty acids 
into adipose tissue and enhance glucose-metabolic insulin sensitivity. All this 
provides the rationale for the use of TZDs in the treatment of diabetes type II. On the 
other hand, PPARa, expressed mainly in the liver, skeletal muscle and heart, is 
involved in fatty acid oxidation and lipoprotein synthesis. PPARa agonists may 
protect against obesity and enhance insulin-mediated muscle glucose 
metabolism.163'164 Also, they could improve small dense VLDL triglyceride hydrolysis 
by lipoprotein lipase.165 Bergeron et al. showed that chronic treatment with a PPARa 
agonist stopped the development of diabetes in Zucker diabetic rats mainly by 
improving the pancreatic insulin response without side effects on body weight gain 
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and cardiomegaly.166 The established actions of PPARy and the positive results 
obtained with PPARa activation have thus led to the hypothesis that combined 
PPARodyactivation could give much better results than single activation of one PPAR 
subtype. The properties of the ligand-binding domains of each of the two subtypes 
are such that dual agonists could be developed. Moreoever, dual activation of 
PPARa and PPARy could also limit the occurrence of certain effects associated with 
currently used glitazones.121 The propensity for adipogenesis from PPARy activation 
could be offset by the propensity of PPARa activation to stimulate lipid catabolism. In 
this respect, a new class of compounds called the glitazars has emerged over the 
past few years.105 Some examples of these synthetic dual agonists are shown in 
Figure 25. 
OCH3 
Figure 25 Structures of different PPARa/ydual agonists 
Plasma triacylglycerol concentrations and hepatic triacylglycerol accumulation were 
reduced by dual PPARa/y agonists.167,168,169,170,171 Treatment of Zucker rats (obese, 
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diabetic rat model) with the dual agonist LY465608 (Eli Lilly) did not enhance food 
consumption and resulted in significantly less fat accumulation and body weight 
gaill.172'173 Another dual agonist, JTT-501 29, was shown to reduce the diabetic 
complications such as cataract, nephropathy and osteopenia in Zucker rats.174 
Muraglitazar 30, developed by Bristol-Myers Squibb, was shown to prevent the 
development of diabetes if administered before the onset of diabetes and, when 
initiated after the onset of diabetes, prevented the worsening of the disease.175 
However, the progress of glitazars to the market has been hampered by idiosyncratic 
side-effects.106 Given the potential of the PPAR nuclear receptor family in glucose 
and lipid metabolism, it is important to find the right optimal activity of the receptor 
subtypes with the best side-effect profile. 
One new development in PPAR activation is its effect on the control of inflammation. 
Indeed, recent studies have shown that PPARa agonists reduce microglial activation 
whereas PPARy activation inhibits TNF-a and interleukins expression in monocytes, 
and inducible nitric acid synthase in macrophages. Feinstein et al. have reported 
some promising data from the treatment of a patient suffering from multiple sclerosis 
with the TZD, pioglitazone 21.13° All these effects strongly suggest that PPAR 
agonists could have a significant potential in the treatment of neurological 
inflammatory diseases. 
Moreover, the studies showing the link between altered glucose regulation and the 
impairment of learning and memory processes in Type II diabetic patients have led to 
the hypothesis that treatments regulating blood glucose and improving insulin 
sensitivity could be useful for the treatment of Alzheimer's disease. 
Our aim is to synthesise and develop new potential drugs for the treatment of the 
metabolic syndrome and diabetes type II and, also for neurological inflammatory 
brain diseases. Given all the findings about the nuclear receptors, PPARs in both the 
regulation of glucose and lipid metabolism, as well as in the control of inflammation, 
we propose to develop new dual or pan PPAR agonists. This thesis describes the 
design and development of two families of orthogonal PPAR agonists; firstly lipid 
analogues of tetradecylthioacetic acid and, secondly, small molecule heterocyclic 
structures. 
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2.2 Synthesis of new lipid analogues 
The first part of the project involved the synthesis of lipids based on work previously 
carried out in our group and in collaboration with Professor Berge from the Institute of 
Medicine, Bergen and Thia Medica AS (Norway). Tetradecylthioacetic acid (TTA) 31 
has been developed as a potential treatment for many of the indications related to the 
metabolic syndrome, including diabetes II, by Thia Medica AS (Figure 26). 
0 
OH 
31 
Figure 26 Tetradecylthioacetic acid 
This acid, found to be a potent PPAR agonist of all three subtypes, has very good 
lipid lowering effects and improved insulin action. However, it is easily excreted by 
the body and has very poor bioavailability. We proposed to synthesise phospholipids 
analogues of TTA as natural "prodrugs" in order to improve the absorption, 
distribution, metabolism and excretion (ADME) properties of this acid. Phospholipids 
(and other classes of lipids) were shown to have better absorption characteristics 
compared to the parent fatty acid as preliminary in vivo data on TTA-PC 32 and TTA-
TAG 33 suggested these new molecules to have better activity than the parent TTA. 
Thus, several new lipid analogues (Figure 27) have been synthesised and were 
screened in vitro and in vivo by Thia Medica AS for their action as potential diabetes 
II treatments. 
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Figure 27 Structures of novel lipid analogues of TTA 
2.3 Design and synthesis of novel heterocycles 
The second part of the project consisted of the synthesis of novel heterocyclic 
structures, designed using de novo design technology. This strategy was adopted in 
order to develop small molecule heterocycles with drug-like properties in order to help 
to achieve the ADME characteristics required for the development of an oral drug. 
Prosarix Ltd is an in silico screening company based in Cambridge, UK. Using its 
proprietary drug design software, Prosarix Ltd modelled the interaction of known 
drugs with the PPAR receptors and subsequently used this data to predict and design 
novel heterocyclic scaffolds as potential PPARedy dual agonists. The first scaffold 
displays the classical carboxylic acid moiety found in many PPAR agonists linked to 
an indole core (Figure 28). 
61 
Yushma BHURRUTH 	 Chapter 2 
OH 
R2 
Figure 28 Indole scaffold 
The screening study suggested the synthesis of molecules 38 to 43, with R1 = H, 
phenyl and naphthylmethyl groups, and R2 = methyl or trifluoro group (Table 5). The 
racemic synthesis of the six indoles leads 38 to 43, as well as their in vitro luciferase 
reporter gene PPAR activation assay, is described in Chapter 4. 
Target R1 R2 
38 H CH3 
39 H CF3 
CH3 
•
40 
41 CF3 
. 
42 
111. 
CH3 
4/11  
43 CF3 
Table 5 Indole leads 38 to 43 
Some indole-based structures have recently been published as PPAR agonists in the 
literature by GlaxoSmithKline and Hoffman-La Roche. GlaxoSmithKline's 2,3-
disubstituted compounds were found to be potent PPARy agonists in vitro and are 
currently being investigated in animal models.176 Hoffman-La Roche's 1,5-
disubstituted indole molecules were found to be potent PPARcdy agonists in vitro and 
are being studied in vivo.177  
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Furthermore, a second heterocyclic scaffold was designed by Prosarix Ltd as 
potential PPARoir dual agonists. It consists of a pyrrolidine core with different aryl 
groups on the 3-position (Figure 29). 
OH 
Figure 29 Pyrrolidine scaffold 
The racemic synthesis of the first pyrrolidine molecule 44, with R = H, is also 
described in Chapter 4. 
63 
CHAPTER 3 
Synthesis of new lipid 
analogues of 
tetradecylthioacetic acid 
64 
Yushrna BHURRUTH 	 Chapter 3 
3.1 Tetradecylthioacetic acid 
Tetradecylthioacetic acid (TTA) 31 is a 3-thia fatty acid with a 14-carbon chain length 
(Figure 30). 
° S---)C0H 
31 
Figure 30 Tetradecylthioacetic acid 
TTA 31 was first synthesised by Spydevold et al. and was found to induce 
peroxosimal /3-oxidation.178 TTA's effects were further studied by Professor Rolf 
Berge at the Institute of Medicine, Bergen, in collaboration with Thia Medica AS, and 
it was found to have powerful effects both in vitro and in vivo.179,180,181 In vivo studies 
of biological effects of TTA in rats have shown the following effects after 
administration: lipid lowering,182 improved insulin aCtiOr1,183.184 hepatic lipid content 
decrease, decrease of hyperinsulinemia, increased fatty acid oxidation:86 anti-
oxidising and anti-inflammatory action,186 as well as modification of cell proliferation 
and apoptosis.187  
TTA is involved in lipid metabolism via its agonist action on the peroxisome 
proliferator-activated receptors (PPARs); it is a potent ligand of the three PPAR 
subtypes.187 The ratio of PPAR cr/7/8 activation is cell specific. Human PPARs are 
activated in the following order: g> a > y188 
TTA is currently in phase III clinical trials. Phases I and II clinical trials have shown 
that it is effective at acceptable doses and that it has little acute toxicity. However, it 
suffers from poor bioavailability due to its poor ADME (absorption, distribution, 
metabolism and excretion) properties.181 Particularly, this fatty acid is poorly absorbed 
into the bloodstream. In order to improve the absorption and bioavailability of TTA, it 
was decided to couple it with phospholipids since these natural prodrugs should be 
better absorbed in the gut. Phospholipids are di-acyl derivatives of 3-glycero-
phosphoric acid 45 (Figure 31).189 Glycerol 46 is a prochiral molecule with the 
prochiral carbon carrying two CH2OH groups (Figure 31). To designate the 
stereochemistry of glycerol-containing components, the carbon atoms are 
stereospecifically numbered (sn). When the glycerol molecule is represented by a 
Fischer projection with the secondary hydroxyl to the left of the central carbon atom, 
and the carbon atoms are numbered 1, 2, and 3 from top to bottom. The major 
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glycerophospholipids are phosphatidylcholines (PC), phosphatidylethanolamines 
(PE), phosphatidylserines (PS), phosphatidylinositols (Pl) and phosphatidylglycerols 
(PG). 
0 
HO 	0—P—OH 
OH 
HOH2C 
3-glycerophosphoric acid 
45 
HO 
CH2OH sn-1 
	H sn-2 
CH2OH sn-3 
Glycerol 
46 
Figure 31 3-glycerophosphoric acid and glycerol 
The mechanism of absorption and digestion of phospholipids explains their better 
absorption in the gut. Degradation by pancreatic lipases releases fatty acids from the 
sn-1 and sn-3 positions of triacyiglycerols and of phospholipids. Micelles are formed 
with 2-monoacylglycerols, /ysophospholipids, cholesterol, bile salts and free acids 
and are absorbed into the enterocytes by simple diffusion across the plasma 
membrane. Within the epithelial cells of the gut wall, a combination of triglycerides, 
and cholesterol, and fatty acids are coated with protein to form large lipoproteins 
known as chylomicrons. These pass into the general circulation via the thoracic duct 
and are transported in the bloodstream to the liver where they are absorbed and 
broken down to contribute to the triglyceride and the cholesterol pool within the liver. 
This is illustrated in Figure 32.190 ' 191  
•••••••••••• Lipase 
L_> 
••....***** 
Triglyceride Monoglyceride and fatty acids 
Exchange surface of small intestine 
Cells in intestinal mucosa 
Figure 32 Absorption of lipids into the blood stream190'191  
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Two new lipid analogues: TTA-PC 32 and TTA-TAG 33 were first synthesised. The 
coupling of TTA with L-a-glycerophosphocholine (GPC) gave di-tetradecylthioacetoyl-
sn-glycero-3-phosphocholine, TTA-PC 32 (Figure 33). 
0 0 
I
oII 	 ,:s / 
sO ° 
32 
Figure 33 Structure of TTA-PC 
TTA was also coupled with glycerol to give tri-tetradecylthioacetoyltriglyceride, TTA- 
TAG 33 (Figure 34). 
OJ~s 
33 o lr
Figure 34 Structure of TTA-TAG 
3.2 Synthesis of the first two analogues of TTA 
3.2.1 Synthesis of TTA-PC 32 
TTA-PC 32, is made from the coupling reaction between TTA 31 and L-a-
glycerophosphocholine 47 (GPC). 
0,/o
e 
HO'Y'0 01\ 4)4 
1-10 GPC 
47 
O 
S 
	
OH 
TTA 
31 
a) 
O 
O 	0, i0„ 
N 0/AN 
s,r,0 
TTA-PC 0 
	32 
a) CDI, DBU, DMSO, CHCI3 
Scheme 2 Coupling reaction between TTA 31and GPC 47 
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TTA 31 was first made by reacting thioglycolic acid 48, under basic conditions, with 
tetradecylbromide 49 (Scheme 3). TTA was isolated as a white solid in an excellent 
yield (91%).178 
Hsic + 
OH 
48 
° S----)C0H 
TTA 
31 
a) NaOH/MeOH, RT, 48 hr, 91% 
Scheme 3 Synthesis of TTA 31 
The coupling reaction between TTA and L-a-glycerophosphatidylcholine (GPC) is 
made difficult by the low solubility of GPC.CdCl2 (as it is commercially provided) in 
most organic solvents. Furthermore, the secondary alcohol in GPC is less 
nucleophilic and becomes more hindered due to the first esterification occurring 
predominantly at the primary alcohol position. 
Many different conditions were investigated to optimise the coupling reaction: 
• coupling reagents: isobutyl and ethyl chioroformates, N-hydroxysuccinimide, 
dicyclohexylcarbodiimide, N,N'-carbonyl-diimidazole and pentafluorophenol. 
bases: 4-methylmorpholine, DBU and triethylamine. 
• solvents: chloroform, dichioromethane, dimethylformamide, acetonitrile and 
dimethylsulfoxide. 
The optimised coupling conditions required a mixed solvent system: 
dichloromethane-DMSO (Scheme 4), adapted from a method developed by Warner 
et a/.192,193,194  Although DMSO is a high boiling solvent, thus difficult to remove, it has 
the advantage of efficiently dissolving GPC.CdC12. TTA 31 was first activated 
separately with N,N'-carbonyldiimidazole (CDI) 50 in anhydrous DCM to form a 
reactive TTA-imidazolide. CO2 is given off as the reaction proceeds, making this 
reaction simple to monitor. Once the acid has been fully activated, the evolution of 
CO2 ceases, and the nucleophile can be introduced. The latter must only be added 
after the activation of the acid has finished, otherwise carbonates will result. The two 
alcohols of GPC were deprotonated with the non-nucleophilic base, DBU and the 
, 
49 
01 
68 
0, /0 
HO 
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in anhydrous DMSO 
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resultant solution reacted with the preformed TTA-imidazolide at slightly elevated 
temperature (ca. 40 °C), thereby giving the desired TTA-PC 32 in a yield 70%.195 
s- or° 
32 
Scheme 4 Synthesis of TTA-PC, 70% 
3.2.2 Synthesis of TTA-TAG 33 
The coupling reaction between TTA 31 and glycerol 45 was conducted using HBTU 
as coupling agent and DMAP as a nucleophilic catalyst (Scheme 5). TTA and 
glycerol were dissolved in anhydrous DCM after which HBTU and DMAP were added 
under inert atmosphere. The reaction was carried out at room temperature overnight. 
An increase in the number of equivalents of TTA significantly improved the yield. 
TTA-TAG 33 was isolated with a yield of 83% after chromatography on silica gel. 
TTA 
S%, HO J- „OH 
Glycerol 
45 31 
a) 
 
   
   
—C 
° 	S TTA-TAG 0 
33 
a) HBTU, DMAP, anhydrous DCM, RT, 83% 
Scheme 5 Synthesis of TTA-TAG 
The mechanism of the reaction is shown in Scheme 6. TTA is represented by 
RCOOH. It is first activated by HBTU 52, giving tetramethylurea 53 as a side product. 
DMAP 55 subsequently further activates intermediate 54. DMAP is a particular type 
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of aminopyridine in which the amino group reinforces the nucleophilic nature of the 
pyridinyl nitrogen atom. The nucleophilic oxygen of the alcohol attacks the carbon of 
the carbonyl group to yield back DMAP 55 which is a good leaving group and gives 
the desired ester product. 
Scheme 6 Mechanism of coupling reaction between TTA and glycerol 
3.2.3 Preliminary biological results with TTA-PC and TTA-TAG 
In order to evaluate the biological potential of the new analogues, biological tests 
were carried out on TTA-PC and TTA-TAG by Thia Medica AS in Norway.195 Male 
Wistar rats (4-5 rats in each treatment group) were fed TTA, TTA-PC or TTA-TAG at 
equimolar doses of TTA (1mmole/day/kg body weight) for 6 days. Negative control 
rats received only 0.5% of carboxymethylcellulose, CMC. The animals were 
sacrificed and lipid lowering effects were evaluated. 
As described in Chapter 1, patients suffering from the metabolic syndrome arid 
diabetes type II have an unusually high level of triacylgycerol and cholesterol. The 
70 
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levels of plasma triacylglycerol, cholesterol and hepatic triacylglycerol levels were 
therefore measured after treatment with the different compounds. The results, 
normalised to the control, are shown in Figure 35. All three treatments showed a 
decrease in plasma triacylglycerol, cholesterol and hepatic triacylglycerol levels, with 
the largest decrease being affected by TTA-PC. 
Triacylglycerol 	Cholesterol 	Hepatic 
levels 	levels triacylglycerol 
levels 
❑ Control ❑  TTA ■ HA-PC ❑  HA-TAG 
Figure 35 Effects of TTA, TTA-PC and TTA-TAG on plasma lipid levels 
Fatty acid oxidation and the activity of key mitochondrian enzymes involved in fatty 
acid oxidation and transport were also measured (Figure 36) as these are very 
important dysfunctions in the metabolic syndrome and diabetes type II as previously 
explained. Palmitoyl-CoA is a fatty acid coenzyme derivative that plays a key role in 
fatty acid oxidation and biosynthesis. The catabolism of fatty acid palmitoyl-CoA 
reduces the production and secretion of VLDL by the liver, therefore a high rate of 
palmitoyl-CoA indicates a high rate of fatty acid metabolism. TTA-PC and TTA-TAG 
led to comparable levels of activity, with respect to TTA. Carnitine palmitoyl 
transferase-II is an important enzyme for the transport of fatty acids into the 
mitochondrion, a high activity of this enzyme implicates a high rate of fatty acid 
metabolism. CPT-II activity was found to be increased with the three compounds, 
with the highest increase effected by TTA-PC. 3-Hydroxy-3-methylglutaryl-CoA 
synthase (HMG-CoA synthase) is a rate-limiting enzyme for the production of ketone 
bodies in the mitochondrion whose activity increases with fatty acid oxidation. 
Similarly to CPT-II activity, HMG-CoA synthase activity was found to be increased 
with the three compounds, with the highest increase effected by TTA-PC. Fatty acyl-
CoA is the rate determining enzyme in peroxisomal oxidation of fatty acids in rodents. 
Its gene expression is regulated by PPARa. The activity of fatty acyl-CoA was 
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strongly increased with the three compounds and the highest activity was given by 
TTA-PC. In the case of these three enzymes, TTA, and TTA-PC showed significant 
activity, whereas TTA-TAG was slightly less effective in general. It must be 
highlighted that TTA-PC improved the activity of the key enzymes by nearly two-fold 
compared to TTA. 
9.0 
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Palm iti4 CoA CPT-11 activity 3-HMG-CoA Fatty acyl-CoA 
oxidation 	 synthase 	oxidase activity 
activity 
❑ Control ❑  TTA ■ HA-PC ❑  HA-TAG 
Figure 36 Effects of TTA, TTA-PC and TTA-TAG on the activity of key enzymes involved in 
fatty acid oxidation 
Given this promising set of data, it was decided to synthesise further lipid analogues 
of TTA, such as phosphoglycerols and phosphoserines which are naturally occurring 
phospholipids in cell membranes, in order to improve the absorption and distribution 
properties of the active molecule TTA (Figure 37). 
i. /yso-di-tetradecylthioacetoyl-sn-g lycero-3-phosphocholine, lyso TTA-PC 34, 
ii. di-tetradecylthioacetoyl-sn-glycero-3-phosphoserine, TTA-PS 35, 
iii. di-tetradecylthioacetoyl-sn-glycero-3-phosphoglycerol, TTA-PG 36, and 
iv. cholesteroltetradecylthioacetate, TTA-Chol 37. 
Lyso TTA-PC, TTA-PG and TTA-PS can be synthesised by enzymatic hydrolysis (in 
the case of lyso TTA-PC) or by enzymatic transphosphatidylation reactions (in the 
case of TTA-PG and TTA-PS) directly from TTA-PC whilst TTA-Choi is formed from 
the direct coupling of cholesterol and TTA. 
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Figure 37 Structures of four novel lipid analogues 
3.3 Synthesis of four new lipid analogues of TTA 
TTA-PC 32 is the precursor to three of the new lipids shown in Figure 37: lyso TTA-
PC 34, TTA-PS 35 and TTA-PG 36. Phospholipases were used to catalyse the 
synthesis of these lipids as shown in Figure 38. Phospholipase A2 causes de-
acylation at the sn-2 position to yield lyso TTA-PC 34 and the fatty acid TTA 31. 
Phospholipase D cleaves the phosphate ester bond to give choline and phosphatidic 
acids. It then re-esterifies the phosphatidic acid to give TTA-PS 35 and TTA-PG 36. 
The overall reaction is an exchange between choline and serine or glycerol 
respectively. This type of enzyme transphosphatidylation reactions has been carried 
out with a wide variety of nucleophiles such as ethanolamine, azasugars, nucleosides 
and peptides by Wong et al.196  The only pre-requisite for the nucleophile is that it 
bears a primary hydroxyl group, for which phospholipase D is chemoselective. 
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Figure 38 New lipid analogues: lyso TTA-PC, TTA-PS and TTA-PG 
Due to limited resources of TTA-PC 32, model studies for the enzymatic 
transformations were initially conducted with distearoyl phosphatidyicholine, DSPC 
57 (Figure 39) which is commercially available and inexpensive. 
57 
Figure 39 DSPC 
The last analogue, TTA-Chol 37, was made by reacting TTA with cholesterol using 
standard coupling conditions. 
3.3.1 Synthesis of lyso TTA-PC 34 
The synthesis of lyso DSPC 58 from DSPC 57 was conducted using the conditions 
shown in Scheme 7.197 To a solution of the starting material in the organic phase 
were added trisHCl buffer (pH — 8.4) and finally the enzyme, phospholipase A2. The 
reaction mixture was stirred at 37 °C for 3-5 hours. The model lyso product was 
isolated with a yield of 87% after chromatography. 
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I 	a ) 
0 o o 
o o o 
OH 
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58 
a) Phospholipase Az diethylether/MeOH 99:1, buffer: TrisHCI (50mM), CaCl2 (40mM), pH 8.4, 37 °C, 87% 
Scheme 7 Synthesis of lyso DSPC 58 
Therefore, the reaction was next carried out on TTA-PC 32 (Scheme 8), furnishing 
lyso TTA-PC in a 70% yield. 
0 	 (:), 0/08 N 
0 
TTA-PC ° 
32 
I a) 
0 	 0 0°  
OH 
Lyso TTA-PC 
34 
a) Phospholipase A2, diethylether/Me0H 99:1, buffer: TrisHCJ (50mM), CaCl2 (40mM), pH 8.4, 37 °C, 70% 
Scheme 8 Synthesis of lyso TTA-PC 34 
3.3.2 Synthesis of TTA-PS 35 
A model reaction was first carried out with DSPC 57 using the system shown in 
Scheme 9 in order to optimise the serine transesterification.196 To a solution of serine 
and phospholipase D in the buffer solution at a pH of 6.2 to 6.5, was added a solution 
of the starting material in chloroform. The reaction mixture was stirred at 30 °C for 
about 4 to 6 hours. In this case, monitoring the progress of the reaction proved 
tedious by thin layer chromatography (TLC). Mass spectrometry indicated that no 
starting material was left but no mass corresponding to product 60 could be detected 
nor was any product isolated after exhaustive column chromatography. 
75 
Yushma BHURRUTH 
	
Chapter 3 
DSPC 
57 
0 00  
=•• 	N 0 	0 ' P 0 
0 
0 
HO 
Cr' 
L-serine 
59 
a) 
a) Phospholipase D, chloroform, buffer: NaOAc (100 mM), CaCl2 (50 mM), pH 6.4, 30 °C 
Scheme 9 Synthesis of DSPS 60 
One important factor preventing the exchange of serine could be the poor solubility of 
serine in chloroform. This could be overcome by using protected serine. Thus the 
serine transphosphatidylation was carried out using BOC-serine 61 (Scheme 10). 
However, this reaction did not proceed to completion and purification of the product 
from the starting material was unsuccessful. De-protection of the amine by cleaving 
the BOC group did not render the purification easier as a more complex mixture of 
products was obtained. 
TTA-PC 	0 
32 
0 
HO 	OH 
NHBOC 
BOC Ser OH 
61 
%/ a) 
O 	0, ,0 
	0 
OH 
0.1„NH 
0 
TTA PBOCSer 
62 
a) Phospholipase D, hipersolv chloroform, buffer: NaOAc (100 mM), CaCl2 (50 mM), pH 6.4, 30 °C 
Scheme 10 Synthesis of TTA PBOC Ser 61 
Due to the difficulties encountered to synthesise TTA-PS, it was decided to employ a 
derivative of serine as the nucleophile. Thus, the transphosphatidylation was carried 
out with serinol 63 as shown in Scheme 11. This reaction proceeded smoothly giving 
the desired product 64 in 87% yield. 
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a) Phospholipase D, hipersolv chloroform, buffer: NaOAc (100 mM), CaCl2 (50 mM), pH 6.4, 30 °C, 87% 
Scheme 11 Synthesis of TTA-PSerinol 64 
3.3.3 Synthesis of TTA-PG 36 
The model reaction for the synthesis of TTA-PG was first performed with DSPC 57 
using the same conditions that proved successful with serinol 63 (Scheme 12). 
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a) Phospholipase D, hipersolv chloroform, buffer: NaOAc (100 mM), CaCl2 (50 mM), pH 6.4, 30 °C 
Scheme 12 Synthesis of DSPG 65 
Again, it proved to be very difficult to follow the reaction by TLC or mass 
spectrometry. At this point the difficulty relating to the detection and handling of 
DSPC as a model study compound resulted in a slight change of strategy. 1,2-
Dioleoyl-sn-glycero-3-phosphocholine (DOPC) would have probably been a better 
candidate for these model studies since unsaturation on its hydrocarbon chain is 
more liable to chemical changes (for e.g. oxidation), hence making it easier to detect 
this compound by TLC stains. Instead, it was decided to optimise the enzymatic 
reaction through the synthesis of di-tetradecyl-thioacetoyl-sn-glycero-3-phospho-
ethanolamine 67 (TTA-PE) as this reaction had been successfully carried out 
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previously in our laboratory. The reaction was carried out as shown in Scheme 13 
and was easily followed by TLC. The sulfur on the fatty acid chain makes it liable to 
chemical changes such as oxidation and thus allows staining of the compounds by 
regular stains such as ammonium molybdate reagent. The product, TTA-PE 67, was 
isolated after chromatography, in an excellent 95% yield. 
OH 
Ethanolamine 
66 
0 	ON o9 e 
NH3 
0 Or'N''' 
S"
6 
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TTA-PE 
67 
a) Phospholipase D, hipersolv chloroform, buffer: NaOAc (100 mM), CaCl2 (50 mM), pH 6.4, 30 °C, 95% 
Scheme 13 Synthesis of TTA-PE 67 
Having validated our experimental procedure, TTA-PG was synthesised in a similar 
fashion (Scheme 14). The conditions were optimised using two units of enzyme per 
mmol of starting material and the desired product was isolated with a yield of 63% 
after silica gel chromatography. 
0 0 \`.•0/ 
S---y" 
	 OH 
TTA-PC 	° 
	
Glycerol 
32 46 
a) 
0 ,0 
& OH 
P 
s,,m(0 
0 
TTA-PG 
36 
a) Phospholipase D, hipersolv chloroform, buffer: NaOAc (100 mM), CaCl2 (50 mM), pH 6.4, 30 °C, 63% 
Scheme 14 Synthesis of TTA-PG 36 
In an effort to improve the yield, the transphosphatidylation was attempted with the 
protected acetal of glycerol 68 as it has a better solubility in chloroform (Scheme 15). 
The reaction proceeded smoothly and TTA-Pdioxolglycerol 69 was isolated with a 
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yield of 97%. The acetal was next cleaved using trifluoroacetic acid in 
dichloromethane. TTA-PG 36 was isolated with an overall yield of 67% over the two 
steps thus providing a slight improvement of the yield compared to the one-step 
synthesis of TTA-PG with unprotected glycerol. 
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a) Phospholipase D, hipersolv chloroform, buffer: NaOAc (100 mM), CaCl2 (50 mM), pH 6.4, 30 °C, 97% b) TFA, 
DCM, 69% 
Scheme 15 Synthesis of TTA-PG 36 in 2 steps 
Proton and carbon NMR of phospholipids can be rendered difficult due to the overlap 
of many diagnostic signals and the splitting of peaks due to the phosphorus-carbon 
coupling. Hence, phosphorus NMR was used as an additional method of 
characterisation of the synthesised phospholipids. Decoupled 31P experiments were 
run, so each peak corresponds to one phosphorus atom. One example of a 31P NMR 
spectrum is shown in Figure 40. 
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Figure 40 31P NMR of DSPC 
The 31P chemical shifts, measured in ppm, are summarised in Table 6. 
1,2-Distearoyl 1,2-TTA 
Phosphocholine -0.52 -0.68 
Lyso phosphocholine -0.18 -0.17 
Phosphoglycerol -1.02 -1.41 
Phosphodioxolaneglycerol -3.20 x 
Phosphoserinol x -0.93 
Phosphoserine -0.56 x 
Table 6 31P NMR shifts in ppm 
3.3.4 Synthesis of TTA-Choi 37 
The last target, TTA-Chol 37, consists in the direct coupling of TTA 31 with 
cholesterol 70. This reaction was conducted using HBTU as coupling agent and 
DMAP as a nucleophilic catalyst, and TTA-Choi 37 was isolated with an excellent 
yield of 99% after chromatography on silica gel (Scheme 16). 
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Scheme 16 Synthesis of TTA-Choi 
The mechanism for the synthesis of TTA-Chol is identical to the one for TTA-TAG 
(Scheme 6). 
The novel lipid analogues lyso TTA-PC 34, TTA-PSer 64, TTA-PG 36 and TTA-Choi 
37 were therefore successfully synthesised using the optimised conditions developed 
on preliminary model studies on the analogue DSPC 57. Phospholipase A2 afforded 
the lyso TTA-PC in a good yield of 70% while transphophatidylation with 
phospholipase D yielded both TTA-Pser 64 and TTA-PG 36 in good yields of 87% 
and 69% respectively. TTA-Chol 37 was obtained in 99% yield by the coupling 
between TTA 31 and cholesterol. The next step was to test the effects of the new 
compounds with respect to TTA. 
3.3.5 Preliminary biology results with the four new analogues 
3.3.5.1 Luciferase reporter gene assay 
The activation of the three PPAR subtypes by the new lipids lyso TTA-PC 34, TTA-
PSer 64, TTA-PG 36 and TTA-Chol 37 was studied in vitro using reporter gene 
assays. It is known that upon activation by potent ligands, PPARs regulate gene 
expression by binding to peroxisome proliferator response elements (PPREs) found 
in the promoter region of specific genes. Hence, a promoter sequence is linked to an 
easily detectable reporter gene such as that encoding for the firefly luciferase, and 
this offers a means to measure PPAR activity. Specifically, a plasmid containing 
genes encoding for each subtype of PPARs, as well as a luciferase reporter gene 
which has PPREs in the promoter region of the gene is transfected into human breast 
cancer MCF-7 cells. The firefly luciferase catalyses the bioluminescent oxidation of 
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luciferin in the presence of ATP, magnesium and oxygen (Scheme 17).198 The 
luciferase protein complexes with the luciferin substrate to form a luciferyl-adenylate 
complex in the presence of magnesium ions and ATP. In the presence of oxygen, this 
complex is oxidised to oxyluciferin with the release of carbon dioxide and adenosine 
as well as a light emission with a wavelength of 560 nm. The measurement of the 
amount of luciferase protein expressed can be detected on a luminometer and is 
expressed in relative light units (RLU), which can be used to quantify the efficiency of 
the PPAR activation. 
Scheme 17 The reaction catalysed by the luciferase enzyme found in Photinus pyralis 
The advantages of the luciferase assay are the high sensitivity, the absence of 
luciferase activity inside most of the cell types, the wide dynamic range, rapidity and 
low costs. 
The procedure, briefly outlined in Figure 41, was carried out as follows: human MCF-
7 breast cancer cells were seeded at a density of 85,000 cells per well of a 12-well 
pate. The following day, they were transiently transfected using a peroxisome 
proliferator response element (PPRE)-luciferase reporter plasmid and DNA with the 
three subtypes of PPARs. The total amount of plasmid was kept constant at 2.65 fig 
by compensating with pCMV-5 which is an empty expression plasmid. 24 hours after 
transfection, the cells were treated with the TTA analogues. After another 48 hours, 
the cells were washed once with PBS, lysed and the cell extracts were used for 
luciferase determination on a LUCY-1 luminometer. The luciferase assay was 
performed in accordance with the protocol of the Luciferase Assay Kit (B10 Thema 
AB, Sweden). 
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Figure 41 Luciferase reporter gene assay 
3.3.5.2 PPAR activation assay results and discussion 
First of all, cells used for the PPAR assays were checked for any endogenous PPAR 
activity through performing transfection in the absence of the PPAR DNA. In these 
conditions, no significant luciferase expression was detected. For each of the 
experiments, the control was done by carrying out the assay without treating the cells 
with any of the compounds. The following selective potent PPAR agonists, whose 
structures are given in Figure 42, were used as positive controls at concentrations of 
1 jiM or 30 ,uM: WY14.643 71 for PPARa, BRL49653 20 (rosiglitazone) for PPAR7, 
and L165.041 14 for PPARc.. Also, TTA, at different concentrations between 1 jiM 
and 75 ,uM, was run in parallel in order to allow for comparison of the new lipid 
analogues. The compounds were prepared in serum solutions as they were insoluble 
in DMSO. Due to the very poor solubility of the lipid analogues TTA-PSer 64 and 
TTA-Chol 37, only lyso TTA-PC and TTA-PG's activities could be tested. It was 
decided to run four to five different concentrations of the compounds (between 1 //M 
and 75 pM) to get a preliminary indication of their effects on the PPARs. 
Subsequently, the lowest concentration which gave activity as well as a higher 
concentration relative to the first one were selected. These experiments were 
performed nine times at these optimum concentrations. All results were normalised 
relative to the control and the standard deviation is calculated from the variability of 
the readings obtained for one compound at a particular concentration. 
Sources of variability in cell work are usually due to several factors. The first one is 
the variability in the number of cells which occurs during the seeding process. Other 
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reasons are the unwanted dilution of DNA/transfection reagent or the unwanted 
dilution of the compound solutions which can happen during washing and treatment 
of cells. Cell lysis is handled one by one, hence differences may affect the results. 
Finally, pipetting errors can occur during the application of the cell lysates on the 
measurement plates. One last source of variability is due to the cell response itself. 
Indeed, cells may respond differently depending on the time they have been 
maintained in culture and how they have been handled. It is important to bear these 
factors in mind when analysing the data. 
PPARalpha agonist 	 PPARgamma agonist 
71 	 20 
PPARdeita agonist 
Figure 42 Specific PPAR agonists used as positive controls 
The assays were carried out by Therese Rost under the supervision of Professor Rolf 
Berge at the Institute of Medicine, Bergen, in collaboration with Thia Medica AS. 
If there is PPAR activation, a high expression of Luciferase relative to the control is 
expected. A high activity relative to the control at low concentrations indicates good 
potency. The lower the concentration, the better the compound since this means that 
a small dose of compound would be enough to activate the PPARs. This would 
reduce any toxicity problems or side-effects. 
The preliminary PPAR activation results with lyso TTA-PC 34 and TTA-PG 36 are 
shown in Figure 43. 
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Figure 43 PPARa, ,wand O'activation results with lyso TTA-PC and TTA-PG 
In the case of PPARa, TTA's effect is more-or-less constant at the three different 
concentrations and close to the response induced by agonist WY14.643. Lyso TTA-
PC dose dependently increased the activity, upto two-fold increase over the specific 
agonist WY14.643 at 30 pM. TTA-PG increased PPARa more than lyso TTA-PC at 1 
and 10 ,uM. A lower concentration of TTA-PG was enough to achieve the same effect 
on PPARa compared to lyso TTA-PC. Overall, both new analogues activated PPARa 
better than TTA itself, and TTA-PG was a better activator than lyso TTA-PC. 
As can be expected, BRL49653 is a very potent agonist of PPAR7 and it leads to an 
increase of PPAR7 by three-fold relative to the control. The high variability in the 
response can be attributed to the factors previously discussed. The activation was 
dose-dependent with all the lipids and higher concentrations of 75 ,uM had to be used 
to obtain significant activity. Neither lyso TTA-PC nor TTA-PG seemed to increase 
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the activity compared to TTA. In general, the lipids were not found to be potent 
activators of PPARy. 
For PPARS, L165.041, the positive control, was found to increase PPAR5 activity by 
three-fold. Lyso TTA-PC and TTA-PG's effects on PPARS were comparable to that of 
TTA. 
If we consider the whole set of results, we can conclude that lyso TTA-PC and TTA-
PG activated the PPARs in the following order in human MCF-7 cells: a> 8> 7. 
3.4 Summary 
In order to improve the bioavailability of the PPAR activator, TTA 31, two novel lipid 
analogues, TTA-PC 32 and TTA-TAG 33, were synthesised as natural prodrugs. The 
release of the active compound, TTA, from the lipids is dependent on various 
hydrolytic enzymes present in the body: phospholipases Al, A2 and lipases. 
Preliminary in vivo experiments carried out with these two analogues showed an 
improvement in the beneficial effects in rats. In particular, the levels of plasma 
triacylglycerol, cholesterol and hepatic triacylglycerol levels were measured after 
treatment with the different compounds. TTA, TTA-PC and TTA-TAG showed a 
decrease in plasma triacylglycerol, cholesterol and hepatic triacylglycerol levels, with 
the largest decrease being affected by TTA-PC. Fatty acid oxidation and the activity 
of key mitochondrian enzymes involved in fatty acid oxidation and transport were also 
measured as these are very important dysfunctions in the metabolic syndrome and 
diabetes type II. Hence, the activities of fatty acid palmitoyl-CoA, carnitine palmitoyl 
transferase-II, 3-hydroxy-3-methylglutaryl-CoA synthase and fatty acyl-CoA were 
measured. In all cases, TTA and TTA-PC showed significant activity, whereas TTA-
TAG was slightly less effective in general. It must be highlighted that TTA-PC 
considerably improved the activity of the key enzymes by nearly two-fold compared to 
TTA. 
Having these promising results in hand, four further analogues were synthesised 
using enzymatic reactions. Starting from TTA-PC 32, phospholipase A2 afforded lyso 
TTA-PC 34 in a good yield of 70% while transphophatidylation with phospholipase D 
and serinol or glycerol yielded TTA-Pser 64 and TTA-PG 36 in good yields of 87% 
and 69% respectively. TTA-Choi 37 was obtained in 99% yield by the coupling 
between TTA 31 and cholesterol. The in vitro PPAR activation of the new lipid 
analogues was tested using a luciferase reporter gene assay at the Institute of 
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Medicine in Norway. Due to solubility and formulation issues, only lyso TTA-PC and 
TTA-PG could be tested in vitro. Preliminary results showed that both lyso TTA-PC 
and TTA-PG are promising compounds, displaying good activity relative to parent 
compound TTA. In human MCF-7 cells, the PPARs were activated in the following 
order by the two new lipids: a> 8> y. Their effects in vivo now need to be assessed. 
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4.1 Identification of leads by de novo design 
Novel heterocyclic leads were designed as potential PPAR duala/y agonists using a 
de novo approach developed by Prosarix Ltd, an in silico screening company based 
in Cambridge, UK. ProtoBuildTM  is proprietary software used to create novel drug-like 
chemical scaffolds and it provides an alternative method of developing lead-like hits. 
This technology offers the following advantages: 
• engineering of novel scaffolds using chemical features present in known active 
compounds; 
• better specificity than the screening of candidates; and 
• design of higher affinity-compounds compared to the screening of pre-existing 
catalogues. 
ProtoBuildTM is the only de novo design tool that incorporates a flexible binding site 
model, a pharmacophore-driven scaffold generation and a fast consensus scoring 
approach. It is outlined in Flowchart 1. 
1. Crystal structure 	2. Creation of active 
of known PPARysite and definition of 
agonist-PPAR 	 key starting 
complex studied fragments "seeds" 
3. Run ProtoBuildTM  
and build new 
IN•1+ molecules output 
highest scoring 
solutions 
4. Filter primary data 	5. Filter for 
way 	by affinity, cluster toxicity and 
into scaffold families 	ADME properties 
6. Select best 
scaffolds 
Flowchart 1 Prosarix Ltd's ProtobuildTM approach 
First of all, the crystal structure of a known dual PPARa/7 agonist GI262570 
complexed with PPARywas studied (Figure 44).199 Two main interactions were found 
to be important: a carboxylic acid moiety maps well into the H-bond donor site whilst 
an aromatic ring fits well into the main hydrophobic site. Analysis of this LBD and also 
of the LBD of PPARa enabled a hypothesis for a pharmacophore required to design 
dual agonists. The critical interactions with the LBDs were used to define the binding 
site for new structures' determination and this provides the starting "seeds" which are 
key fragments for the binding. Next, ProtoBuildTM  was used to build novel molecules 
which fit into the defined binding site, growing the molecules from the starting "seeds" 
into the pharmacophore features defined. This consists of doing separate 
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ProtoBuildTM runs (containing a library of 93 fragments to grow into the 
pharmacophore features). Ten separate runs were conducted and the resulting 
output molecules (about 1000 per run) were ranked for affinity and clustered into 
scaffold families. Next, they were filtered for toxicity substructures and ADME 
properties (e.g. Lipinski descriptors200) in order to choose the molecules with the best 
drug-like properties. ADME properties are very important in drug design as they give 
a preliminary indication on the absorption, distribution, metabolism and elimination of 
the drug in the body. Even if a compound is very potent, it may not become a drug if it 
suffers from poor ADME. The filters used included the molecular weight, the 
solubility, the number of hydrogen bond acceptors and donors and the calculated log 
octanol/water partition coefficient predictions (clogP which is a measure for the 
lipophilicity of a compound).201 The process resulted into two distinct drug-like 
chemical scaffolds as potential dual PPARa/ragonists. 
Figure 44 Structure of G1262570 
The first scaffold consists of an indole core with different aromatic groups, R1, on the 
2-position of the indole and an ethoxy propanoic side chain at the 5-position, with R2 
being a methyl or a trifluoro group (Figure 45). There is one chiral centre alpha to the 
carboxylic acid moiety. A racemic synthesis will be explored first to test for the activity 
of the indole leads. The screening study suggested the synthesis of molecules 38 to 
43, with R1 = H, phenyl and naphthylmethyl groups (Figure 46). Indoles 38 and 39 
would allow us to measure the importance of the aryl group for the binding to the 
receptor in the secondary hydrophobic site. 
OH 
Figure 45 Indole scaffold 
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The ProtoBuildTM runs show that the indole ring can be tolerated in the ligand binding 
domains of both PPARa and PPARy (Figure 47). The 2-naphthylmethyl group fits 
into the hydrophobic site at the entrance of the pocket; the indole ring fits into the 
main hydrophobic one while the carboxylic acid fits into the hydrogen bond donor 
site. As explained in Chapter 1, the ligand binding domains of PPARa and PPARy are 
similar in size, allowing such type of agonists to be developed. 
Figure 46 Indole leads 38 to 43 
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Figure 47 Proposed interaction of indole 42 with PPARy 
The objective is to synthesise these indole-core molecules and test their potential in 
vitro and in vivo as PPARa/7 dual agonists in the aim of developing new treatments 
for metabolic as well as neurological diseases. 
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4.2 Synthesis of the indole scaffold 
4.2.1. Indole scaffold: retrosynthesis and envisaged strategy 
The retrosynthesis envisaged for the indole leads is outlined in Figure 48. This 
convergent synthesis allows for the introduction of the aryl (R1) group on the 2-
position of the indole in the last step of the synthesis. Indeed, a linear strategy would 
be employed to prepare precursors 75 and 76 from para-nitrophenylpyruvic acid 77 
and in the meantime, the different carbonyl compounds 72 to 74 would be prepared, 
allowing a convergent Fischer Indole synthesis in the last step to give the six different 
indole targets 38 to 43. 
Scheme 18 illustrates the proposed forward enantioselective synthesis. Para-
nitrophenyl pyruvic acid 77 would have to be prepared first from para-
nitrophenylacetic acid 78 using a methodology developed by Wasserman et a/.202 The 
next step consists of a stereoselective reduction of the a-keto acid 77 into the 
corresponding a-hydroxy acid 80 using the following enzyme, staphylococcus 
epidermis ID-lactate dehydrogenase.203,204 The ethers 81 and 82 are to be 
synthesised using the corresponding halide and silver oxide.205 Reduction of the nitro 
group into the primary amine by hydrogenation over Pd/C would afford amines 78 
and 84 which will be converted into the corresponding hydrazines 75 and 76 using 
concentrated hydrochloric acid, sodium nitrite and tin(II) chloride.206 This reaction 
goes through the formation of the diazonium salt which is subsequently reduced into 
the hydrazine with tin(II) chloride. The final step consists of a Fischer Indole synthesis 
with carbonyl compounds 72-74 using zinc(II) chloride as catalyst.176 
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Figure 48 Retrosynthesis envisaged for the indole leads 
a) PPh3CHCN, EDCI, DMAP, dry DCM b) 1. 03, dry DCM 2. N2, THE/H20 c) Staphylococcus epidermis D-Iactate 
dehydrogenase d) Ag20, R21 e) Hz, Pd/C f) 1. NaNO2, conc. HCI 2. SnClz , g) ZnC12, EtOH, reflux 
Scheme 18 Proposed forward enantioselective synthesis of indoles 38-43 
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4.2.2. Synthesis of the indole leads: 1st synthetic approach 
A racemic synthetic approach to the indole products was first explored since this 
would allow us to optimise the key steps of the synthesis and still provide a 
compound that could be tested for its pharmaceutical activity. 
4.2.2.1. Racemic synthesis of the precursor to the Fischer indole synthesis 
In the case of the racemic synthesis, we adopted a slight change of strategy to 
synthesise ethers 81 and 82 in order to reduce the total number of synthetic steps. 
Thus, we chose to start the synthesis with iodination of commercially available para-
nitrophenyipropanoic acid 85 (Scheme 19).207208 Transformation of the resultant 
iodide 86 to the corresponding ethers 81 and 82 can be effected by treatment with 
potassium tertbutoxylate and ethanol or 2,2,2-trifluoroethanol respectively and the 
synthesis can be completed as proposed in Scheme 18. 
a) 1. LDA 2. 12 b) Ethanol or 2,2,2-trifluoroethanol, tBuOK 
Scheme 19 Proposed route to the racemic synthesis of precursors 81 and 82 
The synthesis began by iodinating acid 85 with two equivalents of lithium 
diisopropylamine and iodine in dry THF, under anhydrous conditions. To a solution of 
LDA in THF at -78 °C, was added starting material 85. The reaction mixture was 
allowed to warm up to room temperature and then added dropwise to a solution of 
iodine in THF at -78 °C. Initial experiments were carried out with commercially 
available LDA solution in heptane/THF/ethyl-benzene. The reaction was repeated 
with varying experimental conditions: the number of equivalents of LDA and the 
reaction time were increased. However, the reaction did not afford any product 86. 
The use of in situ synthesised LDA from freshly distilled diisopropylamine and n-BuLi 
did not yield any product either. 
In view of this lack of success, it was decided to synthesise ethers 81 and 82 from 
para-nitrophenylpyruvic acid 77 as for the enantioselective synthesis shown in 
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Scheme 18. Reduction of a-keto acid 72 into the racemate a-hydroxy acid 80 can be 
done using sodium borohydride in methanol. 
02N 02N 
OH 
para-nitrophenyl pyruvic acid 
	 80 
77 
a) NaBH4, Me0H 
Scheme 20 Reduction into a-hydroxy acid 80 using NaBH4 
The first step required preparation of para-nitrophenylpyruvic acid 77 from 
commercially available para-nitrophenyl acetic acid 78 (Scheme 21). Thus, acid 78 
was coupled to triphosphoranylidene acetonitrile 87, using EDCI as coupling agent 
and a catalytic amount of DMAP affording the new phosphorane 79 in 82% 
yield.202,209 Ozonolysis of phosphorane 79 in dry DCM at -78 °C, followed by 
quenching with THF/H20 yielded the desired product 77 with a yield of 60% on small 
scale reactions. 
b) 
 
OH 
 
02N 
 
para-nitrophenyl pyruvic acid 
77 
a) EDCI, DMAP, dry DCM, 0 °C to RT, 22 hr, 82% b) 1. 03, dry DCM, -78 °C, 20 min 2. N2, THF/H20, -78 °C to RT, 
24 hr, 60% 
Scheme 21 Synthesis of para-nitrophenyl pyruvic acid 77 
Cyano keto phosphoranes undergo ready oxidation to the highly electrophilic vicinal 
diketo nitrile 88, which can be trapped by reaction with nucleophiles to give transient 
cyanohydrin 89 (Scheme 22). These undergo facile elimination of HCN to form a-
keto acids, esters and amides. 
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Scheme 22 Mechanism of ozonolysis 
However, the purification of acid 77 proved tedious. Crystallisation was unsuccessful 
and chromatography on silica gel had to be employed. Hence, it was decided to 
synthesise methyl ester 90 by conducting the ozonolysis in DCM/methanol, in order 
to render the purification easier (Scheme 23). Furthermore, a protected ester moiety 
would be much easier to carry forward in the synthesis than a more reactive acid. 
 
CN 
a) 
 
OMe 
02N 
 
02N 
79 
  
90 
 
para-nitrophenylpyruvid methyl ester 
a) 1. 03, DCM/MeOH, -78 °C, 30 min 2. N2, -78 °C to RT, 16 hr, 35% 
Scheme 23 Synthesis of the methyl ester 90 
Indeed, the methyl ester 90 was easier to purify by chromatography, however the 
yield from the ozonolysis was less good (35% compared to 60%). Only the enol form 
was observed by NMR. This could be explained by the excellent delocalisation as 
shown in Figure 49. This observation is in accordance with similar reports in the 
literature.21°  
Figure 49 Stabilisation of the enol form by mesomeric effects 
In order to improve the overall synthesis of para-nitrophenylpyruvic methyl ester 90, 
solid phase chemistry was employed in the coupling reaction between para-
nitrophenylacetic acid 78 and triphosphoranylidene acetonitrile 87. This should help 
with the purification of the intermediate phosphorane 79. Different reaction conditions 
were tested employing EDCI and DMAP resins. The use of DMAP resin greatly 
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improved the ease of crystallisation of the phosphorane 79 and pure white crystals 
were obtained in an excellent yield of 94%. The reaction time of the ozonolysis step 
was also reduced slightly and purification of a-keto ester 90 was made easier by 
utilising a silver nitrate work up which decomposes any cyanohydrin 89 left. A yield of 
40% was obtained for the ozonolysis step. 
The reduction of a-keto ester 90 into the corresponding a-hydroxy ester 91 was 
carried out using sodium borohydride in methanol, affording the product in a yield of 
40% (Scheme 24).210,211,212 No diol 92 was obtained as observed in the literature.213 
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Scheme 24 Reduction into the a-hydroxy ester 91 
Efforts to improve the yield of the reduction consisted firstly of the use of solid phase 
chemistry and secondly, of a one-pot ozonolysis-reduction. Two different resins 
(polystyrylmethyl)trimethylammonium cyanoborohydride (resin 1) and (polystyryl-
methyl)trimethylammonium borohydride (resin 2) were tried but neither of them 
yielded the product in a satisfactory yield (Figure 50). Yields of less than 5% were 
obtained. 
Resin 1 
	 Resin 2 
Figure 50 Resins used for solid phase reductions 
In the case of the one pot ozonolysis-reduction (Scheme 25), one equivalent of 
sodium borohydride was added to the reaction mixture after the ozonolysis; however, 
a-hydroxy ester 91 was isolated in only 12% yield. 
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PPh3 
   
CN 1)  
 
 
2)  
02N 02N 	 79 
  
  
91 
a) 1. 03, DCM/MeOH 7:3, -78 °C, 30 min 2. N2, 3.5 hr b) NaBH4, -78 °C to RT, 3 hr, 12% 
Scheme 25 One pot ozonolysis-reduction 
It was therefore decided to proceed with the two steps consecutively, i.e. to isolate 
para-nitrophenylpyruvic methyl ester 90 and subsequently carry out the reduction. 
Experiments to optimise the yield of the reduction focussed on changing the following 
conditions: number of equivalents of NaBH4, the temperature of the reaction, and the 
order of addition of the starting material and NaBH4 to Me0H. Thus, the yield was 
greatly increased from 40 to 66% by adding 1.4 equivalents of sodium borohydride in 
one portion to the a-keto ester 90 in anhydrous methanol at 0 °C and allowing the 
reaction to stir at 0 °C for 2 hours. 
The proposed mechanism of the reduction is outlined in Scheme 26. The hydride 
atoms of sodium borohydride are displaced by the methoxy groups from methanol. 
The first step is a hydride transfer from the reducing agent to the carbonyl group. The 
oxyanion produced can help stabilise the electron-deficient BL3 molecule, giving rise 
to alkoxyborate intermediate 93, hydrolysis of which gives the a-hydroxy ester 91.210 
Scheme 26 Reaction mechanism for the reduction using NaBH4 
The next step was the synthesis of the ether using the corresponding halide and 
silver(I) oxide.205 This reaction was first modelled on a commercially available 
analogue, L-(-)-3-phenyllactic acid 94. The latter was refluxed with ethyl iodide and 
99 
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silver(I) oxide in dry DMF (Scheme 27). Silver(I) oxide weakens the C-I bond of ethyl 
iodide and leads to its fission. Silver(I) iodide thus precipitates, and the nucleophilic 
hydroxyl group of acid 94 reacts with the electrophile. Silver(I) hydroxide is produced 
and it forms a salt with the carboxylic acid. However, no product was obtained. The 
reaction was also unsuccessfully attempted in solvent free conditions. 
a) Ethyl iodide, Ag20, anhydrous DMF, reflux at 100 °C, 5 hr 
Scheme 27 Ether synthesis using silver oxide 
Next, the ether synthesis was attempted on the methyl ester 96, readily prepared 
from acid 94 in 76% yield, in order to avoid any side reactions associated with the 
acid moeity. 
a) Me0H, 	RT, 18 hr, 76% b) Ethyl iodide, Ag20, anhydrous DMF, 60-65 °C, 6 hr 
Scheme 28 Conversion into methyl ester 96, followed by the synthesis of ether 97 
A trace amount of product was observed (mass spectrometry, 1H NMR) but the yield 
could not be improved. One possible explanation for the poor success of this reaction 
could be due to loss of water from the ethoxypropanoate side-chain to give a fully 
conjugated system. It was therefore decided to attempt the ether formation through 
the synthesis of an acetal which would block prevent elimination of the alkoxy side 
chain, followed by opening of the acetal using a Grignard reagent as shown in 
Scheme 29.214'215 The starting material 94 was treated with acetaldehyde dimethyl 
acetal 98 and a catalytic amount of pyridinium p-toluene sulfonate using Dean Stark 
conditions. The crude product 99 was used directly in the second step where it was 
treated slowly with the Grignard reagent, tert-butylmagnesium chloride. However, 
NMR analysis of the crude did not reveal the presence of any product. 
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a) H+, anhydrous toluene, Dean Stark set-up, molecular sieves 4A, reflux, 3.5 hr b) t-BuMgCI, anhydrous ether, 
molecular sieves 4A, RT, 1 hr 
Scheme 29 Ether synthesis by opening the acetal 99 with a Grignard reagent 
Finally we decided to synthesise ether 81 using a basic alkylation procedure with 
sodium hydride and ethyl iodide as outlined in Scheme 30. The main concern with 
this step is that the a-hydroxy ester 91 is prone to elimination under the basic 
alkylation conditions. Moreover, the presence of the electron withdrawing nitro group 
in pars position would make the benzylic protons more acidic, further increasing the 
risk of elimination under basic conditions. 
a) NaH, ethyl iodide, anhydrous DMF, 80 °C, 19 hr 
Scheme 30 Ether synthesis using sodium hydride and ethyl iodide 
After the reaction was carried out on a-hydroxy ester 91 and purification of the crude, 
the presence of a broad doublet integrating for one proton at 2.98 ppm by 1H NMR in 
CDCI3 was observed. When the NMR was run in Me0D, this peak disappeared, 
confirming it was a hydroxyl group. The reaction had yielded the ethyl ester 100 as 
shown in Scheme 31. 
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a) NaH, ethyl iodide, anhydrous DMF, 80 °C, 19 hr, 34% 
Scheme 31 Transesterification observed 
The transesterification could be explained by the presence of traces of water in the 
solvent which could have reacted with sodium hydride to form sodium hydroxide in 
situ. The sodium hydroxide could have saponified the methyl ester to give the 
corresponding acid which would be susceptible to transesterification. The reaction 
was therefore repeated using rigorously dried, anhydrous DMF. In this case, the 
crude NMR indicated a complex mixture and no product could be identified or 
isolated after chromatography. The different side products possible could be due to 
deprotonation alpha to the carbonyl, followed by 0- and/or C-alkylation with ethyl 
iodide or deprotonation of the benzylic proton, followed by elimination. The use of a 
milder base such as sodium tert-butoxide or of phase transfer alkylation conditions 
might have been better conditions to investigate. Other alternatives could have 
included a Homer Wadsworth Emmons coupling from aldehyde 101 and 
phosphonoacetate 102, followed by reduction of the double bond or the insertion of a 
rhodium-generated carbenoid from diazo 103 into ethanol (Figure 51). 
02N 
OMe 
Figure 51 Other alternative routes for the synthesis of the ether 91 
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4.2.2.2. Hydrazine formation and Fischer indole synthesis 
In parallel to the above efforts, some preliminary work was conducted on the Fischer 
indole reaction of the synthesis. The proposed mechanism for the Fischer Indole 
synthesis is shown in Scheme 32. The mechanism involves a [3,3]-sigmatropic 
rearrangement of an ene hydrazine tautomer 104 to give intermediate 105 which 
spontaneously cyclises by loss of ammonia, probably via indoline 106. The reaction is 
driven forward by the loss of ammonia and the formation of an aromatic indole. 
Scheme 32 Mechanism for the Fischer Indole synthesis 
Initial model experiments were carried out on commercially available pare-
nitrophenylpropanoic acid 107 (Scheme 32). The first step was the preparation of the 
primary amine 108 by reduction of the nitro group by hydrogenation over Pd/C at 
room temperature over 15 hours. TLCs clearly indicated complete conversion of the 
starting material into the amine and the ninhydrin stain showed its presence by 
revealing a strong pink spot. Thus, amine 108 was afforded in an excellent yield of 
99%. 
The next step was to prepare hydrazine 109. This reaction proceeds through the 
formation of the diazonium salt which is next reduced into the hydrazine by tin(II) 
chloride.216,217,218 An NMR of the crude reaction in D20 revealed the presence of a 
complex mixture of products which proved difficult to purify or to identify any desired 
product 109. The strongly acidic conditions of the reaction lead to the formation of 
salts which makes it more difficult to purify the crude. 
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para-nitrophenyl propanoic acid 
b) 
  
OH 
 
H2NHN 
a) H2, Pd/C, RT, 15 hr, 99% b) 1. NaN0200 conc HCI, -5 °C, 30 min 2. SnCl2, conc HCI, 0 °C to RT, 3.5 hr 
Scheme 33 Synthesis of hydrazine 109 via formation of the diazonium salt 
It was decided to synthesise ethyl ester 110 from amine 108 first in order to render 
the purification of the hydrazine easier (Scheme 34). However, the hydrazine 
formation on ester 110 led to a complex mixture of products and the desired 
hydrazine 111 could not be isolated. 
a) Et0H,11+, RT, 21 hr, 30% b) b) 1. NaNO2(a0, conc HCI, -5 °C, 30 min 2. SnCl2, conc HCI, 0 °C to RT, 3.5 hr 
Scheme 34 Esterification of amine 96 
In further model studies, the Fischer Indole synthesis was attempted on the crude 
hydrazines 109 with octanal, with and without a Lewis acid catalyst (Scheme 35).219 
Both protic acids such as dilute sulphuric acid22° and acetic acid and a Lewis acid 
such as zinc chloride were employed. However, no indole product 112 was afforded 
in any of the various reactions attempted; complex mixtures were obtained, often 
giving a dark insoluble gum probably as a result of aldehyde polymerisation. 
a) Octane!, Fl+ , EtOH/H20 5:1, reflux, 14 hr 
Scheme 35 Fischer Indole synthesis with octanal 
At this stage, it was decided to attempt the synthesis of unsubstituted indole 113 
using the Fischer Indole synthesis and evaluate different reaction conditions 
(Scheme 36). 
104 
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a) H+, 65 °C, 3 hr b) EtOH/H20 5:1, 80 °C, 14 hr 
Scheme 36 Indole synthesis from phenyl hydrazine hydrochloride 
The first step was to prepare hydrazone 117 from commercially available phenyl 
hydrazine hydrochloride 114 and acetaldehyde 115 or acetaldehyde dimethyl acetal 
116. The acetal is sometimes preferred as it is easier to handle (not volatile like 
acetaldehyde) and also to avoid self-condensation. The conditions used for the 
preparation of the hydrazone 117 are summarised in Table 7.221  
Reagent Conditions Solvent 
Reaction 
time 
1 Acetal 35% aq. HCI, RT Me0H/H20 1:1 15 hours 
2 Acetal Drops of glacial AcOH, 70-80 °C EtOH 15 hours 
3 Acetaldehyde RT ACN/H20 1:1 1 hour 
4 Acetaldehyde 0.1% AcOH, RT ACN/H20 1:1 1 hour 
5 Acetaldehyde RT ACN/H20 1:1 15 hours 
6 Acetaldehyde 0.1% AcOH, RT ACN/H20 1:1 15 hours 
7 Acetaldehyde 1. RT 2. 40 °C d-CHCI3 5 hours 
8 Acetaldehyde 1. cat. BF3OEt2, RT 2. 40 °C d-CHCI3 5 hours 
Table 7 Different experimental conditions for the synthesis of the hydrazone 117 
The product was seen in reactions 2, 3 and 4 by mass spectrometry. However, all 
these reactions gave complicated mixtures by 1H-NMR. Unsubstituted hydrazones 
are very sensitive to oxidation and hydrolysis, making them difficult to handle in 
practice.222 The Fischer Indole synthesis was attempted on the crude hydrazone 117 
by refluxing the mixtures in ethanol/H20 5:1 with an acid catalyst. A few experiments 
were set up using the same catalysts as above, namely dilute sulphuric acid, acetic 
acid and zinc chloride. In all cases, a dark gum was obtained with no trace of indole 
product 113, probably due to polymerisation. 
We next decided to look at the Fischer Indole synthesis using substituted 
hydrazones. Benzylacetone 118 and phenyihydrazine hydrochloride 114 were 
employed to prepare hydrazone 119 (Scheme 37). The reaction was carried out in 
acetic acid at room temperature over one to two hours. 
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Cleaner TLCs were obtained from the hydrazone formation than in the case of 
unsubstituted hydrazone 117, however NMR analysis was still complicated by 
impurities and no desired product 119 could be isolated. The Fischer Indole synthesis 
with the same acid catalysts as above was attempted on a small scale on the crude 
hydrazone 119. However, a mixture of products was obtained, none of which 
corresponded to the desired indole product 120. 
  
 
Ph 
120 
a) AcOH, RT, 1-2 hr b) Et0H/H20 5:1, reflux, 15 hr 
Scheme 37 Fischer Indole synthesis on substituted hydrazone 119 
It is known that the Fischer Indole synthesis can be very difficult, often leading to a 
mixture of products in the case where unsymmetrical ketones are used.222 Indeed, 
two possible isomers of the hydrazone each lead to a different indole. For instance, 
with unsymmetrical ketone RCH2COCH3 121, the two possible isomers would lead to 
indole products 124 and 125 respectively (Scheme 38). 
HCI 
H2N,,... 
N H 
0 
+ 	R...„.........„.„...---....„...,  
121 114 
124 
a) AcOH, RT b) EtOH/H20 5:1, reflux 
Scheme 38 Regioselectivity of the cyclisation in the Fischer Indole synthesis 
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The regioselectivity issue makes this reaction difficult especially when the separation 
between the two different products is not facile. Many factors govern the direction of 
indolisation such as the size, strength and concentration of the Lewis acid, the 
alcoholic solvent and the temperature of the reaction.222 Migration from the 3-position 
to the 2-position can be performed in the presence of a Lewis acid such as aluminium 
chloride at high temperature (130-150 °C). 
In our synthesis, the different R groups are quite bulky (Figure 52) and we would 
expect that this would favour the formation of the desired product which is the 2-
substituted indole. 
Figure 52 Different R groups for the 2-position of the indole 
Given the failure of the indole synthesis from hydrazines and the difficulty to control 
the regioselectivity of the indolisation, we decided to focus on an alternate synthetic 
approach. 
4.2.3. Synthesis of the indole leads: rdsynthetic approach 
The second approach to our racemic indole targets is given in Figure 53. The 
important aspect of this approach is that a suitably aldehyde-functionalised indole 
128 provides an ideal template on which the aryl substituents and PPAR-binding 
carboxylic acid moiety can be built. This second strategy would also allow a 
convergent approach as the R1  substituents would only be introduced after having 
carried out the Homer Wadsworth Emmons (HWE) coupling. The proposed forward 
racemic synthesis for indoles 38 and 39 where R1 is a hydrogen atom is outlined in 
Scheme 39. Starting from commercially available indole-5-carboxaldehyde 128, a 
HWE coupling with the two different phosphonoacetates 129 and 130 respectively, 
would give the corresponding Z and E isomers 131-134. Reduction of the double 
bond can be carried out using magnesium turnings in dry methanol to afford 
precursors 126 and 127. An asymmetric hydrogenation using a chiral rhodium-based 
catalyst could be used in the enantioselective synthesis. Finally, saponification of the 
ethyl ester would give the first two indole targets 38 and 39. 
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Figure 53 2nd retrosynthetic analysis of the indole leads 
a) NaH, dry THF, 0 °C to RT b) Mg, dry Me0H c) KOH, EtOH/H20, reflux 
Scheme 39 Forward racemic synthesis for indoles 38 and 39 (Ri = H) 
For indoles i l 40 to 43, where R1 is an aromatic group, the first two steps would be 
similar to the synthesis of targets 38 and 39 (Scheme 40). Then, the nitrogen of the 
indoles 135 and 136 would have to be protected using a benzenesulfonyl group for 
instance, followed by selective arylation on the 2-position of the indole to yield 
precursors 135-136.223 The final step requires saponification of the ester and 
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deprotection of the benzenesulfonyl group in basic hydrolysis conditions to give the 
final indole targets 40 to 43. 
a) Phosphonoacetate, NaH, dry THF, 0 °C to RT b) Mg, dry IVIe0H c) 1. NaH, DMSO, 0 °C, 1 hr 2. PhS02C1 in THF, 0 
°C to RT d) 1. LDA, -78 °C to 0 °C, 5 min 2. R1l3r, -78 °C to RT, 12 hr e) KOH0q), heat to 100 °C 
Scheme 40 Proposed forward synthesis for indoles 40-43 (Ri # H) 
Phosphonoacetate 129 can be synthesised from commercially available 2-chloro-2-
ethoxyacetic ester 141224 whereas phosphonoacetate 130 can be prepared from 
triethyl phosphonodiazoacetate 142 (Figure 54).225,226 
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Figure 54 Retrosynthesis of the different phosphonoacetates 129 and 130 
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4.2.3.1. Preliminary research on the 2nd synthetic approach 
A number of model studies were carried out in order to test the major steps in this 
route. It was crucial to investigate the HWE coupling and test the feasibility of a 
convergent synthesis. The latter would be done by testing for any side reactions on 
the ethoxy ethylpropanoate side chain of compound 135 with the conditions required 
for the introduction of an aryl group on the 2-position of the indole. Before this could 
be done, we also had to also establish the ideal indole arylation conditions. 
First of all, the HWE coupling reagents were prepared. For R2 being a methyl group, 
triethylphosphite 143 and commercially available 2-chloro-2-ethoxyacetic acid 141 
were coupled using Arbuzov chemistry as described by Grell et al (Scheme 41).224 
This reaction proceeded smoothly, phosphonoacetate 129 was obtained in a 
quantitative yield of 92% and used without any purification. 
2-chloro-2-ethoxyacetic 
ethyl ester 
141 
a) Anhydrous DMF, reflux at 150 °C, 15 hr, 92% 
Scheme 41 Preparation of the phosphonoacetate 129 
The synthesis of the 2,2,2-trifluoro phosphonoacetate 130 is shown in Scheme 42. 
Tosyl azide 146 which is the diazo transfer reagent was first prepared by coupling 
sodium azide 144 and tosyl chloride 145.227 The diazo intermediate 142 was next 
synthesised from tosyl azide 146 and phosphonoacetate 147 using sodium hydride in 
dry THE  225,228  Finally, rhodium(II) acetate dimer was used to generate a carbenoid 
from the diazo compound 142 which was inserted into the 0-H bond of 2,2,2-
trifluoroethanol, as described by Haigh et a/.226  
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a) EtOH, acetone, RT, 23 hr, 96% b) NaH, dry THF, 0 °C to RT, 5 hr, 70% c) 2,2,2-trifluoroethanol, [Rh(OAc)212, 
benzene, reflux, 63% 
Scheme 42 Synthesis of 2,2,2-trifluorophosphonoacetate 130 
Having the two phosphonoacetates in hand, the HWE coupling was tested using 
commercially available benzaldehyde 148 and phosphonoacetate 129 as shown in 
Scheme 43. Briefly, sodium hydride was slowly added to a cooled solution of the 
phosphonoacetate 129 before dropwise addition of benzaldehyde 148.229'23° After 
aqueous work up to remove the phosphate by-product, chromatography on silica gel 
yielded the Z and E isomers 149 and 150 in a 58% yield (Ratio ZIE = 86:14). 
a) NaH, anhydrous THF, 0 °C to RT, 16 hr, 58% 
Scheme 43 HWE coupling 
The mechanism of the HWE coupling is outlined in Scheme 44. Sodium hydride first 
deprotonates the hydrogen alpha to the ester of phosphonoacetate 129 (pKa about 
10), the nucleophilic ylid 151 generated attacks the electrophilic carbonyl group of 
benzaldehyde 148 to form oxaphosphetanes 152-153. The latter is subsequently 
cleaved to give the alkenes 154-155 and a phosphate byproduct 156 which is easily 
removed by aqueous work up. The ratio of olefin isomers depends on the 
stereochemical outcome of the initial addition. 
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Scheme 44 Mechanism of the HWE coupling 
The selective reduction of the double bond can be carried out with magnesium 
turnings in dry methanol. A test reaction on alkene '149 proceeded smoothly as 
described by Lohray et al.229 A mixture of methyl ester 157 and ethyl ester 158 was 
obtained due to transesterification (Scheme 45). The products were isolated in a 
yield of 83% (ratio of methyl ester 157 to ethyl ester 158 = 57:43). The complete 
conversion to the methyl ester can be achieved by increasing the reaction time. 
a) Mg turnings, anhydrous Me0H, RT, 1 hr, 83% 
Scheme 45 Reduction of the double bong using magnesium 
4.2.3.2. Synthesis of indole targets 38 and 39 
Having tested the HWE coupling and magnesium reduction conditions, indole leads 
38 and 39 were next synthesised. Scheme 46 shows the synthesis of indole lead 38. 
Starting from commercially available indole-5-carboxaldehyde 128, the HWE coupling 
was optimised using 2.2 eq of NaH and 2.0 eq of phosphonoacetate 129. After 
purification, the Z and E isomers 131 and 132 were isolated in a ratio of 63:37 with an 
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overall yield of 93%. The reduction of the double bond proceeded smoothly at room 
temperature and the methyl ester 126 was isolated with a yield of 83%. Finally, 
saponification of the methyl ester with potassium hydroxide in a 1:1 mixture of 
ethanol/water gave the desired target 38 in a 92% yield.231  
a) NaH, dry THF, 0 °C to RT, 93% b) Mg turnings, dry Me0H, RT, 83% c) KOH, Et0H/H20, reflux, 92% 
Scheme 46 Synthesis of indole lead 38 
The synthesis of indole lead 39 was conducted in a similar fashion (Figure 48). 
Indole-5-carboxaldehyde 128 was coupled with the 2,2,2-trifluoro phosphonoacetate 
130 to yield the Z and E isomers 133 and 134 in a 99% overall yield. The last two 
steps were carried out as for indole 38. After the reduction of the double bond, indole 
precursor 127 was isolated in a 60% yield. The second indole lead 39 was isolated 
with a yield of 93% after saponification. 
One concern about indoles 126 and 127 was the risk of elimination of the ethoxy 
side-chain to yield a fully conjugated system with the aromatic indole heterocycle. 
NMR analysis of the crude after the reduction of the double bond revealed only a 
trace amount of elimination (< 4-5%) compared to the yield of the desired products 
126 and 127 (between 60 and 83%). 
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a) NaH, dry THF, 0 °C to RT, 99% b) Mg turnings, dry Me0H, RT, 60% c) KOH, Et0H/H20, reflux, 93% 
Scheme 47 Synthesis of indole lead 39 
4.2.3.3. Feasibility of convergent synthesis 
For the preparation of the 2-aryl indole products 40 to 43, it was necessary to 
investigate the introduction of the R1 group on the 2-position of the indole. The 3-
position is the most reactive on an indole ring and is the most prone to electrophilic 
substitution. Indeed, the energy of activation of intermediate 159 is lowered because 
it is possible to delocalise the positive charge through resonance involving the 
nitrogen lone pair of electrons. This is not possible on the C2 position. Any attempt to 
delocalise the positive charge would disrupt the 6rr-electron system of the benzene 
ring ( 
Scheme 48). 
Scheme 48 Electrophilic substitution on an indole ring 
In order to achieve C2 substitution, lithiation is used as it is selective for this position 
due to the influence of the nitrogen atom. For syntheses requiring N-unsubstituted 
114 
Yushma BHURRUTH 	 Chapter 4 
indoles, N-protecting groups are required. The benzenesulfonyl group was chosen as 
it allows chelation of lithium to the oxygen of the benzenesulfonyl group and 
enhances substitution on the C2 position (Figure 55). The lithiated intermediate, 
without isolation, can be reacted with an electrophile. 
Figure 55 C2 lithiation 
It was decided to find the optimum arylation conditions on 1-benzenesulfonyl indole 
160. Thus, the protection of commercially available indole 113 with the 
benzenesulfonyl group was carried out using sodium hydride, DMSO and 
benzenesulfonyl chloride in THF at room temperature (Scheme 49).223 Product 160 
was obtained in a 72% yield after crystallisation from ethanol. A second procedure 
using a phase transfer catalyst was also used.232 In this case, crystallisation from 
ethanol afforded the product 160 in a yield of 88%. 
a) OR b) 
 
H 
o=-. 160 
Ph 
/ -----0 
a) 1. NaH, DMSO, 0 °C, 1 hr 2. PhS02C1 in THF, 0 °C to RT, 72% 
OR b) 1. NaOH 50%(aq), H2O, toluene, tetrabutylammonium bromide 2. PhS02C1 in toluene, RT, 88% 
Scheme 49 Protection of indole 113 with a benzenesulfonyl group 
A number of bases were used for the lithiation step including LDA, n-BuLi and t-BuLi. 
Since one of the required R1 groups (Figure 46) is a benzyl group, a model 
benzylation procedure was carried out on indole 160 using commercially available 
lithium diisopropylamide (LDA) in THF/heptane/ethyl benzene, 2.0M (Scheme 50), 
adapted from lwanowicz et al. and Wenkert et .91.223'233 However, no product 161 was 
isolated at all. LDA was therefore prepared in situ from n-BuLi and freshly distilled 
diisopropylamine and immediately used for the benzylation reaction under the same 
conditions, but still no product 161 was obtained. 
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I 
160 
Ph 
a) 1. LDA, -78 °C to 0 °C, 5 min 2. PhCH2Br, -78 °C to RT, 12 hr 
Scheme 50 Benzylation on the 2-position of the indole 160 using LDA 
Quenching the reaction with Me0D proved that deprotonation of the proton at the 2-
position of indole was successful as deuterated indole 162 was seen by NMR 
(Scheme 51). 
a) b) 
0-=S--, 160 
Ph 
  
162 
Ph 
a) LDA, anhydrous THF, -78 °C to 0 °C, 2.5 hr b) Me0D, 0 °C, 1 hr, RT, 1 hr 
Scheme 51 Deprotonation with LDA and quenching with Me0D 
It was therefore decided to convert the bromide of benzyl bromide into an iodide 
which is a better leaving group. Benzyl iodide 164 was made from benzyl bromide 
163 using the Finkelstein halogen exchange reaction using sodium iodide and 
acetone (Scheme 52).234 The equilibrium is driven to the right as NaBr formed is 
insoluble in acetone. This reaction proceeded smoothly and the product obtained was 
pure by NMR. However, the use of the more reactive benzyl iodide 163 still afforded 
no detectable product 161 in the benzylation reaction. 
+ Nal 
 
+ NaBr 
 
163 
	 164 
Scheme 52 Synthesis of benzyl iodide 164 by Finkeilstein halogen exchange 
The reaction was next tried with n-BULL235'236 Protected indole 160 was added to a 
solution of n-BuLi in a mixture of anhydrous ether and THF at -50 °C, under nitrogen. 
Benzyl bromide was added after one hour and the reaction mixture was slowly 
allowed to warm up to RT. After work up and chromatography, a small amount of 
product (21%) was isolated. 
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In an effort to improve the yield, it was decided to attempt the benzylation with t-BuLi 
as described by Hassan et a/.237 The conditions described herein were unsuccessful 
in our hands. The conditions were then adapted from a method described by 
Sundberg et al. (Scheme 53).238 The reaction was optimised as follows: to the indole 
160 in dry THE at -45 °C, was added t-BuLi dropwise. The solution turned yellow, 
then deep orange. After 50 minutes, benzyl bromide was added dropwise and the 
reaction mixture was allowed to warm up to room temperature over 16 hours. 
Chromatography on silica gel yielded 58% of product 161. Hassan et a/. reported the 
benzylic protons in 1H NMR as a doublet (5.67 ppm and 4.24 ppm with a coupling 
constant of 14.1 Hz), yet we observed a singlet integrating for two protons at 4.27 
ppm. Also, the chemical shift of the benzylic carbon was reported at 53.26 ppm in 
13C NMR whereas we observed a chemical shift of 35.22 ppm.237 
a) Li b) 
   
°=-,---0 160 
Phi  
   
  
Ph 
  
a) t-BuLi, -45 to -40 °C, 50 min b) PhCH2Br, -45 °C to RT, 16 hr, 58% 
Scheme 53 Benzylation of indole 160 using t-BuLi 
The position of the benzyl group on C2 was confirmed by NMR after deprotecting the 
benzenesulfonyl group by refluxing with NaOH 2M and methanol at 110 °C (Scheme 
54), furnishing indole product 165 in a 91% yield after chromatography.238  The NMR 
spectrum was in accordance with the literature.239'240 
a) 
 
 
165 
a) NaOH 2M/MeOH, reflux at 110 °C, 91% 
Scheme 54 Hydrolysis of benzenesulfonyl group of indole 161 
Once the benzylation conditions were optimised, the feasibility of the convergent 
synthesis shown in Scheme 40 (page 109) was investigated. The main concern was 
whether the ethoxy ethylpropanoate side chain would be stable to the arylation 
conditions. It was important to attempt the reaction on the following indole derivative 
135 to evaluate the competition between the two reactive sites: the 2-position of the 
indole and the ethoxy ethylpropanoate side chain. Indole derivative 126, previously 
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synthesised (Scheme 46), was protected using the phase transfer conditions to give 
compound 135. The yield was of only 47% as some of the methyl ester had been 
saponified under the basic conditions of the reaction. One important consideration 
when using indole intermediate 135 is that it has a few acidic protons and an alkoxy 
group which could be a good leaving group. All this could lead to different side-
products. One possibility is the formation of the lithium enolate of the ester which 
would lead to the introduction of the benzyl group on the carbon alpha to the carbonyl 
group. Another possibility could be the abstraction of the proton in the benzylic 
position, followed by elimination of the alkoxy group to give a fully conjugated system. 
Indeed, when indole 135 was subjected to the benzylation conditions, a mixture of 
side-products but no desired product 137 was obtained (Scheme 55). 
a) 1. NaOH 50%(aq), H2O, nBu4NBr, toluene 2. PhS02C1 in toluene, RT, 47% 
b) 1. t-BuLi, -45 °C, 55 min 2. BnBr, -45 °C to RT, 15 hr 
Scheme 55 Feasibility of convergent synthesis with indole 135 
It was decided to attempt the benzylation on intermediate 166 which was first made 
by protecting previously synthesised indole intermediate 131 (Scheme 46). 
Compound 166 isolated in an 89% yield, was subsequently treated with the 
benzylation conditions (Scheme 56). 
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OEt 
CH3 
131 
OEt 0E1 
CH3 
a) 
CH3 
a) 1. NaOH 50%(aq), H2O, nBu4NBr, toluene 2. PhS02C1 in toluene, RT, 89% 
b) 1. t-BuLi, -45 °C, 55 min 2. BnBr, -45 °C to RT, 15 hr 
Scheme 56 Competition between reactive sites of indole 166 under arylation conditions 
A number of different conditions were tried, as summarised in Table 8. Only entry 1 
gave a trace amount of the desired compound. A mixture of side-products indicating 
that side-reactions had occurred preferentially on the ethoxy ethylpropanoate side 
chain was seen by proton NMR. 
Reagents Results 
1 n-BuLi, dry ether, BnBr, -50 °C to RT Trace amount of product 
2 LDA, dry ether/THF, BnBr, -78 °C to RT No product 
3 t-BuLi, dry THF, BnBr, -45 °C to RT No product 
Table 8 Arylation attempts on indole derivative 166 
In order to favour the reaction at the 2-position of the indole, a bromo group was 
introduced at this position to yield bromoindole 168 which was subsequently 
subjected to lithiation and benzylation. A number of bromination conditions tested on 
indole analogue 160 are summarised in Table 9 (Scheme 57).241  
a) Br 
  
a) 1. Strong base 2. Br2 or BrCN 
Scheme 57 Bromination of indole 160 
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Reagents Conditions Results 
1 t-BuLi, Br2 Dropwise addition of base at -60 °C 
25% product, 71% starting 
material 
2 t-BuLi, BrCN Dropwise addition of base at -50 °C 
Very messy reaction, product 
25%, no starting material 
3 t-BuLi, BrCN 
Dropwise addition of base at -55 °C 
Slight change in the temperatures 
Only starting material 
4 t-BuLi, BrCN 
Dropwise addition of base at -55 °C 
Slight change in the temperatures 
Only starting material 
5 LDA, BrCN Commercially available LDA used Only starting material 
6 LDA, BrCN LDA prepared in situ Clean reaction, 57% product 
Table 9 Bromination attempts 
The LDA conditions with cyanogen bromide gave the desired 2-bromo compound 168 
in the best yield and the reaction proceeded cleanly (entry 6). The benzylation was 
attempted on the bromo derivative as shown in Table 10. However, no desired 
product was obtained at all. All of the reactions yielded back indole starting material 
160 with no bromo group. 
Reagents Conditions 
1 t-BuLi, BnBr Dropwise addition of base at -65 °C, BnBr added at -55 °C 
2 t-BuLi, BnBr, TBAI Dropwise addition of base to a mixture of SM, BnBr, TBAI at -60 °C 
3 LDA, BnBr 142 SM added to commercially available base at -78 °C 
4 LDA, BnBr 242 SM added to LDA prepared in situ at -78 °C 
Table 10 Benzylation attempts on the bromo derivative 168 
Scheme 58 Benzylation on the bromo derivative 168 
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Next, it was decided to use a Negishi coupling by making the zinc intermediate by 
transmetallation from the lithiated indole (Table 11).243 The introduction of a benzyl 
group was successful but gave a poor yield (entry 1). When the reaction was 
transposed to the cyano indole (entry 2), only a trace amount of product was 
obtained. Interestingly, the following side product was isolated (Figure 56), indicating 
a side-reaction on the cyano group. After thorough analysis of the reaction conditions, 
it was found that an excess of n-BuLi had been used by mistake for the in situ 
preparation of LDA in this case. The excess n-BuLi had reacted with the cyano group 
to yield side-product 169. 
Starting material Reagents and conditions Results 
1 
/ 
N 
PhO,S
/ 
 
®
1. LDA, TBAI, THF, sieves 4A, -78 °C to 0 °C 
2. ZnCl2, -78 °C to RT 
3. BnBr, Pd(PPh3)4, RT, then reflux 70 °C 
16% product 
2 
/ 
N  
pho2s 
la 
CN 1. LDA, TBAI, THF, sieves 4A, -78 °C to 0 °C  
2. ZnCl2, -78 °C to RT 
3. BnBr, Pd(PPh3)4, RT, then reflux 70 °C 
Trace amount 
product 
Table 11 Arylation conditions through transmetallation using Zn 
PhO2S 
Figure 56 Side-product 169 isolated in entry 2 of Table 11 
Having had no success with any of these conditions, the introduction of R2 would 
have to be carried out before introducing the ethoxy ethylpropanoate side chain. This 
means that it will not be possible to carry out a convergent synthesis of the indole 
targets using this synthetic strategy and a less economic linear strategy would have 
to be followed. 
The following route was chosen for the synthesis of the indole leads (Scheme 59). 
Starting from commercially available indole-5-carboxaldehyde 128, the first step is to 
protect the nitrogen of the indole with a benzenesulfonyl group. The next step is 
protect the aldehyde 170 in the form of an acetal and introduce the appropriate R1 
groups on the 2-position of the indole. The benzenesulfonyl group would have to be 
cleaved before carrying out the HWE coupling. Indeed, some side reactions were 
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observed on the protecting group when a test reaction was carried on 1-
benzenesulfonyl-5-indole carboxaldehyde 170 (Figure 57). After carrying out the 
Homer Wadsworth Emmons (HWE) coupling with the two different 
phosphonoacetates 129 and 130 respectively, the double bond of compounds 179 to 
186 would be selectively reduced using magnesium turnings. The final step is 
saponification of the ester to yield indoles 40 to 43. 
a) 1. NaOH 50%(,,,,,, H2O, (nBu)4NBr, toluene 2. PhS02C1 in toluene, RT b) Ethylene glycol, cat. p-Ts0H, benzene, 
Dean Stark reflux c) 1. t-BuLi, -45 °C, 55 min 2. R1l3r, -45 °C, RT, 12 hr d) Na0H(am, heat to 100 °C e) W, H2O f) NaH, 
dry THF, 0 °C to RT g) Mg turnings, dry Me0H, RT, 1 hr h) KOH(30 reflux 
Scheme 59 Route chosen for the synthesis of the indole leads 
CHO 
Figure 57 1-(phenylsulfonyI)-1H-indole-5-carbaldehyde 
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4.2.3.4. Synthesis of indole leads 40 and 41 
The synthesis of indole target 40 (Figure 58) was therefore started using the route 
described above (Scheme 59). 
OH 
Figure 58 Indole lead 40 
5-Indole carboxaldehyde 128 was protected with a benzenesulfonyl group using 
NaOH, H2O, (nBu)4NBr and phenylsulfonyl chloride in toluene.232 Purification by 
chromatography on silica gel yielded the desired product 170. The acetalisation was 
first carried out with ethylene glycol and a catalytic amount of para-toluenesulfonic 
acid in toluene.244 The reaction mixture was refluxed using a Dean Stark apparatus 
and a dark insoluble gum was obtained. The reaction was therefore repeated using 
benzene as solvent. In this case, the reaction proceeded smoothly and an NMR of 
the crude showed the presence of acetal 172 and a tiny amount of starting material 
170 which was removed by treatment with tosyl hydrazine resin in DCM. The product 
was obtained in a 99% yield. Due to the sensitivity of the indole to light, both 
protecting steps were conducted in the dark. 
The acetal 172 was benzylated using the optimised conditions with t-BuLi and benzyl 
bromide described in Scheme 53. The benzylation reaction was successful, however 
1H NMR of the crude reaction mixture indicated that cleavage of the acetal had 
occurred. This was confirmed after isolation of aldehyde 191 after chromatography. 
This might have occurred due to a slightly acidic work up which had been carried out 
after the benzylation step in order to neutralise the excess base. The purification by 
chromatography proved to be quite tedious and a yield of 28% was obtained for 
aldehyde 191 (Scheme 60). 
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a) 
 
a) 1. t-BuLi, dry THF, -45 °C 2. BnBr, -45 °C to RT, 28% 
Scheme 60 Benzylation of acetal 172 
Aldehyde 191 was subjected to the basic hydrolysis of the benzenesulfonyl group 
(Scheme 61). Indole 177 was isolated, after work up and chromatography, in a yield 
of 39%. 
CHO 
a) 
CHO 
   
  
177 
 
a) Me0H/NaOH 2M 5:1, reflux at 110 °C, 39% 
Scheme 61 Hydrolysis of benzenesulfonyl group of indole 191 
An alternate route was investigated in order to synthesise indole intermediate 177 in 
a better overall yield (Scheme 62). 
c) 
CN 
d) 
	-N.- 	R1 
CHO 
   
H 
 
 
H 
   
196 Ri  = benzyl 
	 177 R1  = benzyl 
197 R1  = naphthylmethyl 
	 178 R1  = naphthylmethyl 
a) 1. NaOH 50%(2q), H2O, (nBu)4NBr, toluene 2. PhS02C1 in toluene, RT b) 1. t-BuLi, -45 °C, 55 min 2. R1Br, 
-45 °C to RT, 12 hr c) NaOH,0q)  heat to 100 °C d) DIBAL, dry THF, RT 
Scheme 62 3rd alternate route towards indole aldehyde precursors 177 and 178 
Commercially available 5-cyanoindole 192 was first protected with a benzenesulfonyl 
group under phase transfer conditions.232 The protected indole product 193 was 
purified by crystallisation from ethanol in a 96% yield. The next step was the 
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benzylation using t-BuLi and benzyl bromide as previously described. 
Chromatography on silica gel gave the desired 2-benzyl indole 194 in a yield of 51%. 
The product 194 was re-crystallised from hexane/DCM 20:1. NOE difference 
experiments were carried out in order to prove the presence of the benzyl group on 
the 2-position of the indole. Irradiation of the benzylic protons H5' at 4.36 ppm 
showed strong interactions with protons H7' and H3 and a milder interaction with H2'. 
Importantly, no interaction of H5' was seen with indole proton H4. Irradiation of the 
indole proton H3 at 6.13 ppm gave a strong signal with the indole proton H4, and 
interactions with aromatic protons H7' as well as a reciprocal interaction with benzylic 
protons H5'. This indicates that the benzyl group is on the 2-position of the indole. 
Figure 59 Structure of 2-benzyl indole 194 
The presence of the benzyl group on the 2-position of the indole was confirmed by 
crystal structures conducted by Dr Andrew White from the crystallography service, 
Imperial College London. The full tables of crystallographic data are included in the 
appendix. 
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Figure 60 Crystal structure of 2-benzyl indole 194 
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The benzenesulfonyl group was next hydrolysed under basic conditions by refluxing 
with aqueous sodium hydroxide 2M and methanol. After work up and column 
chromatography, indole 196 was isolated in a yield of 99%.238 It was subsequently 
reduced to the corresponding aldehyde 177 using diisobutyl aluminium hydride 
(DIBAL). The cyanide 196 was treated slowly with DIBAL in anhydrous THF at RT 
and the desired aldehyde 177 was obtained in a 59% yield after acidic work-up and 
chromatographic purification.245  Efforts to improve the yield of the DIBAL reduction 
consisted in attempting different experimental conditions with three different DIBAL 
solutions in the following three solvents: toluene, THF and DCM. The DIBAL 
reduction was optimised in dry DCM, followed by a Rochelle salt work up which 
afforded aldehyde 177 in 80% yield.246  
A comparison of routes A and B towards indole 177 is shown in Scheme 64. 
Although both routes required the same number of synthetic steps, route B afforded a 
better overall yield (39% versus 9%) and rendered purification and isolation of the 
intermediate products easier. It was therefore validated for the synthesis of indole 
targets 40 to 43. 
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Route A yields: 1 a) 81%, 1 b) 99%, 1c) 28%, 1d) 39%, Route B yields: 2a) 96%, 2b) 51%, 2c) 99%, 2d) 80% 
Scheme 63 Comparison between routes A and B 
The overall synthesis of indole target 40, using route B, is shown in Scheme 64. 
Continuing the synthesis towards indole analogue 40, HWE coupling with 
phosphonoacetate 129 was performed on aldehyde 177. The conditions were 
optimised with 1.80 eq of phosphonoacetate 129 and 2.2 eq of NaH. After an 
aqueous work up was carried out, chromatography on silica gel yielded the desired Z 
and E isomers 179 and 180 in a ratio of 63:37 in an excellent overall yield of 90%. 
After the selective reduction of the double bond of intermediate 187 using magnesium 
turnings in a 76% yield, saponification of the methyl ester yielded indole 40 in a 93% 
yield. 
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a) b) 
CN 
CN 
CN 
0 	0 
II 
Et0 
Et0 
0 
129 
CH3 
e) 
OEt f) OMe 
179-180 CH3 
OH 
g) 
a) 1. n-C4H9NBr, Na01-100 toluene, H2O 2. PhS02C1, RT, 96% b) 1. t-BuLi, -45 °C, 55 min 2. BnBr, -45 °C to RT, 15 
hr 51% c) Na01-10q), Me0H 99% d) DIBAL, dry DCM, 80% e) NaH, dry THF, 0 °C to RT, 90% f) Mg turnings, dry 
Me0H, RT, 76% g) KOH, EtOH/H20, reflux, 93% 
Scheme 64 Synthesis of indole lead 40 
For the preparation of indole lead 41, 2-benzyl aldehyde 177 was coupled with 2,2,2-
trifluorophosphonoacetate 130, affording the Z and E isomers 181 and 182 in a yield 
of 85%. Finally, reduction and saponification proceeded smoothly to give the final 
compound in a yield of 73% over the two steps. 
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a) NaH, dry THF, 0 °C to RT, 85% b) Mg turnings, dry Me0H, RT, 73% c) KOH, Et0H/H20, reflux, 99% 
Scheme 65 Synthesis of indole lead 41 
4.2.3.5. Synthesis of indole leads 42 and 43 
In the case of indole leads 42 and 43, a naphthylmethyl group is found on the 2-
position of the indole. The overall synthesis of indole 42, shown in Scheme 66, was 
carried out similarly to that of indole target 40. The introduction of the naphthylmethyl 
group was again found to be successful with the t-BuLi conditions albeit with a lower 
yield than in the case of the benzyl group. Different conditions were attempted in an 
unsuccessful effort to improve the yield (Table 12). One of the main side-products 
obtained in most cases was found to be indole 198, Figure 61. This is thought to be 
due to the hydrolysis of the benzenesulfonyl group due to the basic conditions of the 
reaction. In order to try to minimise the formation of this side-product, a BOC 
protecting group was used instead of a benzenesulfonyl group, yielding indole 171 
and the introduction of the naphthylmethyl group was then attempted on it (Figure 
62).247 Yet, this did not improve the yield of the reaction. Also, 2-
(bromomethyl)naphthalene was converted into the more reactive iodo analogue 225 
(Naphl)248 using a Finkelstein exchange as described earlier (Scheme 52, page 116). 
This did not improve the yield of the reaction (entries 12 and 13). Entry 7 with the t-
BuLi conditions gave the product in the best yield. 
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Reagents Results 
1 1. n-BuLi, dry ether, -50 °C 2. NaphBr, -50 °C to RT 
SM, trace amount 
of product 
2 1. LDA, dry THF, -78 °C 2. NaphBr, -78 °C to R-12" SM, some product 
3 1. t-BuLi, dry THF, -60 °C 2. NaphBr, -60 °C to RT SM, some product 
4 1. t-BuLi, dry THF, -65 °C 2. NaphBr, -60 °C to RT SM, some product 
5 1. t-BuLi, dry THF, -78 °C 2. NaphBr, -78 °C to RT250 
SM (14%), product 
(21%) 
6 1. t-BuLi, dry THF, -78 °C, 10 min 2. NaphBr, -78 °C to RT 
SM (60%), product 
(23%) 
7 1. t-BuLi, dry THF, -45 °C, 50 min 2. NaphBr, -45 °C to RT SM, product (30%) 
8 1. t-BuLi, dry THF, -100 °C, 10 min 2. NaphBr, -70 °C to RT SM, product (19%) 
9 1. t-BuLi, dry THF, <-100 °C, 10 min 2. NaphBr, -100 °C to RT 
SM, trace amount 
of product 
10 
1. LDA, THF, sieves 4A, -78 °C to 0 °C 2. ZnCl2, -78 °C to 
-15 °C 3. NaphBr, -30 °C to RT 
SM only, no product 
11 
1. LDA, TBAI, THF, sieves 4A, -78 °C to 0 °C 2. ZnCl2, -78 °C to 
RT 3. NaphBr, Pd(PPh3)4, RT, then reflux 70 °C 
SM recovered, no 
product 
12 
1. LDA, THF, sieves 4A, -78 °C to 0 °C 2. ZnCl2, -78 °C to RT 3. 
Naphl, Pd(PPh3)4, RT 4. Reflux 70 °C 
SM recovered, no 
product 
13 1. LDA, THF, sieves 4A, -78 °C to 0 °C 2. Naphl, -78 °C to RT SM only 
Table 12 Different conditions for the introduction of the naphthylmethyl group 
CN 
Figure 61 Indole side-product 198 isolated after arylation reaction 
CN 
Figure 62 BOC protected cyano indole 171 
130 
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a) b) 
CN 
CN 
CN 
O 	0 
Et0------P1'.'"-"----"''''OEt 
Et0 r 130 
CH3 
CHO 
+ 
OH 
9) 
a) 1. n-C4H9NBr, Na0Hoq), toluene, H2O 2. PhS02C1, RT, 96% b) 1. t-BuLi, -45 °C, 55 min 2. NaphBr, -45 °C to RT, 
15 hr, 30% C) Na0Hoo, Me0H 99% d) DIBAL, dry DCM, 86% e) NaH, dry THF, 0 °C to RT, 79% f) Mg turnings, dry 
Me0H, RT, 80% g) KOH, EtOH/H20, reflux, 97% 
Scheme 66 Synthesis of indole lead 42 
2-naphthylmethyl indole 195 was re-crystallised from hexane/DCM 20:1. NOE 
difference experiments were carried out in order to show the presence of the 
naphthylmethyl group on the 2-position of the indole. Irradiation of the protons H5' at 
4.52 ppm showed strong interactions with protons H3, H7', H13' and a milder 
interaction with protons H2'. No interaction was seen with indole proton H4. 
Irradiation of the indole proton H3 at 6.19 ppm gave a strong signal with the indole 
proton H4, a reciprocal interaction with protons H5' and a milder interaction with 
aromatic protons H7' and H13'. This suggests the naphthylmethyl group is on the 2-
position of the indole. 
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Figure 63 Structure of 2-naphthylmethyl indole 195 
The selective introduction of the aryl moiety on the 2-position was confirmed after the 
crystallographic structure was obtained by X-ray crystallography experiments 
conducted by Dr Andrew White. The full tables of crystallographic data are included 
in the appendix. 
Figure 64 Crystal structure of 2-naphthylmethyl indole 195 
Continuing the synthesis towards indole 42 (Scheme 66), the deprotection of the 
benzenesulfonyl group, followed by the DIBAL reduction was carried out to give 
indole 178. HWE coupling with phosphonoacetate 130 was next performed on 
aldehyde 178 and the Z and E isomers 183 and 184 were isolated in a ratio of 63:37 
with an overall yield of 79%. After the selective reduction of the double bond of using 
magnesium turnings to afford indole precursor 189 in an 80% yield, saponification of 
the methyl ester 189 yielded indole lead 43 in a 97% yield. 
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In a similar fashion, aldehyde 178 was coupled with the 2,2,2-
trifluorophosphonoacetate 130 to give the Z and E isomers 185 and 186 in a ratio of 
38:62, with an overall yield of 78% (Scheme 67). Finally, reduction of the double 
bond afforded indole precursor 190 in 79% yield and saponification gave the final 
indole lead 43 in a 98% yield. 
a) NaH, dry THF, 0 °C to RT, 78% b) Mg turnings, dry Me0H, RT, 79% c) KOH, EtOH/H20, reflux, 98% 
Scheme 67 Synthesis of indole lead 43 
The purity of all the indole compounds was assessed by elemental analysis and a 
minimum of 98% purity was targeted for each lead. This was important to us in order 
to have the highest purity possible before proceeding to the biological testing of the 
compounds. It was found that it was best to purify the intermediates at each step in 
order to ensure the maximum purity for the final compound. Thus, chromatography 
on silica gel, followed by crystallisation wherever possible, was carried out affording 
very high purities of at least 97% for the intermediates and final compounds. The 
compounds were kept at -20 °C, under argon. A routine NMR in the appropriate 
solvents showed that the compounds were stable; elimination of the ethoxy side-
chain was not observed. 
4.24. Indoles in vitro PPAR activation assay: results and discussions 
Once the indole leads 38 to 43 were successfully synthesised, it was important to test 
their activity on the PPARs (Figure 65). A Luciferase gene reporter assay in human 
MCF-7 breast cancer cells was carried out by Therese Rost under the supervision of 
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Professor Rolf Berge at the Institute of Medicine of Bergen, in collaboration with Thia 
Medica AS, as previously described in Chapter 3. 
Figure 65 Indole leads tested in vitro 
Again, the negative control consists of transfection without treatment with any of the 
compounds and the positive controls are the same selective potent PPAR agonists at 
concentrations of 30 pM and 75 ,uM: WY14.643 71 for PPARa, BRL49653 20 for 
PPARy, and L165.041 14 for PPAR8 (Figure 42, Chapter 3). Different concentrations 
of TTA (1 ,uM, 30 ,uM and 75 ,uM) were run in parallel as previously. 
Five different concentrations between 1 ,uM and 75 ,uM of the indole leads 38 to 43 in 
DMSO were prepared. There were no solubility issues with the "druglike" designed 
indole leads except for indole 40 at 75 ,uM. The maximum concentration at which it 
was completely soluble was 50 pM, therefore this concentration was used. These five 
different concentrations of the compounds were used to get a preliminary indication 
of their effects on the activation. The lowest concentration which gave activity as well 
as a higher concentration relative to the first one were selected. These experiments 
were performed nine times at these optimum concentrations. All results were 
normalised relative to the negative control and the standard deviation is calculated 
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from the variability of the readings obtained for one compound at a particular 
concentration. 
4.2.4.1 PPARa activation assay with the indole leads 
The PPARa activation results are shown in Figure 66. 
Figure 66 PPARa activation results with the six indole leads 38 to 43 
It can be seen that, in general, indoles 38 and 39 were less potent than the other four 
targets. This supports the fact that the aryl group on the 2-position of the indole is 
important for activation of the receptor. 
With indole 40, the activation of PPARa at 5 pM is comparable to that of VVY14.643 
at 30 pM, showing that it is a potent activator. Indole 41 is also a strong activator 
although a higher concentration is needed to see a comparable effect as with target 
3. Indole 42 is a very potent activator of PPARa, in fact, the best activator out of the 
series. Its activity at a low concentration of 1 pM is already slightly better than that of 
VVY14.643 at 30 ,uM. Indole 43's effect is very significant at low concentrations of 10 
and 30 ,uM. If we compare indoles 40 and 42 to indoles 41 and 43, it indicates that 
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the ethyl ether gives slightly better activation than the 2,2,2-trifluoro ether. 
Comparison of indole leads 40 and 41 with indoles 42 and 43 shows that the last two 
compounds with a 2-naphthylmethyl group activate PPARa better than the first two 
leads 40 and 41 with a 2-benzyl group. 
4.2.4.2 PPARy activation assay with the indole leads 
Figure 67 shows the complete series of PPARyactivation results. 
Figure 67 PPARyactivation with the six indole leads 38 to 43 
Big variability was seen with the positive control's response. This has been discussed 
previously in Chapter 3. As with PPARa, indoles 38 and 39 activated PPARy the 
least, confirming that the aryl group on the 2-position of the indole is necessary for 
strong activation of the receptor. Indole 40 is a potent activator of PPARy at low 
concentrations of 1 to 10 pM. Indole 41 is as effective as indole 40, although its 
activation is slightly less strong. Indoles 42 and 43 are both very potent agonists, with 
indole 42 being very potent at a low concentration of 1 pM. If we compare indoles 38, 
40 and 42 to leads 39, 41 and 43, it seems that the ethyl ether gives better activation 
of PPARy than the 2,2,2-trifluoroethyl ether. Comparison between indoles 40 and 41 
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and indoles 42 and 43 indicates that the naphthylmethyl group is favoured for PPARy 
activation. 
4.2.4.3 PPARS activation assay with the indole leads 
Figure 68 shows the full series of PPARS activation results. In general, the six 
compounds were not found to be as strong activators of PPARS as L165.041. 
Indeed, the indoles had been designed to be dual PPARa/y agonists and the data 
obtained seems to confirm that they are potent activators of PPARa and PPARy, but 
less effective on PPARS. 
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Figure 68 PPARgactivation with the six indole targets 38 to 43 
Indoles 38 and 39 were statistically not different from the control. Indole 40, at 
concentrations of 1 and 5 pM, gives comparable activity to that of TTA at 30 pM 
whereas a much higher concentration of indole 41 is needed to observe similar 
activity to that of TTA at 75 pM. The activation with indole 42 was higher than with 
TTA at a concentration of 30 pM, indicating that this compound is a more potent 
agonist than TTA. Indole 43 was also potent, however at high concentrations of 
75 ,uM. In the case of PPARS, it was not possible to conclude on whether the 2,2,2-
trifluoro ether was better than the ethyl ether as there was no pattern from the data 
observed. Indole 40 seemed to show the best activation of PPARS at low 
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concentrations. Its effect at low concentrations of 1 and 5 pM was comparable to 
TTA's effect at 30 and 75 ,uM which has been proven to be a potent PPARS agonist. 
If we consider the activation results of the three PPAR subtypes (Figure 69) by the 
most potent indoles 40 to 43, it appears that indoles 42 and 43 are slightly better 
PPARcdy dual agonists than indoles 40 and 41. In fact, the indoles activated the 
PPARs in the following order in human MCF-7 cells: 7> a> S. The indoles had been 
designed to be dual PPARa/7 agonists by Prosarix Ltd. and we obtained proof of 
concept of the ProtoBuildTM de novo approach. 
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Figure 69 PPAR activation with indole targets 40 to 43 
Before choosing the most suitable candidate for further biology tests, it would be 
important to carry out some further in vitro assays to test the toxicity of the 
compounds and to measure some preliminary pharmacokinetic properties in order to 
see which compound would have the best druglike properties. Once the best 
candidate is chosen, the enantioselective synthesis can be carried out to give the 
desired enantiomer and to proceed to further testing of the compound as a potential 
treatment of metabolic diseases. 
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4.3 Work towards the pyrrolidine scaffold 
4.3.1. Pyrrolidine scaffold: retrosynthetic analysis 
A pyrrolidine scaffold was also designed as a potential PPARa/7 dual agonist by 
Prosarix Ltd (Figure 70). The aim was to devise a synthetic approach to this new 
scaffold and proceed to the racemic synthesis. 
   
R = H, Me, OMe 
OH 
Figure 70 Pyrrolidine scaffold 
Figure 71 shows the proposed interaction of the pyrrolidine lead with R being an 
OMe group with the PPAR7 active site. The aromatic ring fits in the hydrophobic site 
while the acidic head group fits into the hydrogen bond donor site. 
Figure 71 Proposed interaction of the pyrrolidine scaffold 
with the PPAR7actiye site (R = OMe) 
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The racemic retrosynthetic analysis is shown in Figure 72. The key step involves a 
Buchwald-Hartwig synthesis of tertiary amines between precursors 201 and 
202.251,252 
Figure 72 Retrosynthetic analysis of the pyrrolidine scaffold 
Precursor 201 can be prepared by a Mizoroki-Heck coupling between the aryl halide 
204 and 3-pyrroline 205, followed by a reduction of the pyrroline 207 into the 
corresponding pyrrolidine 201 while precursor 202 can be made by a Homer 
Wadsworth Emmons coupling between 4-bromobenzaldehyde 206 and 
phosphonoacetate 129 which was made using Arbuzov chemistry as previously 
described in section 4.2.3.1 (Scheme 41). The proposed forward, convergent 
synthesis is shown in Figure 73. The Buchwald-Hartwig amination would bring 
together the two key precursors 201 and 202. Finally, reduction of the double bond, 
followed by saponification would give the desired pyrrolidine lead 44. 
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R  	0 
44 R H OH 
a) Pd(dba)2 (3mol%), THF, Pr2Net b) Pd/C, HCO2NH4 c) NaH, dry THF, 0 °C to RT 
d) NaOtBu, 5mol% (DPPF)PdC12, THF, 100 °C e) Mg, dry Me0H, RT f) KOH, Et0H/H20 
Figure 73 Proposed forward synthesis of the pyrrolidine scaffold 
4.3.2. Synthesis of the pyrrolidine scaffold 
The synthesis was attempted with R = H. In order to synthesise pyrroline precursor 
207, the Mizoroki-Heck reaction was attempted between phenyl iodide 204 and 
commercially available 3-pyrroline 205 using various conditions summarised in Table 
13.253,254 Entry 1 involved the use of Pd(dba)2, diisopropylethylamine in anhydrous 
toluene255 while entries 2 and 3 consisted of the use of Pd(OAc)2, NaHCO3, 
nBu4NHSO4, molecular sieves 4A, with and without triphenylphosphine, in either 
acetonitrile or DMF.256 However, none of the reactions were successful. The 
reactions led to a complex mixture of products which was difficult to analyse by NMR, 
even after purification by chromatography. It was therefore decided to protect the 
nitrogen atom of 3-pyrroline before attempting the Heck reaction in order to prevent 
any side-reactions occurring on the nitrogen atom. 
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Reagents 
Anhydrous 
solvent 
Results 
1 
Pd(dba)2, diisopropylethylamine, 
reflux 
Toluene 
No SM left, no product 
isolated 
2 
Pd(OAc)2, NaHCO3, nBu4NHSO4, PPh3, 
molecular sieves 4A, 60 °C 
Acetonitrile 
lodobenzene recovered, 
no product isolated 
3 
Pd(OAc)2, NaHCO3, nBu4NHSO4, 
molecular sieves 4A, 60 °C 
DMF No product isolated 
Table 13 Heck coupling conditions on 3-pyrroline 
A benzoate group was chosen as it requires the same cleavage conditions as those 
required for the reduction of the double bond after the Heck reaction, so both 
transformations could be done simultaneously in one pot. 3-pyrroline 205 was 
therefore treated with benzyl chloroformate and potassium carbonate in dry DCM and 
the desired protected pyrroline 208 was isolated after chromatography. Next, it was 
subjected to the Heck coupling conditions described by Sonesson et al. (Scheme 
68).257 It was thus treated with phenyl iodide 204, Pd(OAc)2, rPr2Net, Ag2CO3 and 
P(o-tol)3 in anhydrous DMF at 100 °C. However, the reaction was unsuccessful and 
no desired product 209 was obtained after purification of the crude. It was not 
possible to conclusively identify the side-products obtained but NMR seemed to 
indicate that there had been a side reaction on the protecting group which contains 
an aromatic phenyl ring. 
a) Benzyl chloroformate, K2CO3, dry DCM, 0 °C to RT, 54% b) Pd(OAc)2, iPr2Nlet, Ag2CO3, P(o-to1)3, dry DMF, 100 °C 
Scheme 68 Protection of 3-pyrroline with benzyl chloroformate, followed by Heck reaction 
Thus, it was decided to use a methyl carbamate protecting group as described by 
Sonesson et .3/.257 In this case, methyl chloroformate was used and once the desired 
pyrroline 210 was obtained, the Heck coupling was attempted using the same 
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conditions as above: phenyl iodide 204, Pd(OAc)2, iPr2Net, Ag2CO3 and P(o-tol)3 in 
dry DMF at 100 °C.2" 
a) Methyl chloroformate, K2CO3, dry DCM, 0 °C to RT, 99% 
b) Pd(OAc)2, ,Pr2Net, Ag2CO3, P(o-tol)3, dry DMF, molecular sieves 4A, 100 °C, 66% 
Scheme 69 Protection of 3-pyrroline with methyl chloroformate, followed by Heck reaction 
The first issue to consider is the competition between arylation to give the desired C-
3 arylated product 211 and double bond isomerisation of protected pyrroline 210 to 
the enamide 212 which would lead to the C-2 arylated product 213 (Figure 74). This 
regioselectivity problem can be overcome by choosing the right phosphine ligand. 
Monodendate ligands have been found to be a lot more effective than bidendate 
ones. Moreover, the use of silver additives controls the double bond migration. 
Sonesson et al. found that a minimum of 0.7 eq of silver carbonate when using 
phenyl iodide as arylating agent was necessary to fully suppress the formation of the 
2-aryl pyrroline. The second issue is the undesired diarylation, which leads to the 
formation of compound 214. An excess of the olefin with respect to the iodide (ratio 
10:1) was required to considerably decrease the formation of the diarylated pyrroline. 
The Heck reaction was successful and the desired product 211 was isolated after 
chromatography in a 66% yield. 
Ph 
Figure 74 Possible side-products of the Heck reaction 
The mechanism for the Heck reaction is outlined in Scheme 70. It involves reduction 
of palladium (II) into the active palladium (0) state, oxidative addition of the halide 
204 to give the 16-electron species 215, insertion of the olefin, and elimination of the 
product 211 by a /3-hydride elimination process. Treatment with base regenerates the 
palladium (0) catalyst. The whole process is a catalytic cycle. Ag2CO3 effectively 
removes the hydrogen halide as soon as it is formed so that fl-hydride elimination 
can take place. 
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Scheme 70 Mechanism of Heck coupling 
Once we had the desired intermediate 211 in hand, we proceeded to the reduction of 
the double bond using a transfer hydrogenation as described by Sonesson et a/.257  
Pyrroline 211 was refluxed with ammonium formate in the presence of a catalytic 
amount of Pd/C in anhydrous methanol under an inert atmosphere. The starting 
material was still seen by NMR after 8 hours. The reaction was attempted several 
times but did not go to completion. It was decided to try the reduction with hydrogen 
gas and a catalytic amount of Pt02 (Scheme 71).258,259 These conditions were 
successful and the desired pyrrolidine 218 was isolated with a yield of 65% after 
purification by chromatography. 
a) 
 
211 
	
218 
0 	 0 
a) H2, cat. Pt02, anhydrous methanol, 65% 
Scheme 71 Reduction of pyrroline 211 into pyrrolidine 218 
The deprotection of the carbamate of the protected pyrrolidine 218 was next carried 
out by refluxing with potassium hydroxide in ethanol (Scheme 72). The reaction did 
not go to completion under these conditions. The number of equivalents of potassium 
hydroxide and the reaction time were increased; however starting material was still 
present. Alternative conditions were investigated as described by Ablordeppey et al. 
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where the starting material was refluxed with potassium hydroxide in diethylene 
glycol and water.26° The purification of the crude mixture proved to be tedious due to 
the ethylene glycol, and still no desired product was isolated. At this stage, the 
reaction was attempted using iodotrimethylsilane in dry DCM.261, 262 These conditions 
were successful and the desired product was obtained with a 99% yield after 
purification. 
a) 
218 
0 
a) (CH3)3Sil, dry DCM, RT, 99% 
Scheme 72 Cleavage of carbamate group of protected pyrroldine 218 
Next, the Buchwald-Hartwig amination conditions were investigated. Some model 
reactions were first carried out on commercially available pyrrolidine 219. It was 
important to determine whether the reaction between the amine and intermediate 202 
would be successful. 4-bromobenzaldehyde was coupled with phosphonoacetate 
129 using the Homer Wadsworth Emmons coupling conditions previously 
investigated. The reaction proceeded smoothly and the bromo Z and E isomers 202 
and 203 were isolated with a yield of 78%. The Buchwald-Hartwig amination was 
attempted using Pd2(dba)3, (±)-BINAP and sodium tert-butoxide in toluene (Scheme 
73) as it had been found to provide an excellent catalyst system for the cross 
coupling of amines with aryl bromides.263,264 However, the reaction yielded only a 
trace amount of the product. 
CH 
219 
0 
Scheme 73 Buchwald-Hartwig synthesis of tertiary amine 220 
It was decided to try the reaction with the protected acetal derivative of 4-
bromobenzaldehyde in order to avoid any side-reactions between the free nitrogen of 
pyrrolidine 219 and the carbonyl group of bromo compound 202. Acetals have been 
found to be stable under these conditions by Buchwald et M.263 The acetal analogue 
220 was synthesised from its corresponding aldehyde using ethylene glycol, catalytic 
para-toluenesulfonic acid and dry toluene with a Dean Stark set up.265  After isolation 
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of the acetal, the Buchwald-Hartwig amination was carried out using the same 
conditions as above (Scheme 74). In this case, the reaction proceeded smoothly and 
only the aldehyde 221 was isolated after chromatography with a yield of 65%. The 
NMR of the crude reaction mixture had not shown the presence of the aldehyde, the 
acetal was therefore cleaved during the purification by chromatography. 
CH 
+ 
a) 
 
 
O 219 
 
220 
 
221 
a) NaOtBu, (±)-BINAP, Pd2(dba)3, dry toluene, 70 °C, 65% 
Scheme 74 Buchwald-Hartwig synthesis of tertiary amine using acetal 220 
Having validated these conditions, the reaction was attempted on pyrrolidine 201 
(Scheme 75). In this case, most of the acetal starting material was obtained after 
purification, together with a trace amount of product 222 (4%). The reaction was 
repeated and the number of equivalents of sodium tert-butoxide, Pd2(dba)3 and (±)-
BINAP was increased. The yield of the reaction was significant improved to 25%. In 
future work, the Buchwald Hartwig amination conditions will have to be further 
optimised. 
a) NaOtBu, (±)-BINAP, Pd2(dba)3, dry toluene, 70 °C, 25% 
Scheme 75 Buchwald-Hartwig amination on the desired pyrrolidine 201 
The last three steps of the synthesis involve a methodology used previously to build 
up the ethoxypropanoic acid side chain on the indole scaffold. The HWE coupling 
with phosphonoacetate 129 proceeded smoothly to give the Z and E isomers 223 
and 224 in a ratio of 63:37, with an overall yield of 92%. Reduction of the double 
bond using magnesium turnings, followed by saponification with potassium hydroxide 
afforded the desired pyrrolidine 44 (Scheme 76). 
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a) Methyl chloroformate, K2CO3, dry DCM, 0 °C to RT, 99% b) Pd(OAc)2, iPr2Net, Ag2CO3, P(o-tol)3, dry DMF, 
sieves 4A, 100 °C, 66% c) H2, Pt02, dry Me0H, 65% d) TMSI, dry DCM, RT, 99% 
e) NaOtu, (±)-BINAP, Pd2(dba)3, dry toluene, 70 °C, 25% f) Phosphonoacetate 129, NaH, dry THF, 0 °C to RT, 92% 
g) Mg, dry Me0H, RT, 68% h) KOH, EtOH/H20, 88% 
Scheme 76 Synthesis of the pyrrolidine target 44 
4.4 Summary 
Our objective is to design and synthesise new potent dual PPARcr/7 agonists as 
potential treatments for the metabolic syndrome and diabetes type II, as well as 
inflammatory neurological diseases. Prosarix Ltd, using its proprietary software, 
designed two novel heterocyclic scaffolds using a de novo approach. 
The racemic synthesis of the six indole leads 38 to 43 derived from the first 
heterocyclic scaffold as well as the PPAR activation assay was described (Figure 
75). A number of synthetic routes were explored before validating the one where the 
starting material is 5-cyano indole. We have obtained proof of concept for Prosarix 
Ltd's software as we showed activation of both PPARa and PPARy using a luciferase 
reporter gene assay. Overall, the indoles activated the PPARs in the following order 
in human MCF-7 cells: y> a> 8. The activation of PPARS was less significant. Indole 
leads 42 and 43 out of the series were the best activators of PPARa and PPARy. We 
have thus synthesised a novel series of 2-aryl indole small molecules with a specific 
activation profile of the PPAR family of nuclear receptors. 
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Figure 75 Indole leads 38-43 
Work towards the second heterocyclic scaffold was also described and the synthesis 
route of the pyrrolidine lead 44 was successful from 3-pyrroline and 4-
bromobenzaldehyde. 
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Scheme 77 Synthesis of the pyrrolidine lead 44 
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Given the importance of metabolic diseases such as the metabolic syndrome and 
diabetes type II today and the lack of adequate treatment which prevents the 
development of these diseases, there is an urgent need for new effective drugs. The 
peroxisome proliferators-activated receptors have been established as powerful 
targets because of their positive actions on insulin sensitivity, glucose and lipid 
metabolism. In fact, one current class of pharmaceutical drugs is the 
thiazolidinediones, which are peroxisome proliferator-activated receptor (PPAR)7 
agonists. However, their side-effects include weight gain, oedema and liver toxicity. 
New effective drugs with an improved side-effect profile are needed. 
PPARs are transcription factors which directly control gene expression by binding to 
specific response elements within promoters; there are three subtypes a, 7,  and a 
Considering the critical physiological role of all the PPAR subtypes as lipid sensors 
and regulators of lipid metabolism, the aim of this project was to synthesise novel 
dual or pan PPAR agonists as potential drugs for the treatment of metabolic 
disorders. 
The first part of the project consisted of the synthesis of lipid analogues in 
collaboration with Professor Rolf Berge at the Institute of Medicine of Bergen and 
ThiaMedica AS, Norway. Tetradecylthioacetic acid (TTA) 31, a fatty acid analogue, 
developed by Thia Medica AS, was found to be a potent pan PPAR agonist. Although 
it is presently in clinical studies, TTA suffers from poor ADME characteristics. In order 
to improve the bioavailability of the PPAR activator, TTA 31, two novel lipid 
analogues, TTA-PC 32 and TTA-TAG 33, were synthesised as natural prodrugs 
(Figure 76). The mechanism of absorption and digestion of phospholipids and 
triglycerides is such that they are better absorbed in the gut. 
„ 
TTA-PC 
32 
Figure 76 First two TTA analogues synthesised 
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In vivo experiments in male Wistar rats were conducted with TTA, TTA-PC and TTA-
TAG by Professor Rolf Berge's team in Norway. Although all three compounds 
showed a decrease in plasma triacylglycerol, cholesterol and hepatic triacylglycerol 
levels, TTA-PC's effects were far better than TTA. Fatty acid oxidation and the 
activity of key mitochondrian enzymes involved in fatty acid oxidation and transport 
were also measured as these are very important dysfunctions in the metabolic 
diseases. It was found that the activities of fatty acid palmitoyl-CoA, carnitine 
palmitoyl transferase-II, 3-hydroxy-3-methylglutaryl-CoA synthase and fatty acyl-CoA 
were all significantly increased with TTA and TTA-PC whereas TTA-TAG was slightly 
less effective in general. Importantly, TTA-PC significantly improved the activity of the 
key enzymes by nearly two-fold compared to TTA. 
These promising results motivated us to synthesise four further TTA analogues using 
a variety of enzymatic reactions (Figure 77). Starting from TTA-PC 32, 
phospholipase A2 afforded lyso TTA-PC 34 in a 70% while transphophatidylation with 
phospholipase D and serinol or glycerol yielded TTA-Pser 64 and TTA-PG 36 in 87% 
and 69% yields respectively. TTA-Chol 37 was obtained in 99% yield by the coupling 
between TTA 31 and cholesterol. The in vitro PPAR activation of the new lipid 
analogues was measured using a luciferase reporter gene assay at the Insitute of 
Medicine of Bergen. Due to solubility and formulation issues, only lyso TTA-PC and 
TTA-PG could be tested in vitro. Preliminary results showed that both lyso TTA-PC 
and TTA-PG are promising compounds, displaying good activity relative to parent 
compound TTA. In human MCF-7 cells, the PPARs were activated in the following 
order by the two new lipids: a > S> y. Their effects in vivo now need to be assessed. 
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Figure 77 Structures of novel lipid analogues of TTA 
The second part of the project consisted of the synthesis of novel indole leads, 
designed as potential PPARcdr dual agonists by Prosarix Ltd, using their proprietary 
de novo approach design ProtoBuildTM. The first synthetic route envisaged, involving 
a final step Fischer Indole synthesis, was unsuccessful. Thus, the indole leads 38 to 
43 targets were synthesised using another approach where the starting material is a 
suitably functionalised indole. Scheme 78 shows the synthetic route employed for 
indoles 38 and 39 (where R1  = H) whereas Scheme 79 shows the methodology 
developed for the synthesis of indoles 40 to 43 (where R1 = benzyl or a 
naphthylmethyl group). An important aspect of the second synthesis focussed on the 
selective introduction of the aryl group on the 2-position of the indole. This was 
achieved by protecting the indole nitrogen with benzenesulfonyl group, followed by 
lithiation and finally treatment with the corresponding bromide. 
152 
OMe OH 
c) 
38 R2 = CH3 
39 R2 = CF3 
b) 
Yushma BHURRUTH 
	
Chapter 5 
0 	0 
P  iMe0 	 OEt 
Me0 
a) OEt 
0 
129 R2 = CH3 
R2 	130 R2 = CF3 
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Scheme 78 Synthesis of indole leads 38 and 39 
The six indole leads 38 to 43 were thus successfully synthesised. The degree of 
purity of the compounds was very important prior to their testing in vitro. A minimum 
of 97% purity of the indoles was achieved by careful purification of all the 
intermediates, followed by crystallisation wherever possible. Full characterisation of 
the indoles included 1H and 13C NMR, HRMS, elemental analysis, IR and the 
measurement of melting points wherever applicable. 
After the 6 indole leads were synthesised, their potential as PPAR activators was 
evaluated using a luciferase reporter gene assay by Professor Berge's research team 
based at the Institute of medicine of Bergen. 
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R1 = benzyl or naphthylmethyl 
R2 = CH3 or CF3 
a) 1. n-C4H9NBr, Na0Hoq), toluene, H2O 2. PhS02C1, RT b) 1. t-BuLi, -45 °C, 55 min 2. RiBr, -45 °C to RT, 15 hr c) 
Na0H(aq), Me0H d) DIBAL, dry DCM e) NaH, dry THF, 0 °C to RT f) Mg turnings, dry Me0H, RT 
g) KOH, EtOH/H20, reflux 
Scheme 79 Route chosen for the synthesis of the last four indole leads 
The assay showed that the indoles 38 to 43 activated the PPARs in the following 
order in the human breast cancer cell line MCF-7: y > a > 6. In terms of structure-
activity relationship, indoles 38 and 39 were much less potent in general, confirming 
that the presence of the aryl group on the 2-position of the indole is important for the 
interaction in the hydrophobic site at the entrance (Figure 47, page 92). The full 
structures of indoles 40 to 43 and their PPAR activation results are summarised in 
Figure 78 and Figure 79. Indoles 42 and 43 were found to be slightly more potent 
PPARa/y dual agonists than indoles 40 and 41 in the indole series. The activation 
assay thereby gave proof of concept for Prosarix Ltd's de novo design software which 
has allowed us to synthesise a novel class of 2-aryl indoles with an ethoxypropanoic 
acid side-chain at the 5-position. Further in vitro tests are to be carried out with this 
family of compounds in order to assess their ADME properties and choose the best 
candidate for future development and in vivo work. 
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Furthermore, the synthesis of the second heterocyclic scaffold was also described in 
Chapter 4. The key pyrrolidine 222 was synthesised using a variety of palladium 
couplings involving a Mizoroki-Heck coupling and a Buchwald-Hartwig amination 
reaction (Scheme 80). The final steps included a Horner Wadsworth Emmons 
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coupling, followed by reduction of the double bond and saponification to give the first 
pyrrolidine target 44. Its potential as a PPAR agonist is now to be evaluated. 
COOH 
a) Methyl chloroformate, K2CO3, dry DCM, 0 °C to RT, 99% b) Pd(OAc)2, iPr2Net, Ag2CO3, P(o-tol)3, dry DMF, 
sieves 4A, 100 °C, 66% c) H2, Pt02, dry Me0H, 65% d) TMSI, dry DCM, RT, 99% 
e) NaOtBu, (±)-BINAP, Pd2(dba)3, dry toluene, 70 °C, 25% f) Phosphonoacetate 129, NaH, dry THF, 0 °C to RT, 92% 
g) Mg, dry Me0H, RT, 68%, h) KOH, EtOH/H20 1:1, reflux, 88% 
Scheme 80 Synthesis of the pyrrolidine lead 44 
To conclude, we have synthesised two series of orthogonal PPAR agonists which 
have very different PPAR activation profiles. A comparison between the PPAR 
activation of the lipids lyso TTA-PC and TTA-PG with respect to the indoles shows 
that the TTA analogues activate PPARa better than the indoles whereas the indoles 
activate PPAR7 better with the exception of indole 40 which was found to be a potent 
activator of PPAR5. The order of activation of the PPARs is as follows in human 
MCF-7 cells: a > 8 > y for the lipids and 7 > a > 8 for the indoles. The difference in 
these activation profiles means that the two families of compounds will have different 
effects in terms of potency, beneficial effects and side-effects. 
The pyrrolidine offers the possibility of developing yet another family of PPAR 
agonists with its own activation profile. 
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6.1 General information 
All reactions were carried out under an atmosphere of nitrogen or argon, in oven-
dried glassware, unless otherwise stated. CH2Cl2 was distilled over P2O5, and other 
solvents were bought and pre-dried as required. Hipersolv chloroform was used for 
some reactions. All chemicals were purchased from Sigma-Aldrich, Lancaster and 
Merck Biosciences. Flash column chromatography was performed on silica gel 60 
(Merck Kieselgel 60 F254 230-240 mesh) according to the method of W C. Sti//.266 
TLC refers to thin layer chromatography performed on pre-coated Merck silica gel 
(0.2 mm, 60 F254) aluminium-backed plates, and visualised with a UV lamp (254 nm) 
and/or stained with acidic ammonium molybdate (IV), basic potassium manganate 
(VII; KMnO4), iodine and phosphomolybdic acid. Special chromatography solvent 
mixtures are: solvent A - CH2C12/Me0H/H20 345:90:10, solvent B - 
CH2C12/Me0H/H20 65:25:4, solvent C - CH2Cl2/MeOH/AcOH 92:7:1. Melting points 
were measured on a Stuart Scientific SMP3 apparatus and are reported without 
correction. Infra red spectra (IR) were measured on a JASCO FT/IR-620 
spectrometer. 1H NMR, 13C NMR and 31P NMR spectra were recorded on Bruker 
Avance 400. 1H NMR was recorded at 400 MHz and chemical shifts, eFi are quoted in 
parts per million (ppm), using residual isotopic solvent as internal reference (CDCI3, 
SH = 7.27 ppm; CD3OD, 4.1 = 3.30 ppm). Data is reported as follows: (integration; br = 
broad; s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet; coupling 
constant(s) J in Hz to the nearest 0.5 Hz; assignment). Peaks split by the presence of 
a phosphorus atom are indicated with a superscript p. 13C NMR spectra were 
recorded at 100 MHz and chemical shifts, Sc are quoted in parts per million (ppm), 
using residual isotopic solvent as internal reference (CDCI3, Sc = 77.00 ppm; CD3OD, 
Sc = 49.05 ppm). Data is reported as follows: (C, CH, CH2, CH3; d = doublet, q = 
quadruplet; coupling constant(s) J in Hz to the nearest 0.5 Hz; assignment). 13C NMR 
has only been assigned when the latter was confirmed by correlation between 1H and 
13C NMR. Peaks split by the presence of a phosphorus atom are indicated with a 
superscript p. Mass spectra were recorded using VG Platform II, VG-070B, Joel SX-
102 or Bruker Esquire 3000 ESI instruments. Mass accuracy is indicated to the 
nearest 0.1 ppm. Elemental analysis was carried out by Stephen Boyer using a 
Perkin Elmer 2400 CHN elemental analyser at the Science Technical Support unit, 
London Metropolitan University. 
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6.2 Chemistry 
2-(Tetradecylthio)acetic acid 31 
b a OH 
Tetradecyl bromide (5.36 ml, 18.0 mmol, 1.00 eq) was added to a solution of 
thioglycolic acid (1.25 ml, 18.0 mmol, 1.00 eq) in 25% NaOH in Me0H (6.03 g in 24.0 
ml) and the mixture was stirred vigorously at RT for 72 hr. After dilution with water, 
the mixture was acidified to pH 1 with concentrated HCI and the aqueous phase was 
extracted with diethyl ether. Drying with MgSO4 and concentration in vacuo afforded a 
cloudy white solid which was purified by flash column chromatography on silica gel 
(hexane/EtOAc 3:1) to yield 4.73 g (91%) of TTA as a fluffy white amorphous solid: 
mp 69.0-71.0 °C (cyclohexane); R1  0.50 [hexane/EtOAc 3:1]; Vmax  (nujol)/cm-1  2952, 
2851, 1685 (C=0), 1461, 1377, 724; aH (CDCI3) 3.27 (2H, s, Ha), 2.68-2.65 (2H, t, J 
7.5, Hb), 1.66-1.58 (2H, m, Hc), 1.41-1.36 (2H, m, Hd), 1.27 (20H, s, 10xCL21 ), 0.908-
0.874 (3H, t, J 7.0, CH3); ac (CDCI3) 176.65 (C, C=0), 33.54 (CH2, Ca), 32.87 (CH2, 
Cb), 31.95 (CH2, Cc), 29.67, 29.65, 29.63, 29.57, 29.48, 29.34, 29.16, 28.90, 28.72 
(9xCH2), 	14.13 	(CH3); 	m/z 	(Elk) 	287 ([M]+, 100); found [M+H]+, 	798.5156, 
C40H81NO8PS2 requires [M+H]+, 798.5141; A = 1.9 ppm. 
di- Tetradecylthioacetoyl-sn-glycero-3-phosphocholine 32 
b 
0 
0„0 
4
„ 
' 
5 
To a solution of tetradecylthioacetic acid 31 (261 mg, 0.905 mmol, 1.00 eq) in DCM 
(5.00 ml), was added CDI (190 mg, 1.17 mmol, 1.30 eq) and the solution stirred for 2 
hr and 45 mins at RT under argon. In the meantime, DBU (135 pL, 0.905 mmol, 1.00 
eq) was added to a solution of L-a-GPC (133 mg, 0.301 mmol, 0.33 eq) in DMSO 
(5.00 ml) and the solution was also stirred at RT, under argon for 2 hr and 45 min. 
The solution became turbid upon addition of DBU. The first solution was next 
transferred to the second one via cannula. The mixture was stirred vigorously at RT 
for 16 hr. A clear yellow solution was obtained. The mixture was acidified with acetic 
acid 0.1M (12.0 ml), and washed with CHCI3/MeOH 2:1 (5x10.0 ml). The organic 
phase was washed with H20/Me0H 1:1 (5x50.0 ml) and the aqueous phase 
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extracted with CHCI3/MeOH 2:1 (3x100 ml). The organic phases were combined and 
concentrated in vacuo to give a brownish oil (2.78 g) which was purified by flash 
column chromatography on silica gel (DCM, solvent A in DCM: 10%, 20%, 80%, 
90%, solvent A, solvent B, methanol) to yield 168 mg (70%) of TTA-PC as a white 
amorphous solid: Rf 0.40 [solvent B]; Vmax  (nujol)/cm-1  3376, 2954-2851, 1733, 1467, 
1248, 1091, 765; SH (CDC13) 5.25 (1H, br, H2), 4.45-4.41 (2H, dd, J 12.0, J 3.0, H1), 
4.28-4.23 (2H, m, 2H3), 4.00-3.97 (2H, t, J 6.0, H4), 3.85-3.74 (2H, m, H5), 3.31-3.28 
(13H, br, 3xNCH3, Ha), 2.63-2.58 (4H, m, Hb), 1.61-1.54 (4H, m, Hc), 1.38-1.35 (2H, 
m, Hd), 1.26 (40H, s, 20xCL21 ), 0.85-0.82 (6H, t, J 7.0, 2xCH3); 	(CDCI3) 170.38, 
170.13 (C, 2xC=O), 71.50-71.43P (CH, d, J 7.0, C2), 66.34-66.27P (CH2, d, J 7.0, C5), 
63.50 (CH2, C1), 63.31-63.25P (CH2, d, J 6.0, C3), 59.40-59.35P (CH2, d, J 5.0, C4), 
54.37 (NCH3), 33.60, 33.45 (CH2, 2xCa), 32.76, 32.68 (CH2, 2xCb), 31.91 (CH2, 
2xCc), 29.71, 29.66, 29.62, 29.60, 29.35, 29.32, 29.02, 29.01, 28.85, 28.82 (18xCH2), 
22.66 (2xCH2), 14.09 (2xCH3); 	(CDCI3/MeOD 2:1) -0.68; rn/z (FAB+) 798 ([M]+,5), 
510 ([M+-one fatty acid chain], 2), 184 ([(1-10)0P(0)0CH2CH2N(CH3)3+], 41), 86 
(ICH2CH2N-(CH3)3I, 100), 72 (53), 57 ([N(CH3)3]+, 30); found [M+H]
+, 798.5156, 
C40H811108PS2 requires [M+H]+, 798.5141; 4 = 1.9 ppm. 
tri-Tetradecylthioacetoylglyceride 33 
0 
19 	17 15 13 11 9 7 	0 	3 njs 
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HBTU (1.16 g, 3.05 mmol, 3.28 eq) and DMAP (1.09 g, 8.95 mmol, 9.64 eq) were 
added to a solution of TTA (834.0 mg, 2.89 mmol, 3.11 eq) and glycerol (85.5 mg, 
0.928 mmol, 1.00 eq) in dry DCM under argon. The mixture was stirred at RT, under 
argon, for 19 hr. The reaction had not gone to completion, thus some more TTA (93.1 
mg, 0.323 mmol, 0.35 eq) was added and the reaction stirred for a further 4 hr. 15.0 
ml of citric acid solution (7%) were added to the reaction mixture. The aqueous phase 
was separated from the organic phase and extracted with DCM (4x25.0 ml). The 
organic phases were combined, dried on MgSO4 and concentrated in vacuo to give a 
white solid (2.49 g) which was purified by flash column chromatography on silica gel 
(hexane, hexane/EtOAc 9:1, 8:2, 6:4, EtOAc) to yield 698 mg (83%) of TTA-TAG 33 
as a white amorphous powder: Rf 0.40 [hexane/EtOAc 8:2]; Vmax  (nujol)/cm-1  3026-
2852, 1737, 1722, 1493, 1377, 1262, 1170, 1028, 770; 4.1 (CDCI3/MeOD 2:1) 5.32-
5.26 (1H, m, H2), 4.39-4.35 (2H, dd, J 12.0, J 4.0, 2xH1), 4.26-4.21 (2H, dd, J 12.0, J 
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6.0, 2xH3), 3.20 (6H, s, 3x2H5), 2.61-2.57 (6H, m, 3x2H6), 1.59-1.52 (6H, m, 3x2H7), 
1.36-1.31 (6H, m, 3x2H8), 1.22 (60H, br, 3x2(H9-H18), 0.86-0.82 (9H, t, J 7.0, 
3x3H19); 	(CDCI3/MeOD 2:1) 171.27, 170.83, 170.49 (C, 3xC=0), 70.26 (CH, 
3xC2), 63.10 (CH2, C1, C3), 33.80-33.68 (CH2, 3xC5), 33.16, 33.13 (CH2, 3xC6), 
32.33 (CH2, 3xC7), 30.09, 30.07, 30.02, 29.95, 29.76, 29.65, 29.64, 29.39, 29.19, 
29.16 (33xCH2, 3x(C8-C18)), 14.33 (CH3, 3xC19); rn/z (FAB+) 901 ([M]+, 59), 705 
(21), 615 ([M-TTA]+, 69), 345 (19), 270 (49), 243 (80), 227 (11), 83 (41), 59 (66), 55 
(94), 43(100); found [M+H]+, 901.5948, C511-19806S3 requires [M+H]+, 901.5906; A = 
4.7 ppm. 
Lyso-di-tetradecylthioacetoyl-sn-glycero-3-phosphocholine 34 
‘1')/ 4 N-N 
d b a OH 
TTA-PC 32 (49.4 mg, 0.062 mmol, 1.00 eq) was dissolved in diethylether/methanol 
99:1 (2.00 ml). Tris-CI 50 mM (2.00 ml) and CaCl2 40 mM (1.00 ml) were added to the 
solution (pH adjusted to 8.4), followed by phospholipase A2 from crotalus 
adamenteus venom (63 units). The mixture was stirred at 37 °C for 4 hr, after which 
the aqueous phase was separated from the organic one and extracted with 
CHCI3/MeOH 2:1 (4x10.0 ml). The organic phases were combined and concentrated 
in vacuo to give a white solid (104 mg) which was purified by flash column 
chromatography on silica gel (DCM, solvent A in DCM: 20%, solvent A, solvent B) to 
yield 20.4 mg (62%) of lyso TTA PC as a sticky white powder: Rf 0.10 [solvent B]; 
vmax (nujol)/cm-1 3348, 2953-2852, 1732, 1463, 1249, 1135, 1054, 721; SH  
(CDCI3/MeOD 2:1) 4.28-4.11 (3H, m, 2xH1, H2, 1xH3), 3.95-3.86 (3H, m, 2xH4, 
1xH3), 3.59 (2H, b, 2xH5), 3.23-3.12 (11H, m, 2xHa, 3xNCH3), 2.60-2.56 (2H, t, J 7.5, 
2xHb), 1.58-1.51 (2H, m, 2xHc), 1.34-1.32 (2H, m, 2xHd), 1.21 (20H, s, 10xClz_21 ), 
0.85-0.81 (3H, t, J 7.0, CH3); et (CDCI3/MeOD 2:1) 171.52 (C, C=0), 69.05-68.99P 
(CH, d, J 6.0, C2), 67.22-67.17P (CH2, d, J 5.0, C5), 66.88 (CH2, C3), 66.28 (CH2, 
C1), 59.63-59.58P (CH2, d, J 5.0, C4), 54.52 (NCH3), 33.99, 33.87 (CH2, 2xCa), 33.12 
(CH2, 2xCb), 32.33 (CH2, 2xCc), 30.05, 30.01, 29.94, 29.75, 29.64, 29.57, 29.42, 
29.16 (9xCH2), 23.06 (2xCH2), 14.30 (CH3); Sp (CDCI3/MeOD 2:1) -0.17; m/z (FAB+) 
528 ([M+H]+, 1), 510 ([M-OH]+, 0.5), 458 (1), 243 ([HO(CH2)3(0)-P0(0)(CH2)2NMe3r, 
7), 104 ([HO(CH2)2-NMe3]+, 61), 86 ([CH2C1-12N-(CH3)3]+, 60), 72 (40), 55 ([N(CF13)3]+, 
95); found [M+H]+, 528.3106, C24H51NO7PS requires [M+H]+, 528.3124; A = -3.4 ppm. 
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di-Tetradecylthioacetoyl-sn-glycero-3-phosphoserinol 64 
0, 0 0 	3 'V 
4 0H 
5 6 
(:)VY b a 	-
O 
el H3 
A 5.5M solution of serinol (1.00 g, 11.0 mmol) in NaOAc 100 mM (1.00 ml) and CaCl2 
50 mM (1.00 ml) was prepared and the pH adjusted to 6.2 with acetic acid. 
Phospholipase D from streptomyces species (63 units, 2.00 eq) was added to serinol 
(0.040 ml, 0.241 mmol, 6.00 eq) solution in a flask. TTA-PC 32 (32.0 mg, 0.040 
mmol, 1.00 eq) dissolved in hipersolv chloroform (1.50 ml) was added to the mixture 
and the latter was stirred at 30 °C for 3 hr and 15 min. The organic phase was 
separated from the aqueous one and washed with water (2x20.0 ml). The aqueous 
phase was extracted with DCM (4x20.0 ml). The organic phases were combined and 
concentrated in vacuo to give a white solid (37.4 mg) which was purified by flash 
column chromatography on silica gel (DCM, solvent A in DCM: 20%, 40%, 60%, 
80%, solvent A, solvent B, methanol) to yield 27.3 mg (87%) of TTA-PSer as a white 
sticky powder: Rf 0.60 [solvent B]; Vmax  (nujol)/cm-1  3420, 2953-2852, 2110, 1732, 
1463, 1279, 1064, 721; 4i  (CDCI3/MeOD 2:1) 5.23 (1H, br, H2), 4.44-4.41 (1H, dd, J 
12.0, J 3.0, H1), 4.27-4.00 (8H, m, 2xH3, 2xH4, NH2, 2xH6), 3.74-3.67 (1H, m, OH), 
3.38 (1H, br, H5), 3.23-3.22 (4H, m, Ha), 2.62-2.57 (4H, m, Hb), 1.56-1.53 (4H, m, 
Hc), 1.35-1.33 (4H, m, Hd), 1.23 (40H, br, 20xC1212), 0.86-0.82 (6H, t, J 6.5, 2xCH3); 
(CDCI3/MeOD 2:1) 170.47, 170.21 (C, 2xC=0), 71.24-71.16P (CH, J 8.0, C2), 
63.45-63.4OP (CH, J 5.0, C5), 63.03 (CH2, C1), 62.76-62.71P (CH2, J 5.0, C4), 58.83 
(CH2, C6), 53.55 (NCH), 33.31, 33.19 (CH2, 2xCa), 32.58, 32.54 (CH2, 2xCb), 31.63 
(CH2, 2xCc), 29.37, 29.33, 29.27, 29.03, 28.98, 28.80, 28.51, 22.33 (20xCH2), 13.49 
(2xCH3); SP (CDC13/Me0D 2:1) -0.93; m/z (FAB-) 784 ([M-H]+, 26), 514 (7), 287 (TTA+, 
17), 229 (21), 170 ([(H0)(0)P0(0)(CH2)-CH(NH2)-CH20Hr, 16), 153 ([(02)P0(CH2)-
CH(NH2)CH2OH]+, 59), 79 (100); m/z (ESI-) 784 (100), 191 (32); found [M+H]+, 
784.4651, C38H75N09PS2" requires [M+H]+, 784.4621; A = 3.8 ppm. 
di-Tetradecylthioacetoyl-sn-glycero-3-phosphoglycerol 36 
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A 16M solution of glycerol (1.00 ml, 1.47 mmol) in NaOAc 100 mM (0.500 ml) and 
CaCl2 50 mM (0.500 ml) was prepared and the pH adjusted to 6.1 with acetic acid. 
Phospholipase D from streptomyces species (76 units, 2.00 eq) was added to 
glycerol 16 M (0.100 ml, 1.60 mmol, 42.3 eq) in a flask. TTA-PC 32 (30.2 mg, 0.038 
mmol, 1.00 eq) dissolved in hipersolv chloroform (1.50 ml) was added to the mixture 
and the latter was stirred at 30 °C for 5 hr. The organic phase was separated from the 
aqueous one and washed with water (2x20.0 ml). The aqueous phase was next 
extracted with DCM (4x20.0 ml). The organic phases were combined and 
concentrated in vacuo to give a white solid (57.5 mg) which was purified by flash 
column chromatography on silica gel (DCM, solvent A in DCM: 20%, 40%, 60%, 
80%, solvent A, methanol) to yield 18.7 mg (63%) of TTA-PG as a white amorphous 
solid: Rf 0.55 [solvent B]; Vmax  (nujol)/cm-1  3567, 2953-2853, 1730, 1462, 1377, 1232, 
1072; SH (CDCI3/MeOD 2:1) 5.22 (1H, br, H2), 4.44-4.40 (1H, dd, J 12.0, J 3.0, H1), 
4.27-4.22 (1H, dd, J 12.0, J 7.0, H1), 4.11-3.89 (4H, m, 2xH3, 2xH4), 3.77 (1H, m, 
H5), 3.23-3.19 (4H, m, Ha), 2.61-2.56 (4H, m, Hb), 1.59-1.52 (4H, m, Hc), 1.36-1.33 
(4H, m, Hd), 1.28-1.18 (40H, br, 20xCLI ), 0.86-0.82 (6H, t, J 7.0, 2xCH3); Sc 
(CDCI3/MeOD 2:1) 171.24, 170.97 (C, 2xC=O), 72.00-71.93P (CH, J 7.0, C2), 71.57-
71.523 (CH, J 5.0, C5), 67.20-67.15P (CH2, J 5.0, C3), 64.10-64.05P (CH2, J 5.0, C4), 
63.82 (CH2, C1), 62.99 (CH2, C6), 34.05, 33.93 (CH2, 2xCa), 33.33, 33.29 (CH2, 
2xCb), 32.37 (CH2, 2xCc), 30.12, 30.08, 30.02, 30.00, 29.77, 29.73, 29.70, 29.54, 
29.26, 29.24 (10xCH2), 23.07 (2xCH2), 14.23 (2xCH3); Sp (CDC13/Me0D 2:1) -1.41; 
m/z (FAB-) 786 ([M]+, 24), 650 (11), 514 (5), 325 (25), 287 ([TTA]+, 15), 229 (22), 153 
([(02)P0-(CH2)CH(OH)CH2OH]+, 75), 92 (15), 79 (57), 46 (49), 16 (100); rn/z (ESI-) 
785 (100), 279 (56); found [M+H]+, 785.4470, C38H74010PS2- requires [M+H]+, 
785.4170; A = 3.8 ppm. 
di-Tetradecylthioacetoyl-sn-glycero-3-phospho(2,2-dimethyl)-1,3-dioxolane-4-
methanol 69 
A 7M solution of (S)-(+)-2,2-dimethy1-1,3-dioxolane-4-methanol solketal (0.900 ml, 
7.29 mmol) in NaOAc 100 mM (0.500 ml) and CaCl2 50 mM (0.500 ml) was prepared 
and the pH adjusted to 6.4 with acetic acid. Phospholipase D from streptomyces 
species (250 units, 6.60 eq) was added to solketal 7M (0.050 ml, 0.356 mmol, 6.00 
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eq) in a flask. TTA-PC 32 (47.4 mg, 0.059 mmol, 1.00 eq) dissolved in hipersolv 
chloroform (1.50 ml) was added to the mixture and the latter was stirred at 30 °C for 5 
hr. The organic phase was separated from the aqueous one and washed with water 
(2x20.0 ml). The aqueous phase was extracted with DCM (4x20.0 ml). The organic 
phases were combined and concentrated in vacuo to give a colourless oil which was 
purified by flash column chromatography on silica gel (DCM, solvent A in DCM: 10%, 
20%, 30%, 40%, solvent A, solvent B, Me0H) to yield 50.9 mg (97%) of TTA-
Pdioxolane as a white solid: Rf 0.55 [solvent B]; Vmax  (DCM film)/cm-1  3398, 3054, 
2987, 1717, 1422, 1265, 740; 	(CDCI3/MeOD 2:1) 5.24-5.22 (1H, br, H2), 4.44-4.40 
(2H, dd, J 12.0, J 3.0, H1), 4.27-4.22 (2H, m, 2xH3), 4.05-3.96 (3H, m, 2xH4, H5), 
3.86-3.76 (2H, m, 2xH6), 3.22-3.20 (4H, m, Ha), 2.61-2.56 (4H, m, Hb), 1.59-1.51 
(4H, m, Hc), 1.42-1.17 (50H, m, 6xH8, 4xHd, 20xCH2), 0.86-0.82 (6H, t, J 7.0, CH3); 
(CDCI3/MeOD 2:1) 171.13, 170.83 (C, 2xC=O), 110.09 (C, C7), 75.23-75.14P (CH, 
J 9.0, C2), 71.84-71.76P (CH, J 8.0, C5), 66.71 (CH2, C1), 66.53-66.48P (CH2, J 9.0, 
C3), 63.95-63.9OP (CH2, J 5.0, C4), 63.72 (CH2, C6), 33.90, 33.78 (CH2, 2xCa), 33.20, 
33.16 (CH2, 2xCb), 32.36 (CH2, 2xCc), 30.11, 30.08, 30.01, 30.00, 29.78, 29.71, 
29.70, 29.44, 29.24, 29.22 (10xCH2), 26.94, 25.52 (CH3, 2xC8), 23.08 (2xCH2), 14.31 
(2xCH3); Sp(CDCI3/MeOD 2:1) -3.20; m/z (ESI-) 825 ([M-1]+, 85), 555 (39), 507 (100), 
329 (38), 30 (42). 
di- Tetradecylthioacetoyl-sn-glycero-3-phosphoethanolamine 67 
0 	2 3 0 	4  
YLO NO4\51-13 5 
Ethanolamine (21.8 pL, 0.351 mmol) was added to NaOAc 100 mM (0.500 ml) and 
CaCl2 50 mM (0.500 ml) and the pH was adjusted to 6.4 with acetic acid. 
Phospholipase D from streptomyces species (58.5 units, 1.00 eq) was added to the 
solution which was transferred to a flask containing TTA-PC 32 (46.6 mg, 0.059 
mmol, 1.00 eq) dissolved in chloroform (1.50 ml). The mixture was stirred at 30 °C for 
6 hr after which the organic phase was separated from the aqueous one and washed 
with water (2x15.0 ml). The aqueous phase was extracted with CHCI3/MeOH 2:1 
(4x15.0 ml). The organic phases were combined and concentrated in vacuo to give a 
white solid (57.5 mg) which was purified by flash column chromatography on silica 
gel (DCM, solvent A in DCM: 20%, 40%, 60%, 80%, solvent A, solvent B, methanol) 
to yield 42.3 mg (95%) of TTA-PE as a white amorphous powder: Rf 0.35 [solvent A]; 
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Vmax (nujol)/cm-1  2953-2853, 1730, 1462, 1377, 1232, 1072; 8Fi (CDCI3/MeOD 2:1) 
5.23 (1H, br, H2), 4.43-4.22 (4H, 2xH1, 2xH3), 4.04-3.99 (4H, 2xH4, 2xH5), 3.22-3.19 
(4H, m, 4Ha), 3.10 (br, NH), 2.61-2.56 (4H, m, Hb), 1.58-1.51 (4H, m, 4xHc), 1.37-
1,22 (44H, m, 4xHd, 20xCE12), 0.90-0.87 (6H, t, J 7.0, 2xCH3); & (CDCI3/MeOD 2:1) 
171.14, 170.86 (C, 2xC=O), 71.78-71.7OP (CH, J 8.0, C2), 64.07-63.98P (CH2, J 5.0, 
C3), 63.64 (CH2, C1), 62.13-62.08P (CH2, J 5.0, C4), 41.01-40.96 (CH2, J 5.0, C5), 
33.89-33.78 (CH2, 2xCa), 33.18-33.13 (CH2, 2xCb), 32.34 (CH2, 2xCc), 30.10, 30.07, 
29.98, 29.77, 29.69, 29.68, 29.42, 29.21, 29.19, 23.07 (20xCH2), 14.09 (2xCH3); 
(CDCI3) -0.31; m/z (ESI+): 755 ([M+H]+, 90), 469 (100), 342 (34); found [M+H]+, 
756.4678, C37H75N08PS2 requires [M+H]+, 756.4672; A = 0.8 ppm. 
Lyso-1,2-distearoyl-sn-glycero-3-phosphocholine 58 
b 
	
1 3 NV 4 
a 0 	0 
LO-5 
OH 
DSPC 57 (99.4 mg, 0.126 mmol, 1.00 eq) was dissolved in diethylether/methanol 
99:1 (3.00 ml). Tris-CI 50 mM (1.00 ml) and CaCl2 40 mM (1.00 ml) were added to the 
solution (pH adjusted to 8.4), followed by phospholipase A2 from crotalus 
adamenteus venom (126 units, 1.00 eq). The mixture was stirred at 37 °C for 1.5 hr, 
after which the aqueous phase was separated from the organic one and extracted 
with DCM (3x20.0 ml). The organic phases were combined and concentrated in 
vacuo to give a white solid (104 mg) which was purified by flash column 
chromatography on silica gel (DCM, solvent A in DCM: 20%, solvent A, solvent B) to 
yield 57.2 mg (87%) of lyso DSPC as a sticky white solid: Rf 0.10 [solvent B]; Vmax 
(nujol)/cm-1  3376, 2953-2851, 1735, 1466, 1377, 1233, 1087, 970; aH (CDCI3/MeOD 
2:1) 4.28 (2H, m, H2, H1), 4.03-3.97 (2H, m, H4), 3.92-3.83 (2H, m, H3), 3.73-3.60 
(3H, m, H), 3.35-3.33 (2H, m, H5), 2.95 (9H, s, 3xNCH3), 2.10-2.06 (2H, t, J 7.5, Ha), 
1.37-1.34 (2H, m, Hc), 1.05-0.95 (28H, br, 14xCL2I ), 0.63-0.60 (3H, t, J 7.0, CH3); et 
(CDCI3/MeOD 2:1) 174.81 (C, C=0), 69.39-69.33P (CH, J 6.0, C2), 67.46-67.41P 
(CH2, J 5.0, C5), 67.08 (CH2, C3), 65.52 (CH2, C1), 59.66-59.61P (CH2, J 5.0, C4), 
54.66, 54.63, 54.59 (3xNCH3), 34.72 (2xCH2, Ca, Cb), 32.33 (CH2, Cc), 30.08, 29.96, 
29.90, 29.81, 29.73, 29.71, 29.60, 25.34, 23.04 (13xCH2), 14.22 (CH3); gip 
(CDCI3/MeOD 2:1) -0.18; m/z (ESI+) 546 ([M+Na]+, 100), 524 ([M+H]+, 26), 487 (11), 
184 (6), 104 (25); found [M+H]+, 524.3716, C26H55NO7P requires [M+H]+, 524.3716; A 
= 0.0 ppm. 
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Cholesteroftetradecylthioacetate 37 
26 
HBTU (50.1 mg, 0.130 mmol, 1.09 eq) and DMAP (47.7 mg, 0.390 mmol, 3.30 eq) 
were added to a solution of TTA 31 (34.0 mg, 0.118 mmol, 1.00 eq) and cholesterol 
(47.1 mg, 0.122 mmol, 1.03 eq) in dry DCM under argon. The mixture was stirred at 
RT, under argon, for 18 hr. 5.00 ml of citric acid solution (7%) were added to the 
reaction mixture. The aqueous phase was separated from the organic phase and 
extracted with DCM (4x10.0 ml). The organic phases were combined and 
concentrated in vacuo to give a yellowish oil (160 mg) which was purified by flash 
column chromatography on silica gel (hexane, hexane/EtOAc 8:2, 7:3, EtOAc) to 
yield 76.0 mg (99%) of TTA-Choi as a sticky white powder: Rf 0.65 [hexane/EtOAc 
8:2]; vma, (nujol)/cm-1  2924-2854, 1700, 1462, 1377; SH (CDCI3) 5.39 (1H, d, J 4.0, 
H6), 4.67-4.65 (1H, m, H3), 3.19 (2H, s, 2xHa), 2.66-2.62 (2H, t, J 7.0, 2xHb), 2.37-
2.35 (2H, d, J 7.5, 2xH4), 2.04-1.86 (2H, m, H25, H14), 1.69-0.69 (66H, m, 2xHc, 
2xHd, 2xH11, 2xH13, 2xH16, 2xH15, H20, H9, H8, H17, 10xCL21 , 2xH24, 2xH1, 
2xH2, 2xH4, 2xH22, 2xH23, 3xH19, 3xH21, 3xH27, 3xH26, 3xH18, 3xH27, CH3); et 
(CDCI3) 170.00 (C, C=0), 139.44 (C, C5), 122.82 (CH, C6), 74.91 (CH, C3), 56.68 
(CH, C14), 56.15 (CH, C17), 50.03 (CH, C9), 42.31 (C, C13), 39.73 (CH2, C12), 
39.52 (CH2, C24), 38.01 (CH2, C4), 36.96 (CH2, C1), 36.58 (C, C10), 36.19 (CH2, 
C22), 35.78 (CH, C20), 33.99 (CH2, Ca), 33.72 (CH2, Cb), 32.64 (CH2, Cc), 31.92 
(CH2, C7), 31.86 (CH, C8), 29.70, 29.66, 29.61, 29.52, 29.36, 29.19, 29.05, 28.76 
(10xCH2), 28.21 (CH2, C16), 28.00 (CH, C25), 27.71 (CH2, C2), 24.27 (CH2, C15), 
23.83 (CH2, C23), 22.80 (CH3, C27), 22.54 (CH3, C26), 21.03 (CH2, C11), 19.29 
(CH3, C19), 18.71 (CH3, C21), 14.15 (CH3), 14.10 (CH3), 11.84 (CH3, C18); m/z 
(FAB+) 658 ([M+H]+, 2), 504 (2), 369 ([M-TTA]+, 53), 243 (11), 154 (62), 133 (88), 91 
(77), 55 (100). 
4-(4-Nitropheny1)-3-oxo-2-(triphenyl-A5-phosphanylidene)-butyronitrile 79 
02N 
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The syringe to be used for the reaction was first washed with DCM a few times. The 
DMAP resin (1.76 g, 2.88 mmol, 0.20 eq), para-nitrophenylacetic acid (2.63 g, 14.5 
mmol, 1.01 eq), (cyanomethylene)triphenylphosphorane (4.32 g, 14.4 mmol, 1.00 
eq), and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (3.68 g, 19.2 
mmol, 1.34 eq) were added to the syringe as well as DCM (20.0 ml). The orange 
mixture was stirred on the solid phase shaker at RT for 15 hr. The solution turned 
greenish after 15 hr. The reaction mixture was transferred to a separating funnel and 
washed with 7% citric acid solution (100 ml). The aqueous phase was separated from 
the organic phase and extracted with DCM (3x40.0 ml). The organic phase was 
washed with water (2x100 ml) and the aqueous phase was extracted with DCM 
(4x80.0 ml). The organic phases were combined and concentrated in vacuo to give a 
greenish solid (7.83 g) which was purified by crystallisation from hexane/DCM 20:1 to 
yield 6.24 g (94%) of the product as shiny white crystals: Rf 0.50 [EtOAc]; Vmax 
(nujol)/cm-1  3026-2854, 2170, 1737, 1582, 1493, 1262, 1028, 759; 8H (CDC13) 8.18-
8.16 (2H, d, J 8.0, H7), 7.64-7.62 (2H, d, J 8.0, H6), 7.57-7.32 (15H, m, Har), 4.06 
(2H, s, H4); Sc (CDCI3) 192.04-192.0OP (C, d, J 16.0, C3), 146.73 (C, C8), 144.16 (C, 
C5), 133.50-133.4OP (CH, d, J 40.0, 6xPhmeta), 133.29-133.26P (CH, d, J 12.0, 
3xPhpara), 130.28 (CH, 2xC6), 129.23-129.10 P (CH, d, J 52.0, 6xPhortho), 123.47 (CH, 
2xC7), 123.10-122.17P (C, d, J 372.0, C1), 122.44-122.28 P (CH, d, J 64.0, 3xPh), 
48.85 (CH2, C4), 46.2546.17P (C, d, J 32.0, C2); m/z (El+) 464 ([M]+, 3), 328 (100), 
262 (8), 201 (6), 184 (3), 183 (15), 165 (5), 108 (6), 77 (4); found [M+H]+, 464.1309, 
C21H28N203P requires [M+H]+, 464.1290; A = 4.1 ppm. 
Methyl 3-(4-nitrophenyl)-2-oxopropanoate 90 
02N 
OMe 
Ozone was bubbled for 30 mins into a solution of phosphorane 79 (4.89 g, 10.5 
mmol, 1.00 eq) in DCM/MeOH 7:3 (100 ml) at -78 °C. The clear pale yellow solution 
turned lilac blue after 20 mins. N2 was then bubbled for 23 mins. The solution turned 
colourless. It was stirred at -78 °C to -70 °C for 30 mins, at -50 °C to -45 °C for 45 
mins, at -10 °C to 0 °C for 40 min, and finally at RT for 14.5 hr. The solution which 
had turned bright yellow was concentrated in vacuo to give a yellow oil (6.42 g). The 
yellow oil was re-dissolved in DCM (50.0 ml) and washed with 0.1M AgNO3(aq) 
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(2x50.0 ml). The aqueous phase was extracted with DCM (5x50.0 ml), the organic 
phases were combined and concentrated in vacuo to give a brownish oil (4.68 g). 
The crude was purified by flash column chromatography on silica gel (hexane/EtOAc 
9:1, 8:2, 7:3, EtOAc) to yield 760.8 mg (37%) of 90 as a yellow amorphous powder: 
Rf 0.40 [hexane/EtOAc 1:1]; Vmax  (nujol)/cm-1  3422, 2924-2854, 1749, 1684, 1594, 
1507, 1473, 1339, 1234, 1069; SH (C D C13) 8.23-8.21 (2H, d, J 9.0, H7), 7.91-7.89 (2H, 
d, J 9.0, H6), 6.79 (1H, S, °Hanoi), 6.56 (1H, S, H4), 3.97 (3H, s, H1); Sc (CDCI3) 
165.95 (C, C2), 146.61 (C, C8), 141.65 (C, C5), 140.61 (C, C3), 130.24 (o, 2xC6), 
123.71 (CH, 2xC7), 108.33 (CH2, C4), 53.71 (CH3, C1); m/z (Ell 223 ([Mr, 39), 164 
(45), 163 ([M-COOMe]+, 100), 136 ([M-COCOOMe]+, 95), 133 (28), 106 (18), 90 (33), 
89 (59), 78 (30), 63 (24), 59 (21), 51 (11), 43 (4); found [M+H]+, 223.0475, CloH9N05 
requires [M+H]+, 223.0481; A = -2.7 ppm. 
Methyl 2-hydroxy-3-(4-nitrophenyl)propanoate 91 
02N 
OMe 
To a stirred yellow solution of a-keto ester 90 (718 mg, 3.22 mmol, 1.00 eq) in 
anhydrous methanol (20.0 ml) at 0 °C, under argon, was added sodium borohydride 
(174 mg, 4.60 mmol, 1.43 eq) in one portion. The solution first turned bright orange, 
then bright fluorescent red. It was stirred for 2 hr at 0 °C, then washed with saturated 
NH4CI (50.0 ml) and water (40.0 ml). The aqueous phase was separated from the 
organic phase and extracted with DCM (4x50.0 ml). The organic phases were 
combined and concentrated in vacuo to give a brownish oil (702 mg) which was 
purified by flash column chromatography on silica gel (1% NEt3, hexane/EtOAc 8:2, 
6.5:3.5, 6:4, 1:1, EtOAc) to yield 476.3 mg (66%) of 91 as a yellow oil: Rf 0.30 
[hexane/EtOAc 1:1]; Vmax  (DCM film)/cm-1  3560, 3025, 2924, 1734, 1602, 1473, 1374, 
1154, 1028, 759; SH (CDCI3) 8.18-8.16 (2H, d, J 8.0, H8), 7.43-7.40 (2H, d, J 8.5, H7), 
4.52-4.48 (1H, m, H3), 3.81 (3H, s, H1), 3.27-3.23 (1H, dd, J 14.0, J 4.0, H5), 3.09-
3,04 (1H, dd, J 14.0, J 7.0, H5), 2.89-2.88 (1H, d, J 5.0, H4); Sc (CDCI3) 174.00 (C, 
C2), 146.94 (C, C6), 144.32 (C, C9), 130.33 (CH, 2xC7), 123.41 (CH, 2xC8), 70.50 
(CH, C3), 52.69 (CH3, C1), 39.90 (CH2, C5); m/z (Elk) 207 ([M-OH]+, 100), 176 (29), 
166 (49), 137 (52), 120 (30), 107 (25), 91 (81), 78 (13), 65 (17). 
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Ethyl 2-hydroxy-3-(4-nitrophenyl)propanoate 100 
021.4 
To a stirred solution of ce-hydroxy ester 91 (74.6 mg, 0.331 mmol, 1.00 eq) and 
iodoethane (0.040 ml, 0.497 mmol, 1.50 eq) in anhydrous DMF (2.50 ml), was added 
sodium hydride (14.2 mg, 0.592 mmol, 1.79 eq). The mixture was stirred at 80 °C, 
under argon, for 19 hr before being concentrated in vacuo. It was re-dissolved in 
DCM (25.0 ml) and washed with water (2x25.0 ml). The aqueous phase was 
separated from the organic phase and extracted with DCM (2x30.0 ml) and 
chloroform (2x30.0 ml). The organic phases were combined and concentrated in 
vacuo to give a brown oil (86.7 mg) which was purified by flash column 
chromatography on silica gel (hexane/EtOAc 8:2, 7:3) to yield 27.0 mg (34%) of 100 
as a yellow oil: Rf 0.60 [hexane/EtOAc 1:1]; Vmax  (nujol)/cm-1  3649, 3059-2849, 1733, 
1493, 1265, 1181, 1028, 758; SH (CDCI3) 8.16-8.14 (2H, d, J 9.0, H8), 7.43-7.41 (2H, 
d, J 9.0, H7), 4.48-4.44 (1H, m, H4), 4.27-4.22 (2H, dd, J 14.5, J 7.0, H2), 3.26-3.21 
(1H, dd, J 14.0, J 4.0, H5), 3.08-3.03 (1H, dd, J 14.0, J 7.0, H5), 2.99-2.98 (1H, d, J 
5.0, H10), 1.31-1.28 (3H, t, J 7.0, H1); Sc  (CDCI3) 173.55 (C, C3), 146.93 (C, C6), 
144.33 (C, C9), 130.35 (CH, 2xC7), 123.36 (CH, 2xC8), 70.41 (CH, C4), 62.07 (CH2, 
C2), 39.88 (CH2, C5), 14.08 (CH3, C1); m/z (El+) 221 (77), 193 (46), 166 (85), 137 
(68), 120 (41), 107 (26), 91 (100), 75 (24). 
(S)-Methyl 2-hydroxy-3-phenylpropanoate 96 
OMe 
Sulphuric acid (24.1 ,uL, 0.451 mmol, 0.10 eq) in anhydrous methanol (0.900 ml) was 
added to a stirred solution of L-(-)-3-phenyllactic acid (759 mg, 4.51 mmol, 1.00 eq) in 
methanol (2.00 ml). After stirring the mixture for 18 hr, under argon, at RT, it was 
concentrated in vacuo to give a white solid which was purified by flash column 
chromatography on silica gel (hexane, hexane/EtOAc 8:2, 7:3, 6:4, EtOAc) to yield 
621 mg (76%) of the ester 96 as a white crystalline solid: Rf 0.55 [EtOAc]; Vmax 
(nujol)/cm-1  3567, 3060-2924, 1734, 1602, 1452, 1375, 1181, 1029, 756; gH (CDCI3) 
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7.34-7.23 (5H, m, Hai), 4.484.45 (1H, dd, J 7.0, J 4.5, H3), 3.77 (3H, s, H1), 3.16-
3.12 (1H, dd, J 14.0, J 4.5, H5), 3.01-2.96 (1H, dd, J 14.0, J 7.0, H5), 2.92 (1H, br, 
H4); et (CDCI3) 175.08 (C, C2), 137.29 (C, C6), 129.78 (CH, C9), 128.72, 127.09 
(CH, C7, C8), 72.17 (CH, C3), 52.35 (CH3, C1), 41.03 (CH2, C5); m/z (Elf) 180 (PAl+, 
24), 162 ([M-OH]+, 52), 131 (15), 121 (25), 103 (24), 92 (23), 91 ([C6H5CH2]+, 100), 77 
(10); found [M+H]+, 180.0794, C101-11203 requires [M+H]+, 180.0786; A = 4.4 ppm. 
3-(4-Aminophenyl)propanoic acid 108 
9 
H2N 
OH 
1 
Para-nitrophenyl propanoic acid (2.72 g, 13.9 mmol, 1.00 eq) was dissolved in a 
mixture of EtOAC/EtOH 1:1 (40.0 ml). The flask was thoroughly flushed with 
hydrogen gas. Pd/C (276 mg, 10% in mass) was added and the mixture stirred at RT, 
under hydrogen, for 15 hr. It was filtered over celite, and the filtrate concentrated in 
vacuo to yield a white solid (2.42 g) which was purified by flash column 
chromatography on silica gel (DCM, DCM/solvent C 1:1, solvent C, methanol) to yield 
2.27 g (98%) of 108 as an off-white powder: Rf 0.15 [solvent C]; vmax (nujol)/cm-1  
3348, 3050-2854, 1696, 1435, 1283; SH (CDCI3/MeOD 2:1) 6.96 (2H, d, J 8.5, H6), 
6.64-6.62 (2H, d, J 8.5, H7), 2.80-2.76 (2H, t, J 8.0, H4), 2.52-2.48 (2H, t, J 8.0, H3); 
Sc (CDCI3/MeOD 2:1) 176.36 (C, C2), 144.80 (C, C8), 131.64 (C, C5), 129.42 (CH, 
2xC6), 116.41 (CH, 2xC7), 36.60 (CH2, C3), 30.61 (CH2, C4); m/z (Elk) 165 ([M]+,25), 
120 (3), 119 (4), 106 ([M-CH2COOH]+, 100), 91 (5), 77 (7), 65 (5); found [M+H]+, 
165.0782, C9H11NO2 requires [M+H]+, 165.0790; A = -1.1 ppm. 
Ethyl 3-(4-aminophenyl)propanoate 110 
10
H2N 
1 
8 
 
To a stirred solution of amine 108 (246 mg, 0.130 mmol, 1.00 eq) in ethanol (5.00 ml) 
were added two drops of concentrated sulphuric acid. A creamy ppt was seen. A few 
drops of concentrated sulphuric acid were added and the solution turned clear pale 
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yellow. The mixture was stirred at RT for 21 hr and was then concentrated in vacuo to 
give a yellow oil (937 mg) which was purified by flash column chromatography on 
silica gel (hexane, hexane/EtOAc 9:1, 8:2, EtOAc) to yield 88.0 mg (30%) of amine 
110 as a yellow oil: Rf 0.65 [EtOAc]; Vmax  (DCM film)/cm-1  3567, 1749, 1540, 1521, 
1044; gH (CDCI3) 7.01-6.99 (2H, d, J 8.5, H7), 6.63-6.61 (2H, d, J 8.5, H8), 4.16-4.10 
(2H, dd, J 14.5, J 7.0, H2), 3.52 (2H, br, H10), 2.87-2.83 (2H, t, J 8.0, H5), 2.59-2.55 
(2H, t, J 8.0, H4), 1.26-1.23 (3H, t, J 7.0, H1); dc (CDCI3) 173.06 (C, C3), 144.57 (C, 
C9), 130.48 (C, C6), 129.02 (CH, 2xC7), 115.19 (CH, 2xC8), 60.22 (CH2, C2), 36.31 
(CH2, C4), 30.13 (CH2, C5), 14.14 (CH3, C1); m/z (Er) 193 ([M]+, 36), 119 (17), 106 
([H2NC6H5CH2]+, 100); found [M+H]+, 193.1107, C11H15NO2 requires [M+H]+, 
193.1103; A = 2.1 ppm. 
Ethyl 2-(diethoxyphospholyl)-2-ethoxyacetate 129224 
	
oI 	0 
. 	
/ 5 
8 	-(3 P  1 	10 	6 
7r-- 0,1  
3 . 
4 
To a colourless solution of 2-chloro-2-ethoxyacetic acid ethyl ester (1.41 g, 8.49 
mmol, 1.00 eq) in anhydrous DMF (10.0 ml) was added triethylphosphite (1.46 ml, 
8.49 mmol, 1.00 eq) and the reaction mixture was refluxed at 145 °C for 15 hr and at 
152 °C for 30 min. The solution which had turned yellow was allowed to cool down to 
RT and water (40.0 ml) was poured onto the reaction mixture. The aqueous phase 
was extracted with DCM (3x40.0 ml). After drying the organic phase over MgSO4, 
concentration in vacuo yielded 2.11 g of 129 as a yellowish oil (92%) which was used 
as such for the HWE couplings: Rf 0.25 [hexane/EtOAc 1:1]; Vmax  (film)/cm-1  1746, 
1265, 1145, 1039; gfi (CDCI3) 4.24-4.09 (5H, m, 4xH7, 2xH5), 3.68-3.61 (1H, m, H3), 
3.54-3.47 (1H, m, H3), 1.29-1.21 (9H, m, 6xH8, 3xH4 or 3xH6), 1.19-1.16 (3H, m, 
3xH4 or 3xH6); Sc (CDCI3) 167.34-167.32P (C, J 2.0, C1), 77.34-75.77P (CH, J 157.0, 
C2), 68.35-68.23P (CH2, J 12.0, C3), 63.46-63.39P (CH2, J 7.0, 1xC7), 63.37-63.30 
(CH2, J 7.0, 1xC7), 61.45 (CH2, C5), 16.15-16.09P (CH3, J 6.0, 2xC8), 14.70 (CH3, C4 
or C6), 13.88 (CH3, C4 or C6); m/z (ESI+) 291 ([M+Na]+, 100), 269 ([M+H]+, 69); 
found [M+H]+, 269.1162, C10H2206P requires [M+H]+, 269.1154; Found: C, 44.6; H, 
7.9. Required: C, 44.8; H, 7.9; A = 3.0 ppm. 
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(Z)-Ethyl 2-ethoxy-3-(1H-indo1-5-yOactylate 131 and (E)-ethyl 2-ethoxy-3-(1H-indo1-5-
yOactylate 132177  
To a milky suspension of sodium hydride, 60% in oil (310 mg, 7.75 mmol, 2.23 eq) 
and molecular sieves 4A in anhydrous THF (40.0 ml) at 0 °C, under a constant flow of 
N2, was added dropwise via syringe pump, phosphonoacetate 129 (1.87 g, 6.97 
mmol, 2.00 eq) in THF (2.00 ml) over 29 min. The suspension turned into a clear pale 
yellow solution. The latter was stirred at 0 °C for 1 hr before the dropwise addition of 
5-indole-carbaldehyde 128 (506 mg, 3.48 mmol, 1.00 eq) in dry THF (4.00 ml) via 
syringe pump over 38 min. The solution turned orange, it was stirred at 0 °C for 1 hr 
and at RT for 44 hrs. The reddish solution was concentrated in vacuo, then re-
dissolved in EtOAc (40.0 ml) and washed with water (2x45.0 ml). Some NaCI was 
added to aid the separation of the two phases. The aqueous phase was extracted 
with EtOAc (4x90.0 ml). After drying the organic phase over MgSO4, concentration in 
vacuo of the organic phase gave a brown liquid which was purified by flash column 
chromatography on silica gel (hexane/EtOAc 20:1, 15:1, 10:1, 9:1, 8:2) to yield 844 
mg (93%) of the product. Ratio Z:E = 63:37. 
Z isomer 131: amorphous white powder; mp 77.5-78.5 °C (hexane/DCM 20:1); Rf 
0.35 [hexane/EtOAc 6:4]; Vmax  (nujol)/cnrfl  3267, 2923-2850, 1731, 1687, 1550, 1378; 
(CDCI3) 8.32 (1H, br, H1), 8.13 (1H, s, H4), 7.74-7.72 (1H, dd, J 8.5, J 1.5, H6), 
7.40-7.38 (1H, d, J 9.0, H7), 7.23-7.22 (1H, t, J 3.0, H2), 7.20 (1H, s, H1'), 6.60-6.58 
(1H, m, H3), 4.35-4.30 (2H, q, J 14.5, J7.0, H3'), 4.06-4.00 (2H, q, J 14.0, J 7.0, H6'), 
1.44-1.38 (6H, m, H4', H7'); & (CDCI3) 165.30 (C, C5'), 142.56, 136.03, 127.98 
(3xC), 126.19 (CH, C1'), 125.60 (C, C3a), 124.90 (CH, C6), 124.56 (CH, C2), 123.46 
(CH, C4), 111.00 (CH, C7), 103.36 (CH, C3), 67.46 (CH2, C6'), 60.92 (CH2, C3'), 
15.55, 14.35 (CH3, C4', C7'); m/z (Elk) 259 ([M]+, 100), 202 ([M-CH2CH3-CH2CH3]+, 
39), 157 (75), 129 (51), 118 ([lndoler, 13); found [M+H]+, 259.1199, C15H17NO3 
requires [M+H]+, 259.1208; Found: C, 69.6; H, 6.7; N, 5.3. Required: C, 69.5; H, 6.6; 
N, 5.4; A = -3.5 ppm. 
E isomer 132: amorphous white powder; mp 98.5-100.5 °C (hexane/DCM 20:1); Rf 
0.28 [hexane/EtOAc 6:4]; Vmax (nujol)/cm-1 3330, 2923-2850, 1702, 1621, 1379, 1227, 
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1176; 4.1 (CDCI3) 8.23 (1H, br, H1), 7.51-7.50 (1H, d, J 0.5, H4), 7.30-7.28 (1H, d, J 
8.5, H7), 7.17-7.16 (1H, t, J 3.0, H2), 7.08-7.06 (1H, dd, J 8.5, J 1.5, H6), 6.50-6.49 
(1H, m, H3), 6.32 (1H, s, H1'), 4.18-4.13 (2H, q, J 14.0, J 7.0, H3'), 3.99-3.94 (2H, q, 
J 14.0, J 7.0, H6'), 1.45-1.42 (3H, t, J 7.0, H7'), 1.09-1.06 (3H, J 7.0, H4'); 	(CDCI3) 
165.24 (C, C5'), 146.23, 134.93, 127.82, 126.17 (4xC, C2', C7a, C5, C3a), 124.54 
(CH, C2), 122.99 (CH, C6), 120.54 (CH, C4), 111.47 (CH, C1'), 110.58 (CH, C7), 
102.57 (CH, C3), 64.62 (CH2, C6'), 61.07 (CH2, C3'), 14.53 (CH3, C4'), 13.68 (CH3, 
C7'); m/z (Elf) 259 ([M]+, 100), 202 ([M-CH2CH3-CH2CH3]+, 37), 157 (68), 129 (49); 
found [M+H]+, 259.1199, C15H17NO3 requires [M-1-1-1]+,259.1208; Found: C, 69.6; H, 
6.5; N, 5.5. Required: C, 69.5; H, 6.6; N, 5.4; A = -3.5 ppm. 
(Z)-Ethyl 2-ethoxy-3-(1-(phenylsulfony1)-1H-indol-5-yOactylate 166 
To a vigorously stirred mixture of indole 131 (475 mg, 1.83 mmol, 1.00 eq) and n-
tetrabutylammonium bromide (59.5 mg, 0.185 mmol, 0.10 eq) in 50% aqueous NaOH 
(1.80 ml), toluene (2.30 ml) and water (2.70 ml) was added dropwise, over 10 min, 
benzenesulfonyl chloride (0.240 ml, 1.89 mmol, 1.03 eq) in toluene (0.900 ml) via 
syringe pump. The reaction mixture turned from yellow to green, then brown and 
finally violet upon addition of the chloride. It was stirred at RT for 18 hr. A yellow 
organic layer on top of a colourless aqueous layer was observed. After removal of the 
aqueous phase, the organic phase was washed with 0.1M NaHCO3 (30.0 ml), water 
(40.0 ml) and saturated brine (40.0 ml). After extractions of the aqueous phases with 
EtOAc (4x25.0 ml, 1x50.0 ml, 1x50.0 ml), the organic phase was dried over MgSO4 
and concentrated in vacuo to give a pale orange oil (798 mg) which was purified by 
flash column chromatography on silica gel (hexane/EtOAc 15:1, 10:1) to give 648 mg 
(89%) of the product as an amorphous white solid; mp 109.5-110.5 °C (hexane/DCM 
20:1); Rf 0.20 [hexane/EtOAc 8:2]; Vmax  (nujol)/cm-1  2954-2850, 1709, 1460, 1373, 
1176, 1089, 723; 4.1 (CDCI3) 8.01 (1H, d, J 1.5, H4), 7.99-7.97 (1H, d, J 9.0, H7), 
7.92-7.89 (2H, m, 2xH4'), 7.78-7.75 (1H, dd, J 9.0, J 1.5, H6), 7.58-7.57 (1H, d, J 3.5, 
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H2), 7.56-7.53 (1H, m, H4'), 7.48-7.44 (2H, m, 2xH3'), 7.05 (1H, s, HI"), 6.68-6.67 
(1H, dd, J 3.5, H3), 4.34-4.28 (2H, q, J 14.5, J 7.0, 2xH3"), 4.04-3.99 (2H, q, J 14.0, 
J 7.0, 2xH6"), 1.40-1.36 (6H, m, 3xH4', 3xH7'); 	(CDCI3) 164.71 (C, C5"), 144.12 
(C), 138.15 (g, 134.67 (C), 133.92 (CH, C4'), 130.89 (CH, C3a), 129.31 (CH, 2xC3'), 
129.13 (C, C5), 126.88 (CH), 126.74 (CH), 123.91 (Cl"), 123.27 (C4), 113.37 (CH, 
C7), 109.46 (CH, C3), 67.62 (CH2, C6"), 61.13 (CH2, C3"), 15.55 (CH3), 14.29 (CH3); 
m/z (Elk) 399 ([M]+, 100), 342 (11), 297 (55), 156 (90); found [M+H]+, 399.1146, 
C211-121NO5S requires [M+H]+, 399.1140; Found: C, 63.1; H, 5.4; N, 3.5. Required: C, 
63.1; H, 5.3; N, 3.5; O = 1.5 ppm. 
Methyl 2-ethoxy-3-(1H-indo1-5-yl)propanoate 126 
To a yellow solution of the starting material 131 (380 mg, 1.47 mmol, 1.00 eq) in 
anhydrous methanol (13.0 ml) at RT, under a constant flow of N2, were added the 
magnesium turnings (648 mg, 26.7 mmol, 18.2 eq) in one portion and the reaction 
mixture was stirred at RT for 3 hr. Effervescence was seen as hydrogen gas was 
evolved. The reaction mixture was poured onto water (60.0 ml) and the two phases 
were separated. The aqueous phase was extracted with DCM (4x60.0 ml) and the 
organic extracts were washed with brine (60.0 ml). After extraction with DCM (4x60.0 
ml) and drying over MgSO4, concentration in vacuo gave a brownish oil which was 
purified by flash column chromatography on silica gel (hexane/EtOAc 9:1, 8:2, 
EtOAc) to yield 300 mg (83%) of the product as a yellow oil: Rf 0.20 [hexane/EtOAc 
7.5:2.5]; Vmax  (film)/cm-1  3408, 2977-2850, 1741, 1444, 1209, 1110; S,i (CDCI3) 8.25 
(1H, br, H1), 7.51 (1H, s, H4), 7.32-7.30 (1H, d, J 8.0, H7), 7.18-7.17 (1H, t, J 3.0, 
H2), 7.11-7.08 (1H, dd, J 8.5, J 1.5, H6), 6.51-6.50 (1H, m, H3), 4.14-4.11 (1H, dd, J 
7.5, J 1.5, H2'), 3.71 (3H, s, H4"), 3.65-3.58 (1H, m, H3'), 3.42-3.35 (1H, m, H3'), 3.15 
(1H, s, H1'), 3.13-3.12 (1H, d, J 3.0, H1'), 1.20-1.16 (3H, t, J 7.0, H4'); Sc  (CDCI3) 
173.30 (C, C5'), 134.80 (C), 128.19 (C), 127.98 (C), 124.38 (CH, C2), 123.54 (CH, 
C6), 121.04 (CH, C4), 110.74 (CH, C7), 102.23 (CH, C3), 80.98 (CH, C2'), 66.21 
(CH2, C3'), 51.73 (CH3, C6'), 39.51 (CH2, C1'), 15.02 (CH3, C4'); m/z (Elk) 247 ([Mr, 
16), 130 (100), 117 (3); found [M+H]+, 247.1205, C14H17NO3 requires [M+H]+, 
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247.1208; Found: C, 68.2; H, 6.9; N, 5.8. Required: C, 68.0; H, 6.9; N, 5.7; A = -1.2 
ppm. 
Methyl 2-ethoxy-3-(1-(phenylsulfonyI)-1H-indol-5-yl)propanoate 135 
To a vigorously stirred mixture of indole 126 (237 mg, 0.960 mmol, 1.00 eq) and n-
tetrabutylammonium bromide (32.0 mg, 0.099 mmol, 0.10 eq) in 50% aqueous NaOH 
(0.900 ml), toluene (0.600 ml) and water (1.40 ml) was added dropwise, over 16 min, 
benzenesulfonyl chloride (0.140 ml, 1.06 mmol, 1.10 eq) in toluene (0.800 ml) via 
syringe pump. The reaction mixture turned from yellow to orange. It was stirred at RT 
for 18.5 hr. After removal of the aqueous phase, the organic phase was washed with 
0.1M NaHCO3 (20.0 ml), water (60.0 ml) and saturated brine (60.0 ml). After 
extractions of the aqueous phases with EtOAc (2x10.0 ml, 4x100 ml), the organic 
phase was dried over MgSO4 and concentrated in vacuo to give an off-white oil which 
was purified by flash column chromatography on silica gel (hexane/EtOAc 9:1, 8:2, 
EtOAc) to give 175 mg (47%) of the product as a colourless oil: Rf 0.15 
[hexane/EtOAc 7.5:2.5]; Vmax  (DCM film)/cm"' 3062-2975, 1743, 1531, 1269, 1178, 
1043; gH (CDCI3) 7.92-7.90 (1H, d, J 8.5, H7), 7.88-7.86 (2H, m, H3'), 7.55-7.51 (2H, 
m, H2, H4'), 7.45-7.40 (3H, m, H2', H4), 7.21-7.19 (1H, dd, J 8.5, J 1.5, H6), 6.62-
6.61 (1H, d, J 3.0, H3), 4.05-4.02 (1H, dd, J 7.5, J 5.5, H2"), 3.67 (3H, s, H4"), 3.61-
3.55 (1H, m, H3"), 3.36-3.29 (1H, m, H3"), 3.08-3.06 (2H, dd, J 7.5, J 5.5, H1"), 1.15-
1.11 (3H, t, J 7.0, H4"); cvc (CDCI3) 172.86 (C, C5"), 138.29 (C), 133.82 (C), 133.73 
(CH, C4'), 132.35 (C), 130.89 (C), 129.19 (CH, 2xC2'), 126.72 (CH, 2xC3'), 126.48 
(CH), 126.19 (CH), 121.97 (CH, C4), 113.21 (CH, C7), 109.18 (CH, C3), 80.28 (CH, 
C2"), 66.19 (CH2, C3"), 51.81 (CH3, C6"), 39.12 (CH2, Cl"), 14.98 (CH3, C4"); rn/z 
(Elk) 387 ([M]+, 15), 274 (20), 270 ([M-ethoxypropanoic side chain]+, 100), 129 (27); 
found [M+H]+, 387.1141, C201-121NO5S requires [M+H]+, 387.1140; A = 0.3 ppm. 
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2-Ethoxy-3-(1H-indo1-5-yl)propanoic acid 38 
OH 
To a pale yellow solution of the starting material 126 (53.4 mg, 0.216 mmol, 1.00 eq) 
in a mixture of ethanol/water 1:1 (1.60 ml), were added the potassium hydroxide 
pellets (15.1 mg, 0.269 mmol, 1.25 eq) and the solution was stirred at 78 °C for 15 hr. 
The yellow solution was allowed to cool down to RT and concentrated in vacuo. With 
vigorous stirring in ice, was added 1M HCI (-8 drops) until a pH of 1 was reached. 
The desired acid crashed out as a brown ppt. It was dissolved in DCM and washed 
with water (2x30.0 ml). The aqueous phase was extracted with DCM (4x50.0 ml). 
After drying over MgSO4, concentration in vacuo gave 46.2 mg (92%) of the product 
as a pale yellow oil: Rf 0.45 [Solvent B]; vm„ (DCM film)/cm-1  3411, 2978-2929, 1724, 
1265, 1105; 4i  (CDCI3) 10.8 (1H, br, OH), 8.47 (1H, br, H1), 7.57 (1H, s, H4), 7.30-
7.28 (1H, d, J 8.5, H7), 7.15-7.13 (2H, m, H2, H6), 6.52 (1H, br, H3), 4.23-4.20 (1H, 
dd, J 8.0, J 4.5, H2'), 3.70-3.62 (1H, m, 1xH3'), 3.49-3.41 (1H, m, 1xH3'), 3.31-3.26 
(1H, dd, J 14.0, J 4.0, H1'), 3.21-3.16 (1H, dd, J 14.0, J 7.5, H1'), 1.21-1.17 (3H, t, J 
7.0, H4'); Sc (CDCI3) 177.33 (C, C5'), 134.76 (C), 127.84 (C), 127.49 (C), 124.63 
(CH), 123.25 (CH), 120.95 (CH, C4), 110.93 (CH, C7), 101.80 (CH, C3), 80.27 (CH, 
C2'), 66.52 (CH2, C3'), 38.91 (CH2, C1'), 14.82 (CH3, C4'); m/z (Elk) 233 ([M]+, 22), 
130 (M-(ethoxypropanoic acid side chain)r, 100); found [M+H]+, 233.1047, 
C13F115NO3 requires [M+H]+, 233.1052; Found: C, 67.0; H, 6.4; N, 5.9. Required: C, 
66.9; H, 6.5; N, 6.0; A = -2.1 ppm. 
4-Methyl-benzenesulfonyl azide 146227  
II 	o G N=--- N=N 
II 
O 
To a solution of sodium azide (5.10 g, 78.4 mmol, 1.00 eq) in ethanol (25.0 ml) was 
added a colourless solution of p-toluene sulfonyl chloride (14.9 g, 78.2 mmol, 1.00 
eq) in acetone (70.0 ml). A precipitate of NaCI formed immediately. The reaction 
mixture was stirred at RT for 17 hr. It was then filtered and the acetone was removed 
by rotary evaporation. The organic phase was diluted with DCM (40.0 ml), and 
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washed with water (3x40 ml). The aqueous phase was extracted with DCM (4x90.0 
ml). After drying the organic phase over Na2SO4, concentration in vacuo yielded 15.1 
g of 146 as a colourless liquid (98%): Rf 0.40 [hexane/EtOAc 8:2]; Vmax  (film)/cm-1  
2129, 1369, 1171; SH (CDCI3) 7.85-7.83 (2H, m, H2), 7.42-7.40 (2H, m, H3), 2.48 (3H, 
br, H1'); 8 (CDCI3) 146.17 (C, C4), 135.42 (C, C1), 130.21 (CH, 2xC3), 127.43 (CH, 
2xC2), 21.65 (CH3, C1'); mlz (El+) 197 ([Mr, 8), 155 ([M-azide]+, 70), 91 
([methylbenzene]+, 100); found [M+H]+, 197.0256, C7H7N302S requires [M+H]+, 
197.0259; Found: C, 42.7; H, 3.6; N, 21.3. Required: C, 42.6; H, 3.6; N, 21.3; A = -1.5 
ppm. 
Ethyl 2-diazo-2-(diethoxyphosphotyl)acetate 147228 
0 	0 
3 	I I 
4 	 6 
3r°liO 
4 	NQ 
To a suspension of sodium hydride (157 mg, 3.92 mmol, 1.23 eq) in dry THF (8.00 
ml) under nitrogen at 0 °C, was added dropwise, over 3 min, triethylphosphono-
acetate (0.630 ml, 3.20 mmol, 1.00 eq). The suspension turned into a clear colourless 
solution. After stirring at 0 °C for 47 min, was added, a solution of tosyl azide 146 
(630 mg, 3.20 mmol, 1.00 eq) in dry THF (2x1.00 ml). The reaction mixture turned 
yellow, it was left to stir in the ice bath overnight. Ether (14.0 ml) and water (14.0 ml) 
were added and the 2 layers were separated. The aqueous phase was extracted with 
ether (4x20.0 ml). The combined ethereal extracts were washed with aq NaOH 0.5M 
(50.0 ml), water (90.0 ml) and brine (80.0 ml). The aqueous phases were extracted 
with ether respectively (4x50.0 ml, 3x80.0 ml, 2x100 ml). After drying the organic 
phase over MgSO4, concentration in vacuo yielded a colourless liquid which was 
purified by flash column chromatography on silica gel (hexane, hexane/EtOAc 8:2, 
6:4) to yield 586 mg (73%) of the product as a pale yellow liquid: Rf 0.20 
[hexane/EtOAc 1:1]; vmax (film)/cm-1  2987, 2131, 1707, 1284, 1026; SH (CDCI3) 4.28-
4.22 (2H, q, J 14.5, J 7.0, 2xH5), 4.23-4.10 (4H, m, 2xH3), 1.36-1.33 (6H, dt, J 7.0, J 
0.5, 2xH4), 1.30-1.27 (3H, J 7.0, H6); Sc (CDCI3) 163.40-163.28P (C, d, J 12.0, C1), 
129.48-126.32P (C, d, J 316.0, C2), 63.59-63.53P (CH2, d, J 6.0, C3), 61.61 (CH2, C5), 
16.09-16.02 (CH3, d, J 7.0, C4), 14.25 (CH3, C6); m/z (El+) 250 ([M]+, 16), 121 (100), 
109 (98), 93 (73), 81 (68), 65 (87); found [M+H]+, 250.0711, C8H15N205P requires 
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[M+H]+, 250.0719; Found: C, 38.5; H, 6.0; N, 11.1. Required: C, 38.4; H, 6.0; N, 11.2; 
A = -3.2 ppm. 
Ethyl 2-(diethoxyphosphoty1)-2-(2,2,2-trifluoroethoxy)acetate 13023° 
0 	0 
c,28 
4 CF- 
A mixture of diazo ester 147 (586 mg, 2.34 mmol, 1.00 eq), trifluoroethanol (0.340 ml, 
4.68 mmol, 2.00 eq) and Rh(II) acetate dimer (10.5 mg, 0.024 mmol, 0.01 eq) in 
benzene (7.00 ml) was heated at 85 °C for 22 hr. The green solution was 
concentrated in vacuo to give a greenish oil which was purified by flash column 
chromatography on silica gel (hexane/EtOAc 8:2, 7:3, 6:4, 1:1) to yield 474 mg (63%) 
of the product as a colourless liquid: Rf 0.21 [hexane/EtOAc 4:6]; vma, (film)/cm-1  
1743, 1265, 1041; 	(CDCI3) 4.52-4.47P (1H, d, J 14.5, H2), 4.37-4.08 (7H, m, 2xH5, 
H7, 1xH3), 3.98-3.89 (1H, m, 1xH3), 1.36-1.30 (9H, m, 2xH6, H8); et (CDCI3) 166.09 
(C, C1), 127.51-119.19 (c., q, J 277.5, C4), 77.89-76.33P (CH, d, J 156.0, C2), 69.09-
67.94P (CH2, dq, J 35.0, J 11.5, C3), 64.05-63.93P (CH2, t, J 6.0, C5), 62.21 (CH2, 
C7), 16.26-16.2OP (CH3, d, J 6.0, C6), 13.99 (CH3, C8); m/z (El+) 322 ([M]+, 1), 249 
([M-ethyl]+, 20), 183 ([M-(trifluoroether + 2 ethyl groups)]+, 61), 155 ([M-(trifluoroether 
+ 3 ethyl groups)]+, 100), 65 (64); found [M+H]+, 322.0787, C1oH18F306P requires 
[M+H]+, 322.0793; Found: C, 37.3; H, 5.6. Required: C, 37.3; H, 5.6; A = -1.9 ppm. 
(Z)-Ethyl 3-(1H-indo1-5-y1)-2-(2,2,2-trifluoroethoxy)actylate 133 and (E)-ethyl 3-(1H-
indo1-5-y1)-2-(2,2,2-trifluoroethoxy)acrylate 134 
6' 
To a milky suspension of sodium hydride (9.8 mg, 0.245 mmol, 1.40 eq) in anhydrous 
THF (0.800 ml) at 0 °C, was added dropwise via syringe pump, phosphonoacetate 
130 (60.0 mg, 0.186 mmol, 1.06 eq) in THF (0.600 ml) over 7 min, under a constant 
flow of N2. The suspension turned into a clear pale yellow solution. The latter was 
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stirred at 0 °C for 24 min before the dropwise addition of 5-indole-carbaldehyde (25.4 
mg, 0.175 mmol, 1.00 eq) in dry THE (0.900 ml) via syringe pump over 34 min. The 
solution which had turned orange was left stirring in the ice bath over 15 hr, and then 
at RT for 25.5 hr. The yellowish solution was concentrated in vacuo, re-dissolved in 
EtOAc (15.0 ml) and washed with water (15.0 ml). The aqueous phase was extracted 
with EtOAc (4x15.0 ml) and the organic extracts were washed with brine (50.0 ml). 
The aqueous phase was extracted with EtOAc (4x50.0 ml). After drying the organic 
phase over MgSO4, concentration in vacuo of the organic phase gave a yellowish 
slurry which was purified by flash column chromatography on silica gel 
(hexane/EtOAc 20:1, 15:1, 10:1, 8:2) to yield 54.3 mg (99%) of the products. Ratio 
Z:E = 59:41. 
Z isomer: amorphous white powder; mp 98.0-99.0 °C (hexane/DCM); Rf 0.20 
[hexane/EtOAc 7.5:2.5]; vmax (nujol)/cre 3343, 2977-2850, 1691, 1459, 1371, 1261, 
1056; 4i  (CDCI3) 8.26 (1H, br, H1), 8.11 (1H, s, H4), 7.70-7.67 (1H, dd, J 8.5, J 1.5, 
H6), 7.42-7.40 (1H, d, J 9.0, H7), 7.27 (1H, br, H1'), 7.25-7.24 (1H, t, J 3.0, H2), 6.61- 
6.60 (1H, m, H3), 4.41-4.31 (4H, m, H3', H6'), 1.42-1.38 (3H, t, J 7.0, H7'); (CDCI3) 
164.05 (C, C5'), 140.54 (C, C2'), 136.37 (C, C7a), 128.08 (C, C5), 127.58-119.27 (C, 
q, J 277.0, C4"), 127.34 (CH, C2), 125.06 (CH), 124.84 (CH), 124.84 (C, C3a), 
124.19 (CH, C4), 111.16 (CH, C7), 103.62 (CH, C3), 68.38-67.34 (CH2, q, J 34.5, 
C3'), 61.34 (CH2, C6'), 14.29 (CH3, C7'); m/z (Elk) 313 ([M]+, 100), 230 (IM-
CH2CF3r,6), 202 ([M-CH2CH3-CH2CF3]+, 39), 157 (33), 129 (44), 118 ([1ndole]+, 13); 
found [M+H]+, 313.0925, C15H14F3NO3 requires [M+H]+, 313.0926; Found: C, 57.6; H, 
4.6; N, 4.5. Required: C, 57.7; H, 4.5; N, 4.5; A = -0.3 ppm. 
E isomer: amorphous pale yellow powder; mp 88.0-89.0 °C (hexane/DCM); Rf 0.16 
[hexane/EtOAc 7.5:2.5]; vmax (nujol)/cm-1  3372, 2950-2850, 1711, 1461, 1378, 1269, 
1157; SH (CDCI3) 8.19 (1H, br, H1), 7.63-7.62 (1H, d, J 1.0, H4), 7.35-7.33 (1H, d, J 
8.5, H7), 7.22-7.21 (1H, t, J 3.0, H2), 7.18-7.15 (1H, dd, J 8.5, J 1.5, H6), 6.74 (1H, s, 
H1'), 6.55-6.53 (1H, m, H3), 4.31-4.25 (2H, q, J 16.5, J 8.5, H3'), 4.23-4.17 (2H, q, J 
14.0, J 7.0, H6'), 1.16-1.12 (3H, t, J 7.0, H7'); 	(CDCI3) 163.51(C, C5'), 143.55 (C, 
C2'), 135.52 (C, C7a), 127.76 (C, C5), 124.77 (CH, C2), 124.54 (C, C3a), 123.42 
(CH, C6), 127.40-119.08 (C, q, J 277.0, C4'), 121.67 (CH, C4), 121.56 (CH, C1'), 
110.62 (CH, C7), 103.00 (CH, C3), 68.19-67.14 (CH2, q, J 35.0, C3'), 61.29 (CH2, 
C6'), 13.75 (CH3,C7'); m/z (Elk) 313 ([M]+, 100), 230 ([M-CH2CF3]+,6), 202 (IM-
CH2CH3-CH2CF3r, 38), 157 (34), 129 (48), 118 ([lndoler, 15); found [M+H]+, 
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313.0926, C15H14F3NO3 requires [M+H]+, 313.0926; Found: C, 57.8; H, 4.6; N, 4.4. 
Required: C, 57.7; H, 4.5; N, 4.5; A = 0.0 ppm. 
Methyl 3-(1H-indo1-5-y1)-2-(2,2,2-trifluoroethoxy)propanoate 127 
To a mixture of the starting material 133 and 134 (1.12 g, 3.59 mmol, 1.00 eq) and 
the magnesium turnings (1.31 g, 53.8 mmol, 15.0 eq) at 0 °C, under a constant flow 
of N2, was added the anhydrous methanol (15.0 ml). Effervescence was seen after a 
few mins and the RM turned darker yellow. The reaction mixture was left in the ice 
bath for 14.5 hr. A white agglomerate was seen, some dry methanol (10.0 ml) was 
added and the reaction mixture was stirred at RT for another 45 min. The RM was 
cooled to 0 °C and and water (22.0 ml) was added, followed by 2M HCI (14.0 ml). 
The mixture was filtered and brine (100 ml) was added. The 2 phases were 
separated and the aqueous phase was extracted with DCM (3x100 ml, 1x150 ml). 
After drying over MgSO4, concentration in vacuo gave an almost colourless oil which 
was purified by flash column chromatography on silica gel (hexane/EtOAc 20:1, 10:1, 
9:1, 8:2) to yield 653 mg (60%) of the product as a pale yellow oil: Rf 0.20 
[hexane/EtOAc 7.5:2.5]; Vmax  (DCM film)/crril  3377, 2933, 1741, 1513, 1278, 1164; 
(CDC13) 8.13 (1H, br, H1), 7.51 (1H, s, H4), 7.34-7.32 (1H, d, J 8.5, H7), 7.21-7.20 
(1H, t, J 3.0, H2), 7.10-7.08 (1H, dd, J 8.5, J 1.5, H6), 6.52-6.51 (1H, m, H3), 4.28-
4.25 (1H, dd, J 7.5, J 5.0, H2'), 4.02-3.93 (1H, m, H3'), 3.75 (3H, s, H6'), 3.73-3.66 
(1H, m, H3'), 3.26-3.21 (1H, dd, J 14.0, J 5.0, H1'), 3.19-3.14 (1H, dd, J 14.0, J 8.0, 
H1'); (CDCI3) 171.50 (C, C5'), 134.91 (C), 128.05 (C), 127.72-119.40 (C, q, J 
277.0, C4'), 127.42 (C), 124.43 (CH, C2), 123.62 (CH, C6), 121.25 (CH, C4), 110.84 
(CH, C7), 102.47 (CH, C3), 82.02 (CH, C2'), 68.40-67.38 (CH2, q, J 34.0, C3'), 52.11 
(CH2, C6'), 39.17 (CH2, C1'); m/z (Elk) 301 ([M]+, 100), 242 (65), 201 ([M-CH2CH3-
CH2CF3]+, 39), 131 (80); found [M+H]+, 301.0923, C14H14F3NO3 requires [M+H]+, 
301.0926; Found: C, 55.9; H, 4.7; N, 4.6. Required: C, 55.8; H, 4.7; N, 4.7; A = -1.0 
ppm. 
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3-(1H-Indo1-5-y1)-2-(2,2,2-trifluoroethoxy)propanoic acid 39 
OH 
To a very pale yellow solution of the starting material 127 (40.4 mg, 0.134 mmol, 1.00 
eq) in a mixture of ethanol/water 1:1 (1.60 ml), were added the potassium hydroxide 
pellets (9.6 mg, 0.171 mmol, 1.30 eq) and the solution was stirred at 78 °C for 15 hr. 
The solution was allowed to cool down to RT and concentrated in vacuo. With 
vigorous stirring in ice, was added 1M HCI (-5 drops) until a pH of 1 was reached. 
The desired acid crashed out. It was dissolved in DCM and washed with water 
(2x30.0 ml). The aqueous phase was extracted with DCM/MeOH 99:1 (4x50.0 ml). 
After drying over MgSO4 and filtration, concentration in vacuo gave 38.1 mg (93%) of 
the product as a pale yellow oil: Rf 0.25 [Solvent B]; Vmax (DCM film)/cm-1  3415, 2933, 
1726, 1279, 1167; 4i  (CDCI3/MeOD 2:1) 9.85 (1H, br, OH), 7.45 (1H, s, H4), 7.29-
7.27 (1H, d, J 8.0, H7), 7.14-7.13 (1H, m, H2), 7.04-7.01 (1H, dd, J 8.5, J 1.5, H6), 
6.38-6.37 (1H, m, H3), 4.20-4.17 (1H, dd, J 8.5, J 4.0, H2'), 3.97-3.87 (1H, m, 1xH3'), 
3.70-3.60 (1H, m, 1xH3'), 3.21-3.16 (1H, dd, J 14.0, J 4.0, H1'), 3.09-3.04 (1H, dd, J 
14.0, J 8.0, H1'); 	(CDCI3/MeOD 2:1) 173.97 (C, C5'), 135.68 (C), 128.53 (C), 
128.33-120.02 (C, q, J 277.0, C4'), 127.67 (CH, C3a), 125.20 (CH, C2), 123.52 (CH, 
C6), 121.31 (CH, C4), 111.40 (CH, C7), 101.73 (CH, C3), 82.44 (CH, C2'), 68.69-
67.66 (CH2, q, J 68.5, J 34.5, C3'), 39.63 (CH2, C1'); m/z (Elk) 287 ([M]+, 18), 130 
([M-(ethoxypropanoic acid side chain)r, 100); found [M+H]+, 287.0763, C13H12NO3F3 
requires [M+H]+, 287.0769; Found: C, 54.7; H, 4.2; N, 4.8. Required: C, 54.4; H, 4.2; 
N, 4.9; A = -2.0 ppm. 
1-(PhenylsulfonyI)-1H-indole Isom 
3' 
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To a solution of sodium hydride (159 mg, 6.46 mmol, 1.57 eq) in anhydrous DMSO 
(1.60 ml) was added a solution of 1H-indole 113 (34.0 mg, 0.118 mmol, 1.00 eq) in 
dry THE (2.40 ml) at 0°C under argon. The milky reaction mixture was stirred at RT, 
under Ar, for 1 hour. It turned into a clear yellow solution, to which benzenesulfonyl 
chloride (0.551 ml, 4.32 mmol, 1.05 eq) was added at 0 °C. After stirring at RT for 19 
hr, the mixture was poured onto water and extracted with EtOAc (4x25.0 ml). 
Concentration in vacuo gave a whitish solid which was purified by crystallisation from 
ethanol to yield 0.765 g (72%) of the product as white needles. 
2nd experimental procedure using phase transfer condtions: 
To a vigorously stirred mixture of 1H-indole 113 (3.02 g, 25.7 mmol, 1.00 eq) and n-
tetrabutylammonium bromide (0.833 g, 7.58 mmol, 0.10 eq) in 50% aqueous NaOH 
(25.0 ml), toluene (18.0 ml) and water (38.0 ml) was added dropwise, over 30 min, 
benzenesulfonyl chloride (3.61 ml, 28.3 mmol, 1.10 eq) in toluene (20.0 ml) via a 
syringe pump. The mixture turned pink upon addition of benzenesulfonyl chloride. 
The reaction flask was covered with aluminium foil and the mixture stirred at RT for 
18 hr. The solution turned green. After removal of the aqueous phase, the organic 
phase was washed with 0.1M NaHCO3 (30.0 ml), water (40.0 ml) and saturated brine 
(40.0 ml). After extractions with EtOAc, the organic phase was dried over Na2SO4 
and concentrated in vacuo to give a pinkish oil (6.70 g) which was purified by 
crystallisation from ethanol to yield 5.81 g (88%) of the product as white needles: mp 
79.5-80.0 °C (ethanol) [lit.,238 mp 77.5-79 °C (DCM/hexane)]; Rf 0.25 [hexane/EtOAc 
8:2]; Vmax  (nujol)/cm-1  2925-2854, 1919, 1771, 1576, 1497, 1396, 1339, 1263, 1069; 
if5H (CDCI3) 8.02-8.00 (1H, d, J 8.5, H7), 7.90-7.88 (21-I, d, J 7.5, 2xH2'), 7.59-7.58 (1H, 
d, J 4.0, H2), 7.55-7.52 (2H, m, H4, H4'), 7.46-7.42 (2H, t, J 8.0, 2xH3'), 7.35-7.31 
(1H, dt, J 8.0, J 1.0, H6), 7.26-7.22 (1H, dt, J 7.5, H5), 6.68-6.67 (1H, d, J 3.5, H3); et 
(CDCI3) 138.30 (C, C1'), 134.85 (C, C7a), 133.76 (CH, C4'), 130.74 (C, C3a), 129.23 
(CH, 2xC3'), 126.73 (CH, 2xC2'), 126.29 (CH, C2), 124.63 (CH, C5), 123.35 (CH, 
C6), 121.39 (CH, C4), 113.52 (CH, C7), 109.21 (CH, C3); m/z (Elk) 257 ([M]+, 93), 
141 (27), 116 ([indoler, 100), 89 (28), 77 (54), 63 (11), 51 (15); found [M+H]+, 
257.0509, C14H11NO2S requires [M+H]+, 257.0511; Found: C, 63.9; H, 4.4; N, 5.7. 
Required: C, 65.4; H, 4.3; N, 5.4; A = -0.8 ppm. 
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2-Benzy1-1-(phenylsulfony1)-1H-indole 161 
To a colourless solution of 1-(phenylsulfonyI)-1H-indole 160 (210 mg, 0.817 mmol, 
1.00 eq) in anhydrous THF (3.00 ml), was added dropwise a 1.7M t-BuLi solution in 
pentane (0.580 ml, 0.980 mmol, 1.20 eq) over 8 min, at -45 °C, under a constant flow 
of N2. The solution which had turned yellow, then bright orange, was stirred at -45 °C 
to -40 °C over 55 min, before the dropwise addition of benzyl bromide (116 ,uL, 0.975 
mmol, 1.19 eq) diluted in dry THF (1.00 ml) over 6 min, at -45 °C. The reaction 
mixture was allowed to warm up to -10 °C over 1 hour, then put in an ice bath for 
another hour, before being allowed to warm up to RT over 22 hr. The reaction mixture 
was poured over 5% citric acid (2x40.0 ml) and the aqueous phase was extracted 
with DCM (4x50.0 ml). The organic phase was dried over MgSO4 and concentrated in 
vacuo to give a brownish gum (245 mg) which was purified by flash column 
chromatography on silica gel (hexane/EtOAc 20:1, 18:1) to yield 165 mg (58%) of the 
product as a white crystalline solid: mp 98.0-100.0 °C (hexane/DCM 20:1); Rf 0.25 
[hexane/EtOAc 10:1]; vimx (nujol)/cm-1  2854, 1460, 1369, 1142, 746, 730, 708; SH 
(CDCI3) 8.09-8.07 (1H, d, J 8.5, H7), 7.56-7.54 (2H, d, J 7.5, 2xH2'), 7.41-7.37 (1H, t, 
J 7.5, H7), 7.28-7.09 (10H, m, H9', 2xH8', 2xH7', 2xH3', H4', H6, H5), 6.04 (1H, br, 
H3), 4.27 (2H, s, H5'); Sc (CDCI3) 140.96 (C, C2), 139.05 (C, C1'), 137.90 (C, C3a), 
137.24 (C, C6'), 133.53 (CH, C4'), 129.41 (C, C7a), 129.34 (CH, 2xC3'), 129.11 (CH, 
2xC2'), 128.47 (CH, 2xC7'), 126.66 (CH, C9'), 126.27 (CH, 2xC8'), 124.13 (CH, C5), 
123.54 (CH, C6), 120.32 (CH, C4), 114.66 (CH, C7), 111.05 (CH, C3), 35.22 (CH2, 
C5'); m/z (Er) 348 ([M+H]+, 21), 347 ([M]+, 75), 206 (72), 205 ([M-Bzsulfonyl group], 
100), 77 (21), 51 (6); found [M+H]+, 347.0970, C21H17NO2S requires [M+H]+, 
347.0980; Found: C, 72.7; H, 4.9; N, 4.0. Required: C, 72.6; H, 4.9; N, 4.0; A = -2.9 
ppm. 
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2-Benzyl-IH-indole 165239' 249 
To a solution of Me0H/NaOH 2M 5:1 (18.0 ml) was added the 2-benzyl indole 161 
(94.9 mg, 0.273 mmol, 1.00 eq) and the reaction mixture was refluxed at 110 °C for 
48 hr. After allowing the reaction mixture to cool down to RT, it was treated with 0.1M 
HCI to a pH of 2 and the aqueous phase was extracted with ether (3x50.0 ml) and 
DCM (3x50.0 ml). Concentration in vacuo of the organic phase gave the crude which 
was purified by flash column chromatography on silica gel (hexane/EtOAc 20:1, 12:1, 
1:1) to yield 51.4 mg (91%) of the product as a yellowish brown oil: Rf 0.20 
[hexane/EtOAc 9:1]; Vmax  (DCM film)/cm-1  3733, 3055, 1422, 1265, 895, 740, 705; ari 
(CDCI3) 7.79 (1H, br, H1), 7.62-7.60 (1H, dd, J 7.5, J 1.0, H4), 7.41-7.37 (2H, m, 
2xH4'), 7.34-7.28 (4H, m, H5', 2xH3', H7), 7.19-7.11 (2H, m, H5, H6), 6.39-6.38 (1H, 
br, H3), 4.18 (2H, s, H1'); et (CDCI3) 138.49 (C, C2'), 137.75 (2xC), 136.26 (C, C3a), 
128.81 (CH, 2xC3'), 128.71 (CH, 2xC4'), 126.72 (CH, C5'), 121.29 (CH), 119.98 (CH, 
C4), 119.70 (CH), 34.70 (CH2, C1'); m/z (Elf) 208 ([M+H]+, 15), 207 ([M]+, 100), 206 
(50), 130 ([M-Ph]+, 62); found [M+H]+, 207.1057, C13F115N requires [M+H]+, 207.1048; 
Found: C, 86.9; H, 6.2; N, 6.8. Required: C, 86.9; H, 6.3; N, 6.8; A = 4.3 ppm. 
1-Benzenesulfonyl-2-bromo-IH-indole 168241' 25° 
4' 
To a clear colourless solution of diisopropylamine (0.110 ml, 0.778 mmol, 1.09 eq) in 
anhydrous THE (1.50 ml) at -78 °C, under a constant flow of N2, was added dropwise, 
n-BuLi, 2.5M in hexanes (0.290 ml, 0.725 mmol, 1.02 eq) over 4 min. The almost 
colourless solution was stirred at a temperature below -75 °C for 34 min before the 
dropwise addition of 1-(phenylsulfonyI)-1H-indole 160 (183 mg, 0.710 mmol, 1.00 eq) 
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in anhydrous THF (1.80 ml) via syringe pump, over 9 min. The reaction mixture 
turned yellowish. After stirring at a temperature below -70 °C for 1.5 hr, it was allowed 
to warm up to 0 °C over 1 hr. The reaction mixture turned orangish. It was cooled 
down to -78 °C again before cyanogen bromide (96.6 mg, 0.912 mmol, 1.28 eq) 
dissolved in dry THF (0.700 ml) was added dropwise, over 2 min. The solution which 
turned brown was allowed to warm up to RT over 18.5 hr before being poured onto 
0.1M NaHCO3 (12.0 ml). After extraction with DCM (4x12.0 ml), the organic extracts 
were washed with water (40.0 ml) and brine (2x50.0 ml). The aqueous phases were 
extracted with DCM (4x40.0 ml and 4x90.0 ml respectively) and the organic extracts 
were dried over anhydrous K2CO3. Concentration in vacuo of the organic phase gave 
a brownish solid which was purified by flash column chromatography on silica gel 
(hexane, hexane/DCM 8:2, 1:1) to yield 136 mg (57%) of the product as a white 
powder: mp 45.0-47.0 °C (hexane/DCM 20:1) [lit.,250 mp 50-51 °C]; Rf 0.30 
[hexane/DCM 1:1]; vmax (DCM film)/cm-1  2923-2850, 1460, 1375, 1186, 1081, 728, 
662; gH (CDCI3) 8.30-8.28 (1H, d, J 8.5, H4), 7.91-7.89 (2H, m, H2'), 7.59-7.55 (1H, 
m, 3J 7.5, H7), 7.47-7.42 (3H, m, H3', H4'), 7.36-7.32 (1H, dt, J 8.0, J 1.5, H6), 7.27-
7.22 (1H, m, H5), 6.74 (1H, s, H3); gc (CDCI3) 138.29 (C, C1'), 137.57 (C, C7a), 
134.09 (CH, C4'), 129.71 (C, C3a), 129.17 (CH, 2xC3'), 127.06 (CH, 2xC2'), 124.92 
(CH), 124.05 (CH), 119.96 (CH, C7), 115.26 (CH), 115.23 (CH), 109.98 (CH, C2); 
m/z (Elk); 337 (79), 194 ([M-(benzenesulfonyl group)]+, 79), 141 (74), 115 ([lndoler, 
42), 77 ([benzene]+, 100); found [M+H]+, 334.9608, C14H1079BrNO2S requires [M+H]+, 
334.9616; found [M+H]+, 336.9587, C74H1081BrNO2S requires [M+H]+, 336.9595; A79Br 
= -2.4 ppm, A81Br = -2.4 ppm. 
tert-Butyl 5-cyano-1H-indole-1-carboxylate 1 71247 
To an orange solution of 5-cyanoindole (1.00 g, 7.03 mmol, 1.00 eq) and DMAP (17.6 
mg, 0.144 mmol, 0.02 eq) in anhydrous DCM (5.00 ml) at RT, under a constant flow 
of N2, was added BOC anhydride (1.69 g, 7.75 mmol, 1.10 eq) in one portion. The 
reaction mixture turned brownish, it was covered with Al foil and stirred ar RT for 15.5 
hr. The reaction was quenched with HCI 1M (5.00 ml). The 2 phases were separated, 
the organic phase was washed with water (25.0 ml). The aqueous phase was 
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extracted with DCM (4x25.0 ml). After drying over MgSO4, concentration in vacuo 
gave an off-white solid which was dissolved in hot methanol (50-60 °C) and cooled to 
RT. Water (2.40 ml) was added to the crystallised product, the flask was put in an ice 
bath for 10 min. Filtration yielded 1.28 g (75%) of the product as shiny white needles: 
mp 127.0-128.0 °C (methanol); Rf 0.35 [hexane/EtOAc 7.5:2.5]; Vmax  (DCM film)/cm-1  
2950-2800, 2212, 1743, 1460, 1371, 1072, 727; cSH (CDC13) 8.27-8.25 (1H, d, J 8.5, 
H7), 7.91-7.90 (1H, d, J 1.0, H4), 7.72-7.71 (1H, d, J 3.5, H2), 7.58-7.55 (1H, dd, J 
8.5, J 1.5, H6), 6.64-6.63 (1H, d, J 4.0, H3), 1.69 (9H, s, 3xH3'); 	(CDC13) 149.03 
(C, C1'), 137.06 (C, C7a), 130.49 (C, C3a), 128.05 (CH, C2), 127.31 (CH, C6), 
125.78 (CH, C4), 119.77 (C, Cl"), 116.00 (CH, C3), 106.92 (CH, C7), 106.08 (CH, 
C5), 84.91 (C, C2'), 28.10 (CH3, C3'); rn/z (Elf) 242 ([M]+, 24), 186 ([M-tert butyl 
group]+, 31), 169 (19), 142 ([M-BOC group]+, 41), 57 (100); found [M+H]+, 242.1051, 
C14H14N202 requires [M+H]+, 242.1055; Found: C, 69.4; H, 5.7; N, 11.5. Required: C, 
69.4; H, 5.8; N, 11.6; A = -1.7 ppm. 
1-(Phenylsulfony1)-1H-indole-5-carbaldehyde 170 
To a vigorously stirred mixture of 1H-indole-5-carbaldehyde 128 (282 mg, 1.94 mmol, 
1.00 eq) and n-tetrabutylammonium bromide (0.646 g, 0.200 mmol, 0.10 eq) in 50% 
aqueous NaOH (1.90 ml), toluene (1.40 ml) and water (2.90 ml) was added dropwise, 
over 30 min, benzenesulfonyl chloride (0.272 ml, 2.14 mmol, 1.10 eq) in toluene (1.50 
ml) via a syringe pump. The reaction flask was covered with aluminium foil and the 
mixture stirred at RT for 18 hr. The solution was orange. After removal of the 
aqueous phase, the organic phase was washed with 0.1M NaHCO3 (10.0 ml), water 
(10.0 ml) and saturated brine (20.0 ml). After extractions with EtOAc (4x25.0 ml), the 
organic phase was dried over MgSO4 and concentrated in vacuo to give an orange oil 
(0.629 g) which was purified by flash column chromatography (hexane, 
hexane/EtOAc 9:1, 8:2, 6:4) to yield 0.447 g (81%) of the product as a pale pink 
crystalline solid: Rf 0.10 [hexane/EtOAc 8:2]; Vmax  (DCM film)/crril  2958, 1695, 1442, 
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1375, 1274, 1118, 727; gH (CDCI3) 10.05 (H1"), 8.15-8.12 (1H, d, J 9.0, 1xH2'), 8.08-
8.08 (1H, d, J 1.0, H7), 7.93-7.86 (3H, m, 1xH2', H6, H4), 7.70-7.69 (1H, d, J 3.5, 
H2), 7.61-7.57 (1H, tt, J 7.5, J 1.0, H4'), 7.51-7.47 (2H, m, 2xH3'), 6.81-6.80 (1H, d, J 
3.5, H3); gc (CDCI3) 191.71 (CHO), 138.10 (C, C7a), 137.95 (C, C1'), 134.29 (CH, 
C4'), 132.34 (CH, C5), 130.87 (C, C3a), 129.50 (2xCH), 128.00 (CH, C2), 126.83 
(2xCH), 125.37 (CH, C4), 124.77 (CH, C6), 113.94 (CH, C7), 109.56 (CH, C3); m/z 
(Elk) 286 ([M+H]+, 21), 285 ([M]+, 80), 141 (63), 116 ([indole]+, 22), 77 (100), 51 (19); 
found [M+H]+, 285.0460, C15H11NO3S requires [M+H]+, 285.0460; A = 0.0 ppm. 
5-(1,3-Dioxolan-2-y1)-1-(phenyisulfony1)-1H-indole 172 
To a clear colourless solution of 1-(phenylsulfonyI)-1H-indole-5-carbaldehyde 170 
(155 mg, 0.542 mmol, 1.00 eq) and ethylene glycol (59.0 mg, 0.951 mmol, 1.75 eq) in 
benzene (60.0 ml) was added a catalytic amount of para-toluenesulfonic acid 
monohydrate (10.8 mg, 0.057 mmol, 0.10 eq) and the reaction mixture was refluxed 
at 105 °C for 14 hr using a Dean Stark set up. The set up was covered with 
aluminium foil. The reaction mixture which had turned brown was allowed to cool 
down to RT, and poured onto sat. NaHCO3 (20.0 ml). The organic phase turned dark 
green. After extracting the aqueous phase with ether (3x20.0 ml), and DCM (3x30.0 
ml), the organic phase was dried over anhydrous K2CO3 and concentrated in vacuo to 
give a dark green oil (162 mg). The crude was treated with polystyrene sulfonyl 
hydrazide resin loading 2.67 mmol/g (245 mg, 0.654 mmol) in DCM (35.0 ml) for 2 hr, 
next the resin was filtered off and the filtrate was concentrated in vacuo to yield 180 
mg (99%) of the product as a dark green oil: Rf 0.15 [hexane/EtOAc 7:3]; vmax (DCM 
film)/cm-1  3055, 2982, 1418, 1265, 738, 705; gii  (CDCI3) 8.04-8.01 (1H, d, J 8.5, H7), 
7.87-7.85 (2H, d, J 8.0, 2xH2'), 7.67 (1H, s, H4), 7.60-7.59 (1H, d, J 3.0, H2), 7.54-
7.51 (1H, t, J 7.0, H4'), 7.47-7.41 (3H, m, H6, 2xH3'), 6.68-6.67 (1H, d, J 3.0, H3), 
5.87 (1H, s, H1"), 4.17-4.11 (2H, m, 2xH2"), 4.06-4.03 (211, m, 2xH2"); et (CDCI3) 
138.15 (C, Cl'), 135.35 (C, C7a), 133.83 (CH, C4'), 133.18 (CH, C5), 130.68 (C, 
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C3a), 129.24 (CH, 2xC3'), 126.89 (CH, C2), 126.67 (CH, 2xC2'), 123.11 (CH, C6), 
119.69 (CH, C4), 113.54 (CH, C7), 109.39 (CH, C3), 103.83 (CH, Cl"), 65.34 (CH2, 
2xC2"); m/z (Elk) 329 ([M]+, 3), 328 (3), 285 ([M-acetal]+, 82), 144 ([M-
benzenesulfonyl group]+,13), 141 (55), 116 ([indoler,19), 77 (100); found [M+H]+, 
329.0712, C17H15NO4S requires [M+H]+, 329.0722; A = -3.0 ppm. 
2-Benzy1-1-(phenylsulfony1)-1H-indole-5-carbaldehyde 191 
To a dark green solution of dioxolanindole 170 (104 mg, 0.315 mmol, 1.00 eq) in 
anhydrous THF (1.25 ml), was added dropwise a 1.7M t-BuLi solution in pentane 
(0.230 ml, 0.393 mmol, 1.25 eq) over 4 min, at -45 °C, under a constant flow of N2. 
The solution which had turned dark brown, then reddish brown was stirred at -45 °C 
to -20 °C over 20-25 min, then at -45 °C for another 20 min, before the dropwise 
addition of benzyl bromide (47 ,uL, 0.393 mmol, 1.25 eq) diluted in dry THF (0.250 ml) 
over 6 min, at -45 °C. The reaction mixture was allowed to warm up to -5 °C over 50 
min, then put in an ice bath for one hour, before being allowed to warm up to RT over 
18 hr. The reaction mixture was poured over 5% citric acid (2x25.0 ml) and the 
organic phase was washed with water (25.0 ml). The aqueous phase was extracted 
with DCM (4x25.0 ml). The organic phase was dried over MgSO4 and concentrated in 
vacuo to give a brownish oil (245 mg) which was purified by flash column 
chromatography on silica gel (hexane, hexane/EtOAc 10:1, 9:1, 8:2) to yield 33.5 mg 
(28%) of the product as an off-white solid: Rf 0.20 [hexane/EtOAc 7.5:2.5]; vmax (DCM 
film)/cre 3055, 2987, 1693, 1417, 1265, 898, 740; gH (CDCI3) 10.03 (1H, s, H1"), 
8.34-8.31 (1H, d, J 9.5, H7), 7.92-7.91 (1H, d, J 1.0, H4), 7.85-7.82 (1H, dd, J 9.0, J 
1.5, H6), 7.68-7.66 (2H, dd, J 7.5, J 1.0, 2xH2'), 7.58-7.54 (1H, dt, J 7.5, H4'), 7.43-
7.39 (2H, t, J 8.0, 2xH3'), 7.32-7.29 (3H, dt, J 7.0, J 1.0, 2xH8', H9'), 7.22-7.18 (2H, 
m, 2xH7'), 6.24 (1H, s, H3), 4.38 (2H, s, 2xH5'); Sc (CDCI3) 191.79 (C, C1"), 143.07 
(C, C7a), 140.61 (C, C1'), 138.71 (C, C6'), 137.26 (CH, C2), 134.03 (CH, C4'), 
132.40 (CH, C5), 129.51 (C, C3a), 129.36 (2xCH), 129.32 (2xCH), 128.62 (CH, 
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2xC8'), 126.92 (CH, C9'), 126.37 (CH, 2xC2'), 125.03 (CH, C6), 123.24 (CH, C4), 
114.99 (CH, C7), 110.99 (CH, C3); m/z (El+) 375 ([K+, 100), 233 ([M-Bzsulfonyl 
group]+, 65), 204 ([M-Bzsulfonyl group and aldehyde]+, 95), 77 (34); found [M+H]+, 
375.0930, C22H17NO3S requires [M+H]+, 375.0929; A = 0.3 PPrn- 
2-Benzy1-1H-indole-5-carbaldehyde 177 
To a solution of Me0H/NaOH 2M 5:1 (7.90 ml) was added the 2-benzyl indole 191 
(44.6 mg, 0.119 mmol, 1.00 eq) and the reaction mixture was refluxed at 110 °C for 
16 hr. After allowing the reaction mixture to cool down to RT, it was treated with 0.1M 
HCI to a pH of 1 and the aqueous phase was extracted with DCM (5x15.0 ml). 
Concentration in vacuo of the organic phase afforded a pink oil which was purified by 
flash column chromatography on silica gel (hexane, hexane/EtOAc 9:1, 8:2, EtOAc) 
to yield 8.7 mg (39%) of the product as a pale orange amorphous powder. 
2nd experimental procedure using D1BAL: 
To a clear colourless solution of 2-benzy1-1H-indole-5-carbonitrile 145 (411 mg, 1.77 
mmol, 1.00 eq) in anhydrous DCM (8.00 ml) under a constant flow of N2, at 0 °C, was 
added dropwise the DIBAL-H solution, 1.0M in DCM (2.20 ml, 2.20 mmol, 1.24 eq) 
over 7 min. The reaction mixture which turned pale yellow was allowed to warm up to 
RT over 16 hrs. To the bright yellowish orange solution was added 1.0M Rochelle 
solution (17.0 ml) at 0 °C. Caution: evolution of gas. The reaction mixture was stirred 
at RT for 4.5 hr. The two phases were separated and the aqueous phase extracted 
with DCM (4x20.0 ml). The solvent was removed in vacuo, and the orange slurry was 
dissolved in DCM (10.0 ml) and stirred with 1M HCI (2.90 ml) at RT for 1 hr 40 min. 
Water (13.0 ml) was added, and the pH adjusted to 14 using 2M NaOH (2.90 ml). 
The produce was extracted with DCM (4x20.0 ml) and the organic phase was 
washed with water (60.0 ml) and brine (60.0 ml). After extraction of the aqueous 
phase with DCM (4x60.0 ml), drying over MgSO4 and concentration in vacuo, an 
orange powder was obtained. It was purified by flash column chromatography on 
silica gel (hexane/EtOAc 10:1, 9:1) to yield 332 mg (80%) of the product as a pale 
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orange amorphous powder: mp 126.5-127.5 °C (hexane/DCM 20:1); Rf 0.20 
[hexane/EtOAc 7.5:2.5]; Vmax  (nujol)/cm-1  3324, 3056-2850, 1671, 1373, 1056, 739; 8,., 
(CDCI3) 10.01 (1H, s, H1"), 8.08 (2H, br, H1, H4), 7.71-7.69 (1H, dd, J 8.5, J 1.5, H6), 
7.38-7.28 (6H, m, 2xH4', H7, H5', 2xH3'), 6.49 (1H, br, H3), 4.17 (2H, s, H5'); et 
(CDCI3) 192.47 (CH, C1"), 139.95 (C), 139.88 (C), 137.76 (C, C2'), 129.67 (CH, C5), 
128.87 (2xCH), 128.81 (2xCH), 128.54 (C, C3a), 127.00 (CH, C5'), 125.05 (CH, C4), 
122.10 (CH, C6), 111.04 (CH, C7), 102.58 (CH, C3), 34.65 (CH2, C1'); m/z (Elk) 235 
([M]+, 100), 206 ([M-aldehyder, 27), 167 (30), 158 (42), 149 (30), 91 (14); found 
[M+H]+, 235.0997, C16H13NO requires [M+H]+, 235.0997; Found: C, 81.6; H, 5.5; N, 
5.9. Required: C, 81.7; H, 5.6; N, 6.0; A = 0.0 ppm. 
1-Benzenesulfony1-1H-indole-5-carbonitrile 193223 
To a vigorously stirred mixture of indole-5-carbonitrile 192 (864 mg, 6.08 mmol, 1.00 
eq) and n-tetrabutylammonium bromide (197 mg, 0.609 mmol, 0.10 eq) in 50% 
aqueous NaOH (5.90 ml), toluene (5.00 ml) and water (9.00 ml) was added dropwise, 
over 30 min, benzenesulfonyl chloride (0.850 ml, 0.688 mmol, 1.10 eq) in toluene 
(4.00 ml) via a syringe pump. The reaction flask was covered with aluminium foil and 
the mixture stirred at RT for 25 hr. The solution was yellow. After removal of the 
aqueous phase, the organic phase was washed with 0.1M NaHCO3 (20.0 ml), water 
(75.0 ml) and saturated brine (75.0 ml). After extractions with EtOAc (3x70.0 ml), the 
organic phase was dried over MgSO4 and concentrated in vacuo to give an off-white 
powder (1.69 g) which was purified by crystallisation from hexane/DCM 20:1 to yield 
1.65 g (96%) of the product as white needles: mp 131.0-133.5 °C (hexane/DCM 
20:1); Rf 0.35 [hexane/EtOAc 6:4]; Vmax  (nujol)/cm-1  2222, 1458, 1375, 1080, 721; gH 
(CDCI3) 8.10-8.08 (1H, d, J 8.5, 1xH2'), 7.90-7.89 (3H, m, 1xH2', H4, H7), 7.71-7.70 
(1H, d, J 3.5, H2), 7.62-7.56 (2H, m, 2xH3'), 7.51-7.47 (2H, t, J 8.0, H4', H6), 6.74-
6.73 (1H, d, J 3.5, H3); et (CDCI3) 137.73 (C, C7a), 136.43 (C, C1'), 134.42 (CH, 
C4'), 130.65 (C, C3a), 129.54 (CH, 2xC3'), 128.37 (CH), 127.59 (CH), 126.77 (CH, 
2xC2'), 126.36 (CH, C4), 119.18 (C, Cl"), 114.27 (CH, C7), 108.65 (CH, C3), 107.03 
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(C, C5); m/z (Elk) 282 ([M]+, 50), 141 ([M-BzSulfonyl group]+, 66), 114 ([unsubstituted 
indole]+, 12), 77 (100); found [M+H]+, 282.0474, C15H1oN202S requires [M+H]+, 
282.0463; Found: C, 63.7; H, 3.5; N, 9.9. Required: C, 63.8; H, 3.6; N, 9.9; A = 3.9 
ppm. 
2-Benzyl-1-(phenylsulfony1)-1H-indole-5-carbonitrile 194223 
To a pale yellow solution of benzenesulfonyl indole 193 (210 mg, 0.743 mmol, 1.00 
eq) in anhydrous THF (2.10 ml), was added dropwise a 1.7M t-BuLi solution in 
pentane (0.520 ml, 0.891 mmol, 1.20 eq) over 8 min, at -45 °C, under a constant flow 
of N2. The solution which had turned dark yellow, then dark green was stirred at -
45 °C to -30 °C over 55 min, cooled down to -45 °C before the dropwise addition of 
benzyl bromide (108 iuL, 0.906 mmol, 1.22 eq) diluted in dry THF (1.50 ml) over 8 
min. The reaction mixture was allowed to warm up to -10 °C over 55 min. The 
reaction mixture turned brown and finally orange. It was put in an ice bath for 55 min, 
before being allowed to warm up to RT over 15 hr. The reddish brown reaction 
mixture was poured over 5% citric acid (30.0 ml) and the organic phase was washed 
with water (30.0 ml). The aqueous phase was extracted with DCM (4x30.0 ml). The 
organic phase was dried over MgSO4 and concentrated in vacuo to give an off-white 
solid (1.02 g) which was purified by flash column chromatography on silica gel 
(hexane/Et0Ac 20:1, 15:1, 10:1) to yield 55.0 mg (51%) of the product as a yellow oil. 
Crystallisation from hexane/DCM 20:1 yielded the product as white needles: mp 
130.5-131.5 °C (hexane/DCM 20:1); Rf 0.20 [hexane/EtOAc 8:2]; Vmax  (nujol)/cm-1  
2220, 1460, 1371, 1053; SH (CDCI3) 8.29-8.27 (1H, d, J 9.0, H7), 7.71 (1H, s, H4), 
7.67-7.65 (21-1, d, J 7.5, H2'), 7.60-7.56 (1H, t, J 7.5, H4'), 7.55-7.53 (1H, dd, J 9.0, J 
1.0, H6), 7.44-7.40 (2H, t, J 9.0, H3'), 7.34-7.29 (3H, m, H8', H9'), 7.20-7.18 (2H, m, 
H7'), 6.16 (1H, s, H3), 4.37 (2H, s, 2xH5'); Sc (CDCI3) 143.63 (C, C6'), 138.98 (C, 
C7a), 138.59 (C, C2), 136.99 (C, C1'), 134.19 (CH, C4'), 129.46 (CH, 2xC3'), 129.38 
(C, C3a), 129.33 (CH, 2xC7'), 128.69 (CH, 2xC8'), 127.18 (CH, C6), 127.03 (CH, 
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C9'), 126.39 (CH, 2xC2'), 125.04 (CH, C4), 119.32 (C, Cl"), 115.35 (CH, C7), 110.07 
(CH, C3), 107.10 (C, C5), 35.12 (CH2, C5'); m/z (Elf) 372 ([ or, 57), 284 ([M-Bn 
group]+, 30), 230 ([M-Bzsulfonyl group]+, 100), 141 (11), 115 ([indole]+, 5), 91 (12), 77 
(47); found [M+H]+, 372.0934, C22H16N202S requires [M+H]+, 372.0932; Found: C, 
71.0; H, 4.2; N, 7.6. Required: C, 71.0; H, 4.3; N, 7.5; A = 0.5 ppm. 
2-Benzy1-1H-indole-5-carbonitrile 196223 
To a solution of Me0H/NaOH 2M 5:1 (25.0 ml) was added the 2-benzyl indole 194 
(141 mg, 0.379 mmol, 1.00 eq) and the reaction mixture was refluxed at 110 °C for 18 
hr. After allowing the reaction mixture to cool down to RT, it was treated with 0.1M 
HCI to a pH of 2 and the aqueous phase was extracted with DCM (4x25.0 ml). 
Concentration in vacuo of the organic phase gave a greenish oil (96 mg) which was 
purified by flash column chromatography on silica gel (hexane, hexane/EtOAc 10:1, 
9:1, 8:2) to yield 87.0 mg (99%) of the product as an off-white solid: mp 119.5-120.5 
°C (hexane/DCM 20:1); Rf 0.25 [hexane/EtOAc 7:3]; vmax (nujol)/cm-1  3300, 3056-
2850, 2229, 1373, 1056, 740; Sy (CDCI3) 8.12 (1H, br, H1), 7.88 (1H, s, H4), 7.38-
7.25 (6H, m, H4', H7, H5', H6, H3'), 6.41 (1H, s, H3), 4.16 (2H, s, H5'); Sc (CDCI3) 
140.38 (C, C2'), 137.94 (C, C7a), 137.53 (C, C2), 128.94 (2xCH), 128.82 (2xCH), 
128.49 (C, C3a), 127.10 (CH, C5'), 125.40 (CH, C4), 124.49 (CH, C6), 120.82 (c., 
C1"), 111.26 (CH, C7), 102.84 (C, C5), 101.66 (CH, C3), 34.59 (CH2, C5'); m/z (Elk) 
232 ([M]+, 100), 231 (64), 155 (71), 91 (16), 84 (21), 49 (23), 43 (25); found [M+H]+, 
232.1002, C76H12N2 requires [M+H]+, 232.1000; Found: C, 82.9; H, 5.1; N, 11.9. 
Required: C, 82.7; H, 5.2; N, 12.1; A = 0.9 ppm. 
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(Z)-Ethyl 3-(2-benzy1-1H-indo1-5-y1)-2-ethoxyacrylate 179 and (E)-ethyl 3-(2-benzy1-
1H-indo1-5-y1)-2-ethoxyactylate 180 
6" 
To a milky suspension of sodium hydride (19.5 mg, 0.488 mmol, 2.31 eq) in 
anhydrous THF (0.400 ml) at 0 °C, was added dropwise, phosphonoacetate 129 (123 
mg, 0.459 mmol, 2.17 eq) in THF (1.00 ml) over 10 min, under a constant flow of N2. 
The pale yellowish solution was stirred at 0 °C for 40 min before the dropwise 
addition of aldehyde 177 (49.7 mg, 0.211 mmol, 1.00 eq) in dry THF (1.00 ml) via 
syringe pump over 37 min. The solution which had turned orange was left stirring in 
the ice bath over 42 hr. The dark yellow solution was concentrated in vacuo, then 
dissolved in EtOAc (30.0 ml) and washed with water (35.0 ml). An emulsion was 
observed, thus some NaCI was added. The aqueous phase was extracted with 
EtOAc (4x45.0 ml). After drying the organic extract over MgSO4, concentration in 
vacuo of the organic phase gave a deep orange slurry which was purified by flash 
column chromatography on silica gel (hexane/EtOAc 15:1, 12:1) to yield 66.0 mg 
(90%) of the product. Ratio Z:E = 63:37. 
Z isomer 179: colourless oil: Rf 0.20 [hexane/EtOAc 8:2]; vmax (DCM film)/cm-1  3441, 
3055, 1743, 1646, 1051, 740; SH (CDCI3) 8.03 (1H, br, H4), 7.89 (1H, br, H1), 7.65-
7.62 (1H, dd, J 8.5, J 1.5, H6), 7.37-7.33 (2H, m, H4'), 7.30-7.22 (4H, m, H3', H7, 
H5'), 7.17 (1H, s, H1"), 6.36-6.35 (1H, d, J 1.0, H3), 4.34-4.29 (2H, q, J 14.5, J 7.0, 
H6"), 4.14 (2H, s, H1'), 4.04-3.98 (2H, q, J 14.0, J 7.0, H3"), 1.42-1.37 (6H, m, H7", 
H4"); et (CDCI3) 165.31 (C, C5"), 142.43 (C, C2"), 138.67 (C, C2'), 138.21 (C, C2), 
136.56 (C, C7a), 128.81 (2xCH), 128.77 (2xCH), 126.82 (CH, C5'), 126.30 (CH, Cl"), 
125.53 (2xC, C3a, C5), 124.08 (CH, C6), 122.71 (CH, C4), 110.43 (CH, C7), 101.73 
(CH, C3), 67.41 (CH2, C3"), 60.87 (CH2, C6"), 34.69 (CH2, C1'), 15.56 (CH3, C4"), 
14.36 (CH3, C7"); m/z (Elk) 349 ([M]+, 100), 292 ([M-ethyl]+, 17), 292 (32), 247 (36), 
219 (26), 91 (50); found [M+H]+, 349.1672, C22H23NO3 requires [M+H]+, 349.1678; 
Found: C, 75.6; H, 6.5; N, 3.9. Required: C, 75.6; H, 6.6; N, 4.0; A = -1.7 ppm. 
E isomer 180: pale yellow oil: Rf 0.15 [hexane/EtOAc 8:2]; Vmax  (DCM film)/crril  3441, 
3055-2850, 1725, 1644, 1548, 1266, 1043, 738; c (CDCI3) 7.75 (1H, br, H1), 7.40 
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(1H, s, H4), 7.36-7.32 (2H, m, 2xH4'), 7.28-7.25 (3H, m, 2xH3', H5'), 7.16-7.14 (1H, 
d, J 8.5, H7), 7.00-6.97 (1H, dd, J 8.5, J 1.0, H6), 6.29 (1H, s, H1"), 6.27 (1H, br, H3), 
4.18-4.12 (4H, m, 2xH6", 2xH1'), 3.98-3.93 (2H, q, J 14.0, J 7.0, 2xH3"), 1.44-1.41 
(3H, t, J 7.0, 3xH4"), 1.11-1.08 (3H, t, J 7.0, 3xH7"); (5c (CDCI3) 165.20 (C, C5"), 
146.16 (C, C2"), 138.41 (C, C2'), 138.16 (C, C2), 135.44 (C, C7a), 128.81 (2xCH) 
128.74 (2xCH), 126.76 (CH, C5'), 126.26 (2xC, C3a, C5), 122.40 (CH, C6), 119.96 
(CH, C4), 111.60 (CH, Cl"), 110.00 (CH, C7), 101.20 (CH, C3), 64.63 (CH2, C3"), 
61.05 (CH2, C6"), 34.73 (CH2, C1'), 14.58 (CH3, C4"), 13.77 (CH3, C7"); mlz (Elk) 
349 ([M]+, 16), 232 ([M-(benzyl+ethyr, 100), 155 (77), 84 (42), 49 (56); found 
[M+H]+, 349.1671, C22H23NO3 requires [M+H]+, 349.1678; Found: C, 75.7; H, 6.8; N, 
3.9. Required: C, 75.6; H, 6.6; N, 4.0; A = -2.0 ppm. 
Methyl 3-(2-benzy1-1H-indo1-5-y1)-2-ethoxypropanoate 187 
To a yellow solution of the starting material 179 and 180 (55.2 mg, 0.158 mmol, 1.00 
eq) in anhydrous methanol (2.00 ml) at RT, under a constant flow of N2, were added 
the magnesium turnings (20.6 mg, 0.847 mmol, 5.36 eq) in one portion and the 
reaction mixture was stirred at RT for 7 hr. A few more magnesium turnings were 
added as well as some dry methanol (1.00 ml) and the reaction mixture was stirred at 
RT for another 12 hr before being poured onto water (35.0 ml). The aqueous phase 
was extracted with DCM (4x30.0 ml) and the organic extracts were washed with brine 
(70.0 ml). After extraction with DCM (4x100 ml) and drying over MgSO4, 
concentration in vacuo gave a yellowish oil which was purified by flash column 
chromatography on silica gel (hexane/EtOAc 15:1, 10:1) to yield 40.6 mg (76%) of 
the product as a pale yellow oil: Rf 0.25 [hexane/EtOAc 7.5:2.5]; vmax (DCM film)/cre 
3392, 3027-2900, 1741, 1644, 1446, 1115, 705; 4i  (CDC13) 7.77 (1H, br, H1), 7.41 
(1H, br, H4), 7.36-7.32 (2H, m, H4'), 7.29-7.26 (3H, m, H3', H5'), 7.17-7.15 (1H, d, J 
8.5, H7), 7.02-7.00 (1H, dd, J 8.5, H6), 6.28 (1H, s, H3), 4.12 (2H, s, H1'), 4.11-4.07 
(1H, t, J 6.5, H2"), 3.71 (3H, s, 3xH6"), 3.64-3.56 (1H, m, 1xH3"), 3.41-3.34 (1H, m, 
1xH3"), 3.11-3.09 (2H, m, 2xH1"), 1.20-1.16 (3H, t, J 7.0, H6"); gc (CDC13) 173.28 (C, 
C5"), 138.51 (C, C2'), 138.03 (C, C2), 135.28 (C, C7a), 128.83 (C, C5), 128.80 
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(2xCH), 128.68 (2xCH), 128.24 (C, C3a), 126.69 (CH, C5'), 122.91 (CH, C6), 120.44 
(CH, C4), 110.16 (CH, C7), 100.86 (CH, C3), 81.04 (CH, C2"), 66.19 (CH2, C3"), 
51.73 (CH2, C6"), 39.55 (CH2, Cl"), 34.72 (CH2, C1'), 15.06 (CH3, 04"); m/z (Er) 
337 ([M]+, 37), 234 ([M-(benzyl + methyl groups)]+, 81), 220 ([M-(benzyl+2 methyl 
groups)]+,100), 91 (29); found [M+H]+, 337.1664, C211-123NO3 requires [M+H]+, 
337.1678; Found: C, 74.8, H, 6.8; N, 4.1. Required: C, 74.8; H, 6.9; N, 4.2; A = -4.1 
ppm. 
3-(2-Benzy1-1H-indo1-5-y1)-2-ethoxy-propanoic acid 40 
OH 
To a yellow solution of the starting material 187 (33.4 mg, 0.099 mmol, 1.00 eq) in a 
mixture of ethanol/water 1:1 (1.00 ml), were added the potassium hydroxide pellets 
(10.0 mg, 0.178 mmol, 1.80 eq) and the yellow solution was stirred at 82 °C for 14 hr. 
The yellow solution was allowed to cool down to RT and concentrated in vacuo. With 
vigorous stirring in ice, was added 1M HCI (-10 drops) until a pH of 1 was reached. 
The desired acid crashed out as a brown ppt. It was dissolved in DCM and washed 
with water (35.0 ml). The aqueous phase was extracted with DCM (4x30.0 ml). After 
drying over MgSO4, concentration in vacuo gave 29.8 mg (93%) of the product as a 
yellowish oil: Rf 0.20 [hexane/EtOAc 1:1]; vmax (DCM film)/cm-1  3620, 3398, 1710, 
1646, 1461, 1108; 	(CDCI3) 7.77 (1H, br, H1), 7.42 (1H, s, H4), 7.36-7.32 (2H, m, 
H4'), 7.29-7.25 (3H, m, H3', H5'), 7.18-7.16 (1H, d, J 8.5, H7), 7.03-7.00 (1H, dd, J 
8.0, J 1.5, H6), 6.28 (1H, s, H3), 4.14-4.12 (3H, m, 1xH2", 2xH1'), 3.63-3.56 (1H, m, 
1xH3"), 3.49-3.42 (1H, m, 1xH3"), 3.25-3.20 (1H, dd, J 14.0, J 4.0, H1"), 3.11-3.09 
(1H, dd, J 14.0, J 8.0, H1"), 1.20-1.16 (3H, t, J 7.0, H4"); Sc  (CDC13) 175.40 (C, C5"), 
138.45 (C), 138.15 (C), 135.35 (C, C7a), 128.86 (C, C5), 128.81 and 128.70 (2xCH 
each, 2xC4', 2xC3'), 127.69 (C, C3a), 126.71 (QH, C5'), 122.95 (CH, C6), 120.63 
(CH, C4), 110.27 (CH, C7), 100.89 (CH, C3), 80.36 (CH, 02"), 66.82 (CH2, C3"), 
38.85 (CH2, C1"), 34.71 (CH2, C1'), 15.05 (CH2, 04"); m/z (Elf) 323 ([M]+, 16), 220 
([M-(benzyl+methyl group)]+, 88), 199 (29), 171 (M-(benzyl + ether side chain + 
OH)]+, 100), 127 (51), 57 (53); found [M+H]+, 323.1520, C201-121NO3 requires [M+H]+, 
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323.1521; Found: C, 74.2; H, 6.5; N, 4.4. Required: C, 74.3; H, 6.6; N, 4.3; A = -0.3 
ppm. 
(Z)-Ethyl 3-(2-benzy1-1H-indo1-5-y1)-2-(2,2,2-trifluoroethoxy)acfylate 181 and (E)-ethyl 
3-(2-benzy1-1H-indo1-5-y1)-2-(2,2,2-trifluoroethoxy)acrylate 182 
To a milky suspension of sodium hydride (17.0 mg, 0.425 mmol, 1.37 eq) and 
molecular sieves 4A in anhydrous THF (1.40 ml) at 0 °C, under a constant flow of N2, 
was added dropwise via syringe pump, phosphonoacetate 130 (112 mg, 0.347 mmol, 
1.12 eq) in THF (1.20 ml) over 12 min. The suspension turned into a clear pale yellow 
solution. The latter was stirred at 0 °C for 29 min before the dropwise addition of 
aldehyde 177 (73 mg, 0.310 mmol, 1.00 eq) in dry THF (1.60 ml) via syringe pump 
over 38 min. The solution turned dark yellow. It was left to stir in the ice bath over 24 
hr and at RT for another 16 hr, before being concentrated in vacuo. It was re-
dissolved in EtOAc (30.0 ml) and washed with water (35.0 ml). Some NaCI was 
added. The 2 phases were separated and the aqueous phase was extracted with 
EtOAc (4x50.0 ml). After drying the organic extracts over MgSO4, concentration in 
vacuo of the organic phase gave a yellowish slurry which was purified by flash 
column chromatography on silica gel (hexane/EtOAc 15:1, 10:1) to yield 107 mg 
(85%) of the product. Ratio Z:E = 39:61. 
Z isomer 181: yellow amorphous powder; mp 120.5-121.5 °C (hexane/DCM 20:1); Rf 
0.30 [hexane/EtOAc 7.5:2.5]; vmax (DCM film)/cm-1  3441, 1743, 1548, 1371, 1265, 
1055; SH (CDCI3) 8.02 (1H, s, H4), 7.90 (1H, br, H1), 7.60-7.58 (1H, dd, J 8.5, J 1.5, 
H6), 7.37-7.34 (2H, m, 2xH4'), 7.30-7.24 (5H, m, 2xH3', H5', H1", H7), 6.38-6.37 (1H, 
d, J 1.0, H3), 4.40-4.30 (4H, m, 2xH3", 2xH6"), 4.14 (2H, s, 2xH1'), 1.42-1.38 (3H, t, 
J 7.0, 3xH7"); Sc (CDCI3) 164.08 (C, C5"), 140.33 (C, C2"), 138.91 (C), 138.10 (C), 
136.91 (C, C7a), 128.88 (C, C5), 128.81 (2xCH), 128.80 (2xCH), 127.57-119.27 (C, 
q, J 277.0, C4"), 127.52 (CH, C5'), 126.87 (CH, C1"), 124.33 (CH, C6), 124.24 (C, 
C3a), 123.36 (CH, C4), 110.61 (CH, C7), 101.85 (CH, C3), 68.32-67.28 (CH2, q, J 
35.0, C3"), 61.30 (CH2, C6"), 34.66 (CH2, C1'), 14.28 (CH3, C7'); m/z (El+) 403 ([M]+, 
45), 252 (25), 221 ([M-propanoic acid side chain]+, 100), 91 (27); found [M+H]+, 
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403.1392, C22H20F3NO3 requires [M+H]+, 403.1395; Found: C, 65.4; H, 4.9; N, 3.5. 
Required: C, 65.5; H, 5.0; N, 3.5; A = -0.7 ppm. 
E isomer 182: pale yellow oil: Rf 0.25 [hexane/EtOAc 7.5:2.5]; Vmax  (DCM film)/cm-1  
3441, 1743, 1548, 1265, 1053; SH (CDCI3) 7.84 (1H, br, H1), 7.53 (1H, s, H4), 7.37-
7.33 (2H, m, 2xH3'), 7.30-7.25 (3H, m, 2xH4', H5'), 7.19-7.16 (1H, d, J 8.5, H7), 7.10-
7.07 (1H, dd, J 8.5, J 1.5, H6), 6.71 (1H, s, H1"), 3.61 (1H, br, H3), 4.30-4.23 (2H, q, 
J 17.0, J 8.5, 2xH3"), 4.23-4.18 (2H, q, J 14.5, J 7.0, 2xH6"), 4.12 (2H, s, 2xH1'), 
1.18-1.15 (3H, t, J 7.0, 3xH7"); et (CDCI3) 163.53 (C, C5"), 143.28 (C, C2"), 138.55 
(C), 138.26 (C), 136.03 (C, C7a), 128.79 (2xCH), 128.74 (2xCH), 128.54 (C, C5), 
127.38-119.08 (C, q, J 277.0, C4"), 126.79 (CH, C5'), 124.31 (C, C3a), 122.75 (CH, 
C6), 121.76 (CH, Cl"), 120.95 (CH, C4), 110.08 (CH, C7), 101.32 (CH, C3), 68.16-
67.11 (CH2, q, J 35.0, C3"), 61.26 (CH2, C6"), 34.65 (CH2, C1'), 13.78 (CH3, C7'); m/z 
(El+) 403 ([M]+, 45), 252 (25), 221 ([M-propanoic acid side chain]+, 100), 91 (27); 
found [M+H]+, 403.1392, C22H2oF3NO3 requires [M+H]+, 403.1395; Found: C, 65.5; H, 
5.0; N, 3.4. Required: C, 65.5; H, 5.0; N, 3.5; A = -0.7 ppm. 
Methyl 3-(2-benzyl-1H-indo1-5-y1)-2-(2,2,2-trifluoroethoxy)propanoate 188 
To a mixture of the starting material 181 and 182 (67.6 mg, 0.168 mmol, 1.00 eq) and 
the magnesium turnings (61.9 mg, 2.55 mmol, 15.2 eq) at RT, under a constant flow 
of N2, was added the anhydrous methanol (2.50 ml). After stirring at RT for 4 hr, the 
yellowish orange solution turned into a pale yellowish slurry. It was poured onto water 
(20.0 ml). The 2 phases were separated and the aqueous phase was extracted with 
DCM (4x25.0 ml). The organic extracts were washed with brine (80.0 ml). The 
aqueous phase was extracted with DCM (4x65.0 ml). After drying over MgSO4, 
concentration in vacuo gave an orangish slurry which was purified by flash column 
chromatography on silica gel (hexane/EtOAc 15:1, 10:1, 9:1, 8:2) to yield 48 mg 
(73%) of the product as a very pale yellow oil: Rf 0.15 [hexane/EtOAc 8:2]; Vmax  (DCM 
film)/cm-1  3361, 2920-2846, 1741, 1448, 1275, 1157, 790; SH (CDCI3) 7.76 (1H, br, 
H1), 7.40 (1H, s, H4), 7.36-7.32 (2H, m, 2xH4'), 7.28-7.25 (3H, m, 2xH3', H5'), 7.18-
7.16 (1H, d, J 8.5, H7), 7.01-6.98 (1H, dd, J 8.0, J 1.5, H6), 6.28 (1H, br, H3), 4.26- 
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4.23 (1H, m, H2"), 4.128 (2H, s, 2xH1'), 3.99-3.93 (1H, m, H3"), 3.74-3.66 (4H, m, 
3xH6", H3"), 3.21-3.11 (2H, m, 2xH1"); et (CDCI3) 171.50 (C, C5"), 138.43 (C), 
138.16 (C), 135.37 (C, C7a), 128.86 (C, C5), 128.81 (2xCH), 128.70 (2xCH), 128.08-
119.39 (C, q, J 278.0, C4"), 127.28 (C, C3a), 126.72 (c1-1, C5'), 122.85 (CH, C6), 
120.54 (CH, C4), 110.29 (CH, C7), 100.88 (CH, C3), 82.02 (CH, C2"), 68.36-67.34 
(CH2, q, J 34.5, C3"), 52.08 (CH3, C6"), 39.17 (CH2, Cl"), 34.69 (CH2, C1'); m/z (Elf) 
391 ([M]+, 27), 220 ([M-propanoic acid side chain]+, 100), 49 (23); found [M+H]+, 
391.1394, C211-120F3NO3 requires [M+H]+, 391.1395; Found: C, 64.5; H, 5.1; N, 3.5. 
Required: C, 64.4; H, 5.2; N, 3.6; A = -0.3 ppm. 
3-(2-Benzy1-1H-indol-5-y1)-2-(2,2,2-trifluoroethoxy)propanoic acid 41 
OH 
Indole 188 (14.6 mg, 0.037 mmol, 1.00 eq) was refluxed with potassium hydroxide 
pellets (4.9 mg, 0.087 mmol, 2.34 eq) in a mixture of ethanol/water 1:1 (1.60 ml) at 
82 °C for 15 hr. The pale yellow solution was allowed to cool down to RT and 
concentrated in vacuo. With vigorous stirring in ice, was added 1M HCI (-5 drops) 
until a pH of 1 was reached. The desired acid crashed out as a brown ppt. DCM was 
added and the 2 phases were separated. The aqueous phase was extracted with 
DCM (4x20.0 ml). After drying over MgSO4, concentration in vacuo gave 14.0 mg 
(99%) of the product as a pale yellow oil: Rf 0.20 [hexane/EtOAc 1:9]; vm„ (DCM 
film)/cre 3289, 2950-2850, 1702, 1651, 1425, 1053; 51_, (CDCI3) 7.76 (1H, br, H1), 
7.43 (1H, s, H4), 7.34-7.32 (2H, m, 2xH4'), 7.28-7.25 (3H, m, 2xH3', H5'), 7.19-7.17 
(1H, d, J 8.5, H7), 7.03-7.01 (1H, dd, J 8.0, J 1.5, H6), 6.29 (1H, d, J 1.0, H3), 4.31-
4.27 (1H, dd, J 8.0, J 4.5, H2"), 4.13 (2H, s, 2xH1'), 3.96-3.87 (1H, m, 1xH3"), 3.77-
3.70 (1H, m, 1xH3"), 3.30-3.26 (1H, J 14.0, J 4.0, 1xH1"), 3.18-3.13 (1H, J 14.0, J 
8.0, 1xH1"); (Sc  (CDCI3) 174.74 (C, C5"), 138.37 (C), 138.31 (C), 135.46 (C, C7a), 
128.93 (C, C5), 128.83 (2xCH), 128.74 (2xCH), 127.57-119.26 (C, q, J 277.0, C4"), 
126.92 (C, C3a), 126.77 (CH, C5'), 122.86 (CH, C6), 120.67 (CH, C4), 110.43 (CH, 
C7), 100.93 (CH, C3), 81.63 (CH, C2"), 68.64-67.61 (CH2, q, J 34.5, C3"), 38.98 
(CH2, Cl"), 34.72 (CH2, C1'); m/z (Elk) 377 ([M]+, 30), 220 ([M-propanoic acid side 
chain]+, 100), 142 (9), 91 (12); found [M+H]+, 377.1244, C20H18F3NO3 requires 
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[M+H]+, 377.1239; Found: C, 63.5; H, 4.7; N, 3.7. Required: C, 63.7; H, 4.8; N, 3.7; A 
= 1.3 ppm. 
2-(lodomethyOnaphthalene 225248 
To a clear pale yellow solution of 2-(bromomethyl)naphthalene (1.17 g, 5.30 mmol, 
1.00 eq) in acetone (15.0 ml) at RT, was added sodium iodide (795 mg, 5.30 mmol, 
1.00 eq) in one portion. A creamy ppt immediately crashed out. The reaction mixture 
was stirred at RT for 16-17 hr. The reaction mixture was filtered, the yellow filtrate 
was concentrated in vacuo to give an off-white solid which was re-dissolved in DCM 
(25.0 ml) and washed with water (2x25.0 ml). The aqueous phase was extracted with 
DCM (4x50.0 ml). After drying over MgSO4, concentration in vacuo gave a pale 
orangish powder. A progressive colour darkening was observed as soon as the 
product was isolated. The crude solid was purified by flash column chromatography 
on silica gel (hexane/DCM 99:1, hexane/EtOAc 1:1) to yield 1.07 g (75%) of the 
product as a pale orange powder: Rf 0.40 [hexane/EtOAc 10:1]; at (CDCI3) 7.85-7.80 
(4H, m), 7.52-7.47 (3H, m), 4.65 (211, s, 2xH1'); Sc (CDCI3) 136.54 (C), 133.22 (C), 
132.75 (C), 128.72 (CH), 127.77 (CH), 127.70 (CH), 127.00 (CH), 126.90 (CH), 
126.44 (CH), 126.35 (CH), 6.49 (CH2, C1). The product decomposed into a black tar 
before any further characterisation could be carried out, as described in the 
literature.267 
2-(Naphthalen-2-ylmethyl)-1-(phenylsulfony1)-1H-indole-5-carbonitrile 195 
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To a very pale yellow solution of indole-carbonitrile 193 (905 mg, 3.20 mmol, 1.00 eq) 
in anhydrous THF (10.0 ml), was added dropwise a 1.7M t-BuLi solution in pentane 
(2.30 ml, 3.91 mmol, 1.22 eq) over 8 min, at -48 to -45 °C, under a constant flow of 
N2. The solution which had turned dark yellow, then dark green was stirred at -45 °C 
to -30 °C over 55 min, cooled down to -45 °C before the dropwise addition of 2-
(bromomethyl)naphthalene (887 mg, 4.01 mmol, 1.25 eq) diluted in dry THF (2.00 
ml) over 7 min. The reaction mixture was allowed to warm up to -10 °C over 50 min 
whereupon it turned brown. It was next put in an ice bath for 50 min, before being 
allowed to warm up to RT over 25 hr. The brown reaction mixture was poured over 
5% citric acid (10.0 ml) and the organic phase was washed with brine (50.0 ml). The 
aqueous phase was extracted with DCM (4x50.0 ml). The organic phase was dried 
over anhydrous K2003 and concentrated in vacuo to give a brown oil (1.73 g) which 
was purified by flash column chromatography on silica gel (hexane/EtOAc 25:1, 20:1, 
15:1) to yield 406 mg (30%) of the product as a yellow oil. Crystallisation from 
hexane/DCM 20:1 afforded shiny white needles: mp 142.0-143.0 °C (hexane/DCM 
20:1); Rf 0.30 [hexane/EtOAc 7:3]; Vmax  (nujol)/cm-1  2950-2850, 2222, 1651, 1548, 
1379, 1055; (5H (CDC13) 8.32-8.30 (1H, d, J 9.0, H7), 7.86-7.83 (1H, m), 7.81-7.87 (1H, 
d, J 8.5), 7.73-7.71 (2H, m), 7.64-7.62 (2H, dd, J 8.5, J 1.0), 7.59 (1H, br, H4), 7.57-
7.54 (1H, dd, J 9.0, J 1.5, H6), 7.50-7.46 (3H, m, 2xH3'), 7.32-7.28 (3H, m), 6.21 (1H, 
br, H3), 4.53 (2H, s, 2xH5'); Sc  (CDCI3) 143.41 (C), 139.07 (C), 138.57 (C, C7a), 
134.41 	C1'), 134.09 (CH, 2xC4'), 133.47 (C, C12a'), 132.44 (C, C8a'), 129.34 
(CH, 2xC3'), 128.36 and 127.95 (2xCH, C2 and C4), 127.65, 127.61, 127.45, 
127.25, 126.29, 126.25, 125.92, 125.08 (8xCH), 119.32 (C, Cl"), 115.38 (CH, C7), 
110.30 (CH, C3), 107.14 (C, C5), 35.24 (CH2, C5'); m/z (Elk) 422 ([M]+, 61), 280 ([M-
methyl naphthyl group]+, 100), 141 (34), 77 (34); found [M+H]+, 422.1087, 
C26H18N202S requires [M+H]+, 422.1089; Found: C, 74.0; H, 4.2; N, 6.6. Required: C, 
73.9; H, 4.3; N, 6.6; A = -0.5 ppm. 
2-(Naphthalen-2-ylmethyl)-1H-indole-5-carbonitrile 197 
200 
Yushma BHURRUTH 	 Chapter 6 
To a solution of Me0H (65.0 ml), NaOH 2M (12.5 ml) was added the indole 195 (503 
mg, 1.19 mmol, 1.00 eq) and the reaction mixture was refluxed at 76 °C for 17 hr. 
After allowing the reaction mixture to cool down to RT, the clear colourless solution 
was poured onto 2M HCI (14.0 ml) to a pH of 3 and the aqueous phase was extracted 
with DCM (5x70.0 ml). Concentration in vacuo of the organic phase gave a white 
solid which was washed with water to yield 335 mg (99%) of the product as an 
amorphous white powder: mp 152.0-153.0 °C (hexane/DCM 20:1); Rf 0.25 
[hexane/EtOAc 7:3]; Vmax  (nujol)/cre 3206, 2980-2850, 2215, 1461, 1371, 1053; oFi 
(CDCI3) 8.13 (1H, br, H1), 7.89 (1H, s), 7.86-7.80 (3H, m), 7.73 (1H, s, H4), 7.54-7.47 
(2H, m), 7.37-7.34 (2H, m, H6), 7.28-7.26 (1H, d, J 8.5, H7), 6.46 (1H, d, J 1.0, H3), 
4.33 (2H, s, H1'); 	(CDCI3) 140.25 (C, C2'), 137.95 (C, C7a), 134.96 (C, C2), 
133.54 (C, C3a'), 132.47 (C, C7a'), 128.76 (CH), 128.51 (C, C3a), 127.74, 127.54, 
127.30, 127.23, 126.99, 126.47, 125.99, 125.44, 124.53 (11xCH), 120.81 (C, C1"), 
111.28 (CH, C7), 102.88 (C, C5), 101.77 (CH, C3), 34.79 (CH2, C1'); m/z (Elf) 282 
([M]+, 100), 155 (52); found [M+H]+, 282.1142, C20H14N2 requires [M+H]+, 282.1157; 
Found: C, 85.1; H, 4.9; N, 9.9. Required: C, 85.1; H, 5.0; N, 9.9; A = -5.3 ppm. 
2-(Naphthalen-2-ylmethyl)-1H-indole-5-carbaidehyde 178 
6' 	7' 
To a clear colourless solution of indole 197 (312 mg, 1.10 mmol, 1.00 eq) in 
anhydrous DCM (5.50 ml) under a constant flow of N2, at 0 °C, was added dropwise 
the DIBAL-H solution, 1.0M in DCM (1.50 ml, 1.50 mmol, 1.36 eq). The reaction 
mixture turned pale yellow, it was allowed to warm up to RT over 14 hr. To the bright 
yellow solution was added a 1.0M Rochelle solution (10.2 ml) at 0 °C. Caution: 
evolution of gas. The reaction mixture was stirred at RT for 5 hr. The two phases 
were separated and the aqueous phase extracted with DCM (4x25.0 ml). The solvent 
was removed in vacuo, and the yellowish orange slurry was dissolved in DCM (10.0 
ml) and stirred with 1M HCI (1.70 ml) at RT for 2 hr 20 min. Water (7.70 ml) was 
added, and the pH adjusted to 13 using 2M NaOH (1.10 ml). The two phases were 
extracted with separated, the aqueous phase was extracted with DCM (4x20.0 ml) 
and the organic extracts washed with water (40.0 ml) and brine (40.0 ml). After 
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extraction of the aqueous phase with DCM (4x40.0 ml), drying over MgSO4 and 
concentration in vacuo, the off-white solid isolated was purified by flash column 
chromatography on silica gel (hexane/EtOAc 12:1, 10:1, 9:1, 7:3) to yield 272 mg 
(86%) of the product as an amorphous pale yellow powder: mp 162.5-163.5 °C 
(hexane/DCM 20:1); R1  0.20 [hexane/EtOAc 7.5:2.5]; vr. (nujol)/cm-1  3221, 2980-
2850, 1660, 1306, 796; SH (CDCI3/MeOD 1:2) 9.86 (1H, s, H1"), 8.00 (1H, s, H4), 
7.78-7.73 (3H, m), 7.69 (1H, s, H1), 7.61-7.59 (1H, d, J 8.5, H6), 7.44-7.33 (4H, m, 
H7), 6.36 (1H, br, H3), 4.25 (2H, s, 2xH1'); 	(CDCI3/MeOD 1:2) 194.21 (CH, C1"), 
141.47 (C), 141.20 (C), 136.49 (C, C5), 134.11 (C), 132.84 (C), 129.29 (C), 129.08 
(C), 128.65, 128.03, 127.96, 127.63, 	127.51, 126.54, 126.02 (7xCH), 125.93 (CH, 
C4), 121.94 (CH, C6), 111.83 (CH, C7), 102.50 C3), 35.13 (CH2, C1'); 	m/z (Elf) 
285 ([M]+, 100), 254 ([M-aldehyde]+, 38), 158 (50), 158 (42); found [M+H]+, 285.1146, 
C20H15NO requires [M+H]+, 285.1154; Found: C, 84.1; H, 5.3; N, 4.9. Required: C, 
84.2; H, 5.3; N, 4.9; A = -2.8 ppm. 
(Z)-Ethyl 2-ethoxy-3-(2-(naphthalen-2-ylmethyl)-1H-indol-5-yl)actylate 183 and (E)-
ethyl 2-ethoxy-3-(2-(naphthalen-2-ylmethyl)-1H-indo1-5-yOaciylate 184 
To a milky suspension of sodium hydride, 60% in oil (31.0 mg, 0.775 mmol, 2.18 eq) 
and molecular sieves 4A in anhydrous THF (4.00 ml) at 0 °C, under a constant flow of 
N2, was added dropwise, phosphonoacetate 129 (173 mg, 0.644 mmol, 1.81 eq) in 
THF (1.20 ml) over 12 min. The pale yellowish solution was stirred at 0 °C for 52 min 
before the dropwise addition of aldehyde 178 (102 mg, 0.356 mmol, 1.00 eq) in dry 
THE (2.00 ml) via syringe pump over 58 min. The solution which turned dark yellow 
was left to stir in the ice bath over 42 hr. The yellowish orange solution was 
concentrated in vacuo, re-dissolved in EtOAc (25.0 ml) and washed with water (30.0 
ml). An emulsion was observed, thus some NaCI was added. The aqueous phase 
was extracted with EtOAc (4x40.0 ml). After drying the organic extracts over MgSO4, 
concentration in vacuo of the organic phase gave an orange slurry which was purified 
by flash column chromatography on silica gel (hexane/EtOAc 12:1, 9:1, 8:2, EtOAc) 
to yield 112 mg (79%) of the product. Ratio Z:E = 63:37. 
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Z isomer 183: colourless oil: Rf 0.30 [hexane/EtOAc 7:3]; vmax (DCM film)/cm-1  3352, 
3053-2900, 1701, 1620, 1252, 1095, 740; gfi (CDCI3) 8.06 (1H, s, H4), 7.98 (1H, br, 
H1), 7.86-7.78 (3H, m), 7.72 (1H, s), 7.66-7.64 (1H, dd, J 8.5, J 1.0, H6), 7.52-7.47 
(2H, m), 7.39-7.37 (1H, dd, J 8.5, J 1.0), 7.23-7.21 (1H, d, J 8.5, H7), 7.19 (1H, s), 
6.41 (1H, br, H3), 4.34-4.29 (4H, m, 2xH6", 2xH1'), 4.05-4.00 (2H, q, J 14.0, J 7.0, 
2xH3"), 1.43-1.37 (6H, m, 3xH4", 3xH7"); & (CDCI3) 165.32 (C, C5"), 142.39, 138.60, 
136.60, 135.70, 133.52, 132.36, 128.81 (7xC, C7a, C2', C5, C2, C3a', C7a', C3a), 
128.45, 127.67, 127.53, 127.16, 127.12, 126.34, 126.26, 125.74 (8xCH), 125.48 (C), 
124.07 (CH, C6), 122.70 (CH, C4), 110.50 (CH, C7), 101.81 (CH, C3), 67.40 (CH2, 
C3"), 60.87 (CH2, C6"), 34.83 (CH2, C1'), 15.54 (CH3), 14.32 (CH3); m/z (Elf) 399 
([M]+, 78), 342 ([M-both ethyl groups]+, 25), 297 (24), 141 (100); found [M+H]+, 
399.1830, C26H25NO3 requires [M+H]+, 399.1834; Found: C, 78.3; H, 6.2; N, 3.6. 
Required: C, 78.2; H, 6.3; N, 3.5; A = -1.0 ppm. 
E isomer 184: colourless oil: Rf 0.30 [hexane/EtOAc 7:3]; vmax (DCM film)/cm-1  3392, 
3050-2900, 1712, 1635, 1228, 1153, 740;8H (CDCI3) 7.85-7.79 (4H, m), 7.71 (1H, s), 
7.52-7.45 (2H, m), 7.42 (1H, s, H4), 7.38-7.36 (1H, dd, J 8.5, J 1.5), 7.14-7.12 (1H, d, 
J 8.5, H7), 7.00-6.98 (1H, dd, J 8.5, J 1.5, H6), 6.33-6.32 (1H, d, J 1.0, H3), 6.29 (1H, 
s, H1"), 4.28 (2H, s, H1'), 4.18-4.11 (2H, q, J 14.5, J 7.0, 2xH6"), 3.98-3.93 (2H, q, J 
14.0, J 7.0, 2xH3"), 1.44-1.41 (3H, t, J 7.0, 3xH4"), 1.11-1.08 (3H, t, J 7.0, 3xH7"); 
(CDCI3) 165.19 (C, C5"), 146.09, 138.06, 135.90, 135.46, 133.52, 132.33, 128.67 (7x 
C, C7a, C2', C5, C2, C3a', C7a', C3a), 128.39, 127.66, 127.52, 127.19, 127.07, 
126.23 (6xCH), 126.20 (C), 125.69 (CH), 122.37 (CH, C6), 119.92 (CH, C4), 111.61 
(CH, Cl"), 110.05 (CH, C7), 101.25 (CH, C3), 64.60 (CH2, C3"), 61.04 (CH2, C6"), 
34.70 (CH2, C1'), 14.53 (CH3, C4"), 13.73 (CH3, C7"); m/z (EI-') 399 ([M]+, 72), 342 
([M-both ethyl groups]+, 24), 282 (34), 141 (100); found [M+H]+, 399.1832, C26H25NO3 
requires [M+H]+, 399.1834; Found: C, 78.3; H, 6.2; N, 3.6. Required: C, 78.2; H, 6.3; 
N, 3.5; A = -0.5 ppm. 
Methyl 2-ethoxy-3-(2-(naphthalen-2-ylmethyl)-1H-indo1-5-yl)propanoate 189 
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To a clear orange-brown solution of the starting material 183 and 184 (110 mg, 0.275 
mmol, 1.00 eq) in anhydrous methanol (4.00 ml) at RT, under a constant flow of N2, 
were added the magnesium turnings (68.5 mg, 2.82 mmol, 10.3 eq) in one portion. 
After stirring at RT for 4.5 hr, some starting material was still seen by MS. Therefore, 
were added, more magnesium turnings (46.7 mg, 1.92 mmol, 7.00 eq) and the 
reaction mixture was stirred for another 18 hr. The pale orangish suspension was 
poured onto water (30.0 ml). The 2 phases were separated and the aqueous phase 
was extracted with DCM (4x25.0 ml). The organic extracts were washed with brine 
(50.0 ml). The aqueous phase was extracted with DCM (4x45.0 ml). After drying over 
MgSO4, concentration in vacuo gave a pale yellow oil which was purified by flash 
column chromatography on silica gel (hexane/EtOAc 10:1, 9:1, 8:2) to yield 85 mg 
(80%) of the product as a yellowish oil: Rf 0.15 [hexane/EtOAc 8:2]; Vmax  (DCM 
film)/cm-1  3392, 3050-2900, 1741, 1643, 1273, 1114, 740; SH (CDCI3) 7.84-7.79 (4H, 
m), 7.71 (1H, s, H1), 7.51-7.45 (2H, m), 7.42 (1H, s, H4), 7.39-7.36 (1H, dd, J 8.5, J 
1.5), 7.16-7.13 (1H, d, J 8.5, H7), 7.01-6.99 (1H, dd, J 8.0, J 1.5, H6), 6.33-6.32 (1H, 
d, J 1.0, H3), 4.28 (2H, s, H1'), 4.10-4.07 (1H, dd, J 7.0, J 6.0, 2xH2"), 3.71 (3H, s, 
H6"), 3.63-3.58 (1H, m, 1xH3"), 3.40-3.33 (1H, m, 1xH3"), 3.11 (1H, s, 1xH1"), 3.09-
3.08 (1H, d, J 1.5, 1xH1"), 1.19-1.16 (3H, t, J 7.0, 3xH4"); gc (CDC13) 173.30 (C, C5"), 
137.89, 135.97, 135.30, 133.53, 133.18, 132.33, 128.90 (7xC, C7a, C2', C5, C2, 
C3a', C7a'), 128.41 (CH), 128.26 (C, C3a), 127.72, 127.52, 127.24, 127.09, 126.35, 
125.69 (6xCH), 122.95 (CH, C6), 120.47 (CH, C4), 110.19 (CH, C7), 101.02 (CH, 
C3), 81.02 (CH, C2"), 66.20 (CH2, C3"), 51.77 (QH3, C6"), 39.53 (CH2, C1"), 34.92 
(CH2, C1'), 15.07 (CH3, C4"); m/z (El+) 387 ([Mr, 27), 270 ([M-side chain on 5-
position]+, 100), 146 (67); found [M+H]+, 387.1835, C25H25NO3 requires [M+H]+, 
387.1834; Found: C, 77.5; H, 6.4; N, 3.7. Required: C, 77.5; H, 6.5; N, 3.6; A = 0.3 
ppm. 
2-Ethoxy-3-(2-(naphthalen-2-ylmethyl)-1H-indol-5-yl)propanoic acid 42 
OH 
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The starting material 189 (62.1 mg, 0.160 mmol, 1.00 eq) was refluxed with 
potassium hydroxide pellets (18.0 mg, 0.321 mmol, 2.00 eq) in a mixture of 
ethanol/water 1:1 (1.60 ml) at 75 °C for 15 hr and at 90 °C for a further 2.5 hr. Some 
starting material was still seen by MS, thus more potassium hydroxide (31.0 mg, 
0.552 mmol, 3.40 eq) was added and the RM was stirred for a further 4 hr. The light 
orange solution was allowed to cool down to RT and concentrated in vacuo. With 
vigorous stirring in ice, was added 1M HCI (-30 drops) until a pH of 1 was reached. 
The desired acid crashed out as an off-white ppt. DCM was added and the 2 phases 
were separated. The aqueous phase was extracted with DCM (4x10.0 ml). The 
extracts were washed with water (2x25.0 ml). The aqueous phase was extracted with 
DCM (4x45.0 ml, 3x20.0 ml, 2x50.0 ml). After drying over MgSO4, concentration in 
vacuo gave 58.5 mg (98%) of the product as a yellowish oil: Rf 0.25 [hexane/EtOAc 
1:9]; vmax (DCM film)/cm-1  3403, 3053-2900, 1720, 1644, 1267, 1110, 739; SH (CDCl3) 
7.85-7.79 (4H, m), 7.71 (1H, s), 7.51-7.45 (2H, m), 7.43 (1H, s, H4), 7.39-7.36 (1H, 
dd, J 8.5, J 1.5), 7.16-7.14 (1H, d, J 8.5, H7), 7.02-7.00 (1H, dd, J 8.0, J 1.5, H6), 
6.34 (1H, br, H3), 4.28 (2H, s, H1'), 4.14-4.11 (1H, dd, J 7.5, J 4.5, 2xH2"), 3.62-3.54 
(1H, m, 1xH3"), 3.50-3.42 (1H, m, 1xH3"), 3.25-3.21 (1H, dd, J 14.0, J 4.0, 1xH1"), 
3.11-3.06 (1H, dd, J 14.0, J 8.0, 1xH1"), 1.19-1.16 (3H, t, J 7.0, 3xH4"); Sc (CDC13) 
174.59 (C, C5"), 138.03, 135.90, 135.39, 133.53, 132.35, 128.87 (6xC, C7a, C2', C5, 
C2, C3a', C7a'), 128.44 (CH), 127.68 (CH), 127.65 (C, C3a), 127.53, 127.24, 127.12, 
126.25, 125.72 (5xCH), 123.01 (CH, C6), 120.69 (CH, C4), 110.32 (CH, C7), 101.04 
(CH, C3), 80.31 (CH, C2"), 66.89 (CH2, C3"), 38.75 (CH2, Cl"), 34.93 (CH2, C1'), 
15.07 (CH3, C4"); mlz (Elk) 373 ([M]+, 33), 270 ([M-side chain on 5-position]+, 100), 
142 (36); found [M+H]+, 373.1676, C24H23NO3 requires [M+H]+, 373.1678; Found: C, 
77.1; H, 6.1; N, 3.6. Required: C, 77.2; H, 6.2; N, 3.8; A = 0.9 ppm. 
(Z)-Ethyl 3-(2-(naphthalen-2-ylmethyl)-1H-indo1-5-y1)-2-(2,2,2-trifluoroethoxy)acrylate 
185 and (E)-ethyl 3-(2-(naphthalen-2-ylmethyl)-1H-indol-5-y1)-2-(2,2,2-trifluoro-
ethoxy)-acrylate 186 
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To a milky suspension of sodium hydride, 60% in oil (29.4 mg, 0.735 mmol, 1.41 eq) 
and molecular sieves 4A in anhydrous THF (3.60 ml) at 0 °C, under a constant flow of 
N2, was added dropwise, phosphonoacetate 130 (180 mg, 0.560 mmol, 1.08 eq) in 
THF (1.20 ml) over 12 min. The pale yellowish solution was stirred at 0 °C for 35 min 
before the dropwise addition of aldehyde 178 (148 mg, 0.520 mmol, 1.00 eq) in dry 
THF (1.60 ml) via syringe pump over 42 min. The solution which had turned bright 
yellow was left to stir in the ice bath over 39 hr. The light yellow solution was 
concentrated in vacuo, re-dissolved in EtOAc (30.0 ml) and washed with water (30.0 
ml). An emulsion was observed, thus some NaCI was added. The aqueous phase 
was extracted with EtOAc (4x30.0 ml). After drying the organic extracts over MgSO4, 
concentration in vacuo of the organic phase gave a very pale orangish slurry which 
was purified by flash column chromatography on silica gel (hexane/EtOAc 10:1) to 
yield 183 mg (78%) of the product. Ratio Z:E = 38:62. 
Z isomer 185: almost colourless oil: Rf 0.35 [hexane/EtOAc 7:3]; vmax (DCM film)/cm"' 
3408, 2975, 1702, 1620, 1263, 1167, 742; gH (CDCI3) 8.06 (1H, s, H4), 7.93 (1H, br, 
H1), 7.88-7.82 (3H, m), 7.75 (1H, s), 7.62-7.60 (1H, dd, J 8.5, J 1.5, H6), 7.56-7.48 
(2H, m), 7.48-7.38 (1H, dd, J 8.5, J 1.5), 7.29 (1H, s, H1"), 7.25-7.23 (1H, d, J 8.5, 
H7), 6.45-6.44 (1H, d, J 1.0, H3), 4.42-4.34 (4H, m, 2xH3", 2xH6"), 4.32 (2H, s, 
2xH1'), 1.43-1.40 (3H, t, J 7.0, 3xH7"); Sc  (CDCI3) 164.08 (C, C5"), 140.38, 138.80, 
136.95, 135.56, 133.56, 132.42, 128.93 (7xC, C7a, C2', C2", C5, C2, C3a', C7a'), 
128.58 (CH), 127.71 (CH), 127.59-119.28 (C, q, J 277.0, C4"), 127.55, 127.48, 
127.18, 127.15 126.34, 125.82 (6xCH), 124.38 (CH, C6), 124.30 (C, C3a), 123.39 
(CH, C4), 110.64 (CH, C7), 102.00 (CH, C3), 68.34-67.30 (CH2, q, J35.0, C3"), 61.30 
(CH2, C6"), 34.88 (CH2, C1'), 14.28 (CH3, C7"); m/z (Er) 453 ([M]+, 100), 342 (17), 
141 (93); found [M+H]+, 453.1553, C26H22F3NO3 requires [M+H]+, 453.1552; Found: 
C, 68.8; H, 4.8; N, 2.9. Required: C, 68.9; H, 4.9; N, 3.1; A = 0.2 ppm. 
E isomer 186: off-white powder: mp 123.0-124.5 °C (hexane/DCM 20:1); Rf 0.30 
[hexane/EtOAc 7:3]; vmax (DCM film)/cm-1  3441, 2970-2850, 1709, 1645, 1267, 1132, 
740; b  (CDCI3) 7.86-7.79 (4H, m), 7.71 (1H, s, H1), 7.55 (1H, s, H4), 7.53-7.49 (2H, 
m), 7.38-7.34 (1H, dd, J 8.5, J 1.5), 7.17-7.15 (1H, d, J 8.5, H7), 7.10-7.08 (1H, dd, J 
8.5, J 1.5), 6.72 (1H, s, H1"), 6.36 (1H, d, J 1.0, H3), 4.30-4.23 (4H, m, 2xH3", 2xH1'), 
4.23-4.18 (2H, q, J 14.0, J 7.0, 2xH6"), 1.18-1.15 (3H, t, J 7.0, 3xH7"); et (CDCI3) 
163.51 (C, C5"), 143.33, 138.42, 136.08, 135.73, 133.54, 132.38, 128.58 (7xC, C7a, 
C2', C2", C5, C2, C3a', C7a'), 128.49, 127.70, 127.53 (3xCH), 127.40-119.09 (CH2, 
q, J 277.0, C4"), 127.16, 127.13, 126.31, 125.78 (4xCH), 124.37 (C, C3a), 122.82 
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(CH, C6), 121.82 (CH, Cl"), 121.00 (CH, C4), 110.11 (CH, C7), 101.49 (CH, C3), 
68.20-67.15 (CH2, q, J 35.0, C3"), 61.26 (CH2, C6"), 34.87 (CH2, C1'), 13.79 (CH3, 
C7"); m/z (El+) 453 ([M]+, 61), 342 (10), 210 (100), 141 (46), 105 (69); found [M+H]+, 
453.1548, C26H22F3NO3 requires [M+H]+, 453.1552 Found: C, 69.0; H, 5.0; N, 3.0. 
Required: C, 68.9; H, 4.9; N, 3.1; A = -0.9 ppm. 
Methyl 	3-(2-(naphthalen-2-ylmethyl)-1H-indol-5-yl)-2-(2,2,2-trifluoroethoxy)propa- 
noate 190 
0 
To a mixture of the starting material 185 and 186 (14.7 mg, 0.032 mmol, 1.00 eq) and 
the magnesium turnings (19.2 mg, 0.790 mmol, 24.3 eq) at RT, under a constant flow 
of N2, was added the anhydrous methanol (1.50 ml). A white slurry was observed, it 
was stirred at RT for 14 hr before being poured onto water (25.0 ml) and the aqueous 
phase was acidified with 1M HCI (2.00 ml). The 2 phases were separated and the 
aqueous phase was extracted with DCM (4x25.0 ml). After drying over MgSO4, 
concentration in vacuo gave a pale yellow oil which was purified by flash column 
chromatography on silica gel (hexane/EtOAc 9:1, 8:2) to yield 11.3 mg (79%) of the 
product as a colourless oil: Rf 0.25 [hexane/EtOAc 7.5:2.5]; Vmax (DCM film)/cm-1  
3403, 3054-2850, 1743, 1645, 1279, 1165, 739; 5H (CDC13) 7.85-7.79 (3H, m), 7.77 
(1H, br, H1), 7.72 (1H, s), 7.52-7.46 (2H, m), 7.42 (1H, s, H4), 7.39-7.37 (1H, dd, J 
8.5, J 2.0), 7.17-7.15 (1H, d, J 8.0, H7), 7.00-6.98 (1H, dd, J 8.5, J 1.5, H6), 6.34 (1H, 
m, H3), 4.29 (2H, s, 2xH1'), 4.27-4.24 (1H, dd, J 7.5, J 5.0, H2"), 4.01-3.92 (1H, m, 
1xH3"), 3.74 (3H, s, 3xH6"), 3.74-3.66 (1H, m, 1xH3"), 3.23-3.18 (1H, m, 1xH1"), 
3.17-3.12 (1H, m, 1xH1"); Sc  (CDCI3) 171.49 (C, C5"), 138.05, 135.90, 135.44, 
133.56, 132.38, 128.92 (7xC, C7a, C2', C2", C5, C2, C3a', C7a'), 128.46 (CH), 
127.74-119.42 (C, q, J 277.0, C4"), 127.69 (CH), 127.55 (CH), 127.36 (C), 127.24, 
127.13, 126.26, 125.73 (4xCH), 122.93 (CH, C6), 120.60 (CH, C4), 110.33 (CH, C7), 
101.07 (CH, C3), 82.04 (CH, C2"), 68.40-67.37 (CH2, q, J 34.5, C3"), 52.09 (CH3, 
C6"), 39.18 (CH2, Cl"), 34.94 (CH2, C1'); m/z (El+) 441 ([M]+, 56), 270 ([M-propanoate 
side chain]+, 100); found [M+H]+, 441.1548, C26H22F3NO3 requires [M+H]+, 441.1552; 
Found: C, 72.7; H, 4.9; N, 3.8. Required: C, 68.2; H, 5.0; N, 3.2; A = 0.9 ppm. 
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3-(2-(Naphthalen-2-ylmethyl)-1H-indo1-5-y1)-2-(2,2,2-trifluoroethoxy)propanoic acid 43 
The starting material 190 (5.9 mg, 0.013 mmol, 1.00 eq) was refluxed with potassium 
hydroxide pellets (1.5 mg, 0.027 mmol, 2.00 eq) in a mixture of ethanol/water 1:1 
(1.00 ml) at 78 °C for 15 hr. The light yellow solution was allowed to cool down to RT 
and concentrated in vacuo. With vigorous stirring in ice, was added 1M HCI (-2 
drops) until a pH of 1 was reached. The desired acid crashed out as an off-white ppt. 
DCM was added and the 2 phases were separated. The aqueous phase was 
extracted with DCM (4x20.0 ml). The extracts were washed with water (25.0 ml). The 
aqueous phase was extracted with DCM (4x25.0 ml). After drying over MgSO4, 
concentration in vacuo gave 5.6 mg (98%) of the product as a pale yellow oil: Rf 0.40 
[Solvent B]; vmax (DCM film)/cm-1  3441, 3000-2700, 1706, 1646, 1267, 1049, 740; 5,.., 
(CDC13/Me0D 2:1) 9.53 (1H, br, H6"), 7.76-7.71 (3H, m), 7.65 (1H, s), 7.51 (1H, s, 
H4), 7.42-7.38 (2H, m), 7.35-7.32 (1H, dd, J 8.5, J 1.0), 7.17-7.15 (1H, d, J 8.5, H7), 
7.09-7.07 (1H, m, H6), 6.59 (1H, s, H1"), 6.18 (1H, br, H3), 4.26-4.20 (4H, m, 2xH3", 
2xH1'); 	(CDC13) 174.21 (C, C5"), 138.19, 135.85, 135.50, 133.55, 132.38, 128.96 
(7xC, C7a, C2', C2", C5, C2, C3a', C7a'), 128.48, 127.69 (2xCH), 127.58-119.27 (C, 
q, J 277.0, C4"), 127.54, 127.23, 127.14 (3xCH), 126.98 (C), 126.27, 125.74 (2xCH), 
122.91 (CH, C6), 120.70 (CH, C4), 110.46 (CH, C7), 101.07 (CH, C3), 81.65 (CH, 
C2"), 68.64-67.61 (CH2, q, J 34.5, C3"), 38.98 (CH2, C1'), 34.93 (CH2, Cl"); mlz (El+) 
427 ([M]+, 47), 270 (100), 141 (53); found [M+H]+, 427.1389, C24H20F3NO3 requires 
[M+H]+, 427.1395; Found: C, 67.3; H, 4.6; N, 3.2. Required: C, 67.4; H, 4.7; N, 3.3; A 
= 0.9 ppm. 
1-(MethoxycarbonyI)-2,5-dihydropyrrole 210257  
0 
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To a round-bottomed flask were added 3-pyrroline (5.50 ml, 65% pure, 47.07 mmol, 
1.00 eq), powdered potassium carbonate (19.5 g, 141 mmol, 3.00 eq) and anhydrous 
DCM (120 ml). The mixture was cooled to 0 °C and methyl chloroformate (6.10 ml, 
78.9 mmol, 1.64 eq) was added dropwise via syringe pump over 100 min. The 
reaction mixture was allowed to warm up to RT over 14 hr. It turned yellowish. The 
reaction mixture was filtered and the filtrate concentrated in vacuo. Next, it was 
treated with 10% Na2CO3 (2x60.0 ml). After extracting the aqueous phase with DCM 
(4x120 ml) and drying over MgSO4, concentration in vacuo yielded a yellow liquid 
which was purified by flash column chromatography on silica gel (hexane/EtOAc 8:2, 
6:4) to yield 5.92 g (99%) of the product as a colourless liquid: Rf 0.25 [hexane/EtOAc 
7.5:2.5]; vma, (film)/cm-1  3081-2850, 1707, 1548, 1462, 1393, 1120; Srf  (CDCI3) 5.80-
5.78 (2H, d, J 10.0, 2xH3), 4.19-4.11 (4H, m, 4xH2), 3.73 (3H, s, 3xH2'); sc  (CDCI3) 
155.28 (C, C1'), 125.77 and 125.65 (CH, C3 rotamers), 53.39 and 52.84 (CH2, 
rotamers, C2), 52.36 (CH3, C2'); m/z (Elf) 127 ([M]+, 100), 112 ([M-Me]+, 85), 67 ([M-
carbamate group]+, 63); found [M+H]+, 127.0629, C6H9NO2 requires [M+H]+, 
127.0633; Found: C, 56.5; H, 7.2.; N, 10.9. Required: C, 56.7; H, 7.1; N, 11.0; A = -
0.8 ppm. 
1-(MethoxycarbonyI)-3-phenyl-2,3-dihydropyrrole 211257 
To a stirred solution of pyrroline 210 (529 mg, 4.16 mmol, 9.91 eq) and molecular 
sieves 4A in anhydrous DMF (1.00 ml), under N2, were added iodobenzene (0.050 
ml, 0.420 mmol, 1.00 eq), P(o-tol)3 (15.3 mg, 0.050 mmol, 0.12 eq), Ag2CO3 (80.3 g, 
0.291 mmol, 0.69 eq), Pd(OAc)2 (5.0 mg, 0.022 mmol, 0.05 eq) and iPr2NEt (0.290 
ml, 1.67 mmol, 3.96 eq). The brown reaction mixture was stirred at 100 °C for 19.5 hr. 
It was allowed to cool down, filtered over celite, and treated with 10% Na2CO3 (10.0 
ml). After extracting the aqueous phase with ether (4x20.0 ml) and drying over 
MgSO4, concentration in vacuo yielded a brown oil which was purified by flash 
column chromatography on silica gel (hexane/ether 10:1, 2:1) to yield 56.1 mg (66%) 
of the product as a yellow oil: Rf 0.25 [hexane/ether 2:1]; Vmax  (DCM film)/cm'' 3050-
2850, 1707, 1549, 1452, 1384, 1126, 744; gH (CDCI3) 7.36-7.32 (2H, m, 2xH3"), 7.28-
7.20 (3H, m, 2xH2", H4"), 6.84-6.69 (1H, m, rotamers, H5), 5.19-5.15 (1H, m, 
rotamers, H4), 4.21-4.11 (2H, m, H3, H2), 3.79-3.66 (4H, m, 3xH2', H2); Sc (CDCI3) 
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152.4, 152.3 (C, C1' rotamers), 143.76 (C, Cl"), 130.36 and 129.45 (CH, C5 
rotamers), 128.69 (2xCH), 127.11 (2xCH), 126.89 (CH), 112.41 and 112.07 (CH2, C4 
rotamers), 53.88 (CH3, C2'), 52.60-52.53 (CH2, C2), 48.27 and 47.10 (CH2, C3 
rotamers); m/z (Elk) 203 ([M]+, 81), 188 ([M-Me]+, 60), 144 ([M-carbamate group]+, 
42), 115 (57), 84 (82); found [M+H]+, 203.0938, C12H13NO2 requires [M+H]+, 
203.0946; Found: C, 70.9; H, 6.4.; N, 7.0. Required: C, 70.9; H, 6.5; N, 6.9; A = -3.9 
ppm. 
1-(MethoxycarbonyI)-3-phenylpyrrolidine 218257 
0 
To a colourless solution of pyrroline 211 (647 mg, 3.18 mmol, 1.00 eq) in anhydrous 
Me0H (15.0 ml), under N2, was added the platinum oxide (34.2 mg, 0.151 mmol, 0.05 
eq). The reaction mixture was flushed with hydrogen gas and the RM was stirred at 
RT for 15.5 hr. The reaction mixture was flushed with N2 and filtered over celite. 
Concentration in vacuo yielded an almost colourless oil which was purified by flash 
column chromatography on silica gel (hexane/ether 9:1, 8:2, 2:1) to yield 467 mg 
(72%) of the product as a colourless oil: Rf 0.15 [hexane/ether 2:1]; Vmax  (film)/cre 
3050-2850, 1705, 1548, 1456, 1390, 1122, 760; SH (CDC13) 7.36-7.32 (2H, m, 2xH3"), 
7.27-7.22 (3H, m, 2xH2", H4"), 3.95-3.82 (1H, m, H5), 3.73 (3H, s, H2'), 3.70-3.30 
(4H, m, H5, 2xH2, H3), 2.35-2.23 (1H, m, H4), 2.09-1.93 (1H, m, H4); et (CDCI3) 
155.47 (C, C1'), 141.21 (C, Cl"), 128.59, 126.96, 126.79 (3xCH aromatic, C3", C2", 
C4"), 52.31 (CH3, C2'), 52.28 and 52.08 (CH2, C2 rotamers), 46.12 and 45.63 (CH2, 
C5 rotamers), 44.15 and 43.24 (CH, C3 rotamers), 33.25 and 32.39 (CH2, C4 
rotamers); m/z (Eli) 205 ([M]+, 64), 190 ([M-Me]+, 41), 117 (37), 101 (100), 42 (68); 
found [M+H]+, 205.1103, C12H15NO2 requires [M+H]+, 205.1103; Found: C, 70.2; H, 
7.5; N, 7.1. Required: C, 70.2; H, 7.4; N, 6.8; A = 0.0 ppm. 
3-Phenylpyrrolidine 201257  
H1  
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To a colourless solution of 218 (43.8 mg, 0.216 mmol, 1.00 eq) and molecular sieves 
4A in anhydrous DCM (4.00 ml), under N2, was added iodotrimethylsilane (0.040 ml, 
0.281 mmol, 1.30 eq). The reaction mixture turned yellow, it was stirred at RT for 16 
hr. The reaction mixture was quenched with methanol (4.00 ml), filtered and 
concentrated in vacuo. Purification of the crude by flash column chromatography on 
silica gel (DCM, DCM/solvent B 9:1, 1:1, 0:1) to yield 27.0 mg (99%) of the product as 
a yellow powder: mp 83.5-85.0 °C (EtOAc); Rf 0.25 [Solvent B]; vm„ (DCM film)/cm-1 
3441, 3030-2850, 1548, 1068, 742; 4i  (CDCI3/MeOD 2:1) 7.34-7.20 (5H, m, 2xH3', 
H4', 2xH2'), 3.73-3.66 (1H, dd, J 11.0, J 8.0, H2), 3.61-3.51 (2H, m, H3, H5), 3.44-
3.35 (1H, m, 1xH5), 3.25-3.17 (1H, t, J 11.0, H2), 2.50-2.41 (1H, m, 1xH4), 2.20-2.08 
(1H, m, 1xH4); 	(CDC13/Me0D 2:1) 138.49 (C, C1'), 129.34, 128.01, 127.54 (3xCH 
aromatic, C3", C2", C4"), 51.18 (CH2, C2), 46.01 (CH2, C5), 43.76 (CH, C3), 32.54 
(CH2, C4); m/z (Elf) 147 ([M]+, 20), 84 (66), 49 (74), 43 (100); found [M+H]+, 
147.1043, C13H13N requires [M+H]+, 147.1048; A = -3.3 ppm. 
(Z)-Ethyl 3-(4-bromophenyl)-2-ethoxyacrylate 202 and (E)-ethyl 3-(4-bromophenyl)-2-
ethoxyacrylate 203 
Br 
203 
To a milky suspension of sodium hydride, 60% in oil (508.1 mg, 12.7 mmol, 2.20 eq) 
and molecular sieves 4A in anhydrous THF (60.0 ml) at 0 °C, under a constant flow of 
N2, was added dropwise, via syringe pump, phosphonoacetate 129 (2.79 g, 10.4 
mmol, 1.80 eq) in THF (5.00 ml) over 54 min. The suspension turned pale yellow. It 
was stirred at 0 °C for 57 min before the dropwise addition of 4-bromobenzaldehyde 
(1.07 g, 5.78 mmol, 1.00 eq) in dry THF (5.00 ml) via syringe pump over 64 min. The 
solution which had turned yellow was left to stir in the ice bath over 39 hr. The dark 
yellowish orange solution was concentrated in vacuo, re-dissolved in EtOAc (60.0 ml) 
and washed with water (2x50.0 ml). An emulsion was observed, thus some NaCI was 
added. The aqueous phase was extracted with EtOAc (4x100 ml) and DCM (2x100 
ml). After drying the organic extracts over MgSO4, concentration in vacuo of the 
organic phase gave a yellow oil which was purified by flash column chromatography 
on silica gel (hexane/EtOAc 40:1, 30:1) to yield 1.34 g (78%) of the product. Ratio 
Z:E = 66:34. 
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Z isomer 202: white amorphous solid: mp 31.0-32.0 °C (hexane/EtOAc); Rf 0.25 
[hexane/ether 15:1]; Vmax (nujol)/cm-1  3020-2850, 1726, 1645, 1548, 1045, 662; (51-1 
(CDCI3) 7.67-7.64 (2H, m, 2xH2), 7.51-7.48 (2H, m, 2xH3), 6.90 (1H, s, H1'), 4.34-
4.29 (2H, q, J 14.0, J 7.0, 2xH3'), 4.05-4.00 (2H, q, J 14.0, J 7.0, 2xH6'), 1.40-1.34 
(6H, m, H4', H7'); Sc  (CDCI3) 164.38 (C, C1), 145.23 (C, C2), 132.62 (C, C4), 131.65 
(2xCH), 131.45 (2xCH), 122.73 (C, C7), 122.32 (CH, C3), 67.75 (CH2, C1'), 61.27 
(CH2, C1"), 15.54 (CH3), 14.27 (CH3); m/z (Elk) 298 ([M]+, 41), 196 ([M-ethoxy 
propanoic acid side chain]+, 100), 89 (56); found [M+H]+, 298.0207, C13H1503Br 
requires [M+H]+, 298.0205; Found: C, 52.1; H, 5.0. Required: C, 52.2; H, 5.1; A = 0.7 
ppm. 
E isomer 203: colourless oil Rf 0.15 [hexane/ether 15:1]; Vmax  (film)/cm-1  2983, 1731, 
1641, 1548, 1161, 662; b1  (CDCI3) 7.42-7.39 (2H, m, 2xH2), 7.08-7.06 (2H, m, 2xH3), 
6.00 (1H, s, H1'), 4.18-4.13 (2H, q, J 14.5, J 7.0, 2xH3'), 3.96-3.91 (2H, q, J 14.0, J 
7.0, 2xH6'), 1.45-1.41 (3H, t, J 7.0, H6'), 1.16-1.12 (3H, t, J 7.0, H3'); 	(CDCI3) 
164.25 (C, C1'), 148.02 (C, C2'), 134.06 (C, C4), 131.13 (2xCH), 130.05 (2xCH), 
120.61 (C, C7), 107.83 (CH, C3), 64.59 (CH2, C1'), 61.41 (CH2, Cl"), 14.39 (CH3, 
C2'), 13.69 (CH3, C2"); m/z (Elf) 298 ([M]+, 38), 196 ([M-ethoxy propanoic acid side 
chain]+, 100), 89 (60); found [M+H]+, 298.0209, C13H1503Br requires [M+H]+, 
298.0205; Found: C, 52.1; H, 5.0. Required: C, 52.2; H, 5.1; A = 0.9 ppm. 
2-(4-Bromopheny0-1,3-dioxolane 220265  
Ethylene glycol (0.450 ml, 8.07 mmol, 1.99 eq) and para-toluenesulfonic acid (36.3 
mg, 0.191 mmol, 0.05 eq) were dissolved in dry toluene (7.50 ml) under N2 in a Dean 
Stark apparatus. The mixture was vigorously stirred under reflux at 114 °C for 17 hr 
to remove the water from the ethylene glycol. It was allowed to cool down, 4-
bromobenzaldehyde (749 mg, 4.05 mmol, 1.00 eq) dissolved in toluene (3.50 ml) was 
added and the mixture was refluxed at 116 °C for another 17.5 hr. The cooled 
reaction mixture was quenched with sat. NaHCO3 and the product extracted with 
EtOAc (4x25.0 ml). The combined organic layers were washed with brine. After 
drying the organic extracts over MgSO4, concentration in vacuo of the organic phase 
gave a pale yellow oil which was purified by flash column chromatography on silica 
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gel (hexane/ether 20:1, 15:1, 10:1) to yield 106 mg (14%) of the SM and 537 mg 
(57%) of the product as a pale yellow solid: mp 33.0-35.0 °C [lit.,265  37-38 °C]; Rf 0.30 
[Petroleum ether/ether 9:1]; Vmax  (nujol)/cm-1  2950-2850, 1646, 1078, 809, 662; gH 
(CDCI3) 7.56-7.50 (2H, d, J 8.5, 2xH2'), 7.40-7.34 (2H, d, J 8.5, 2xH3'), 5.78 (1H, s, 
H2), 4.16-3.98 (4H, m, 2xH3, 2x1-14); et (CDCI3) 136.99 (C, C1'), 131.40 (2xCH), 
128.11 (2xCH), 123.12 (C, C4'), 102.93 (CH, C2), 65.22 (CH2, 2xC4); m/z (Elk) 229 
([M (81Br)]+, 100), 227 ([M (79130]+, 97), 183 ([M-acetal]+, 37), 149 ([M-bromor, 41), 84 
(56), 49 (65); found [M+H]+, 227.9776, C9H9O2Br requires [M+H]+, 227.9786; Found: 
C, 47.2; H, 4.0. Required: C, 47.2; H, 4.0; A = -4.4 ppm. 
4-(Pyrrolidin-1-yObenzaldehyde 221111 
CHO 
To a stirred solution of pyrrolidine (0.031 ml, 0.369 mmol, 1.20 eq) and acetal 220 
(70.5 mg, 0.308 mmol, 1.00 eq) in anhydrous toluene (3.10 ml), under N2, were 
added Pd2(dba)3 (6.0 mg, 0.007 mmol, 0.02 eq), (±)-BINAP (8.5 mg, 0.014 mmol, 
0.04 eq) and sodium Pert-butoxide (41.4 mg, 0.431 mmol, 1.40 eq) and the brown 
reaction mixture was stirred at 71 °C for 15.5 hr. It was allowed to cool down, diluted 
with ether, filtered over celite and the celite washed with ether. Concentration in 
vacuo yielded a bright yellowish orange oil which was purified by flash column 
chromatography on silica gel (hexane/ether 9:1, 8:2, 6:4) to yield 35.0 mg (65%) of 
the product as a white crystalline solid: Rf 0.20 [hexane/ether 6:4]; vmax (DCM 
film)/cm-1  3000-2900, 1658, 1610, 1533, 1157, 813; SH (CDCI3) 9.72 (1H, s, CHO), 
7.45-7.71 (2H, dd, J 9.0, J 2.0, 2xH2), 6.59-6.56 (2H, d, J 9.0, 2xH3), 3.41-3.38 (4H, 
m, 4xH2'), 2.07-2.04 (4H, m, 4xH3'); et (CDCI3) 190.18 (CHO), 151.95 (C, C4), 
132.12 (CH, 2xC2), 124.84 (C, C1), 111.17 (CH, 2xC3), 47.62 (CH2, 2xC2'), 25.39 
(CH2, 2xC3'); mlz (Elk) 175 ([M]+, 87), 174 (100), 119 (43), 84 (57), 49 (68); found 
[M+H]+, 175.0989, G111-113N0 requires [M+H]+, 175.0997; A = -4.6 ppm. 
4-(3-Phenylpyrrolidin-1-yObenzaldehyde 222 
CHO 
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To a stirred solution of pyrrolidine 201 (63.7 mg, 0.433 mmol, 1.18 eq) and acetal 220 
(83.7 mg, 0.365 mmol, 1.00 eq) in anhydrous toluene (3.60 ml), under N2, were 
added Pd2(dba)3 (7.2 mg, 0.008 mmol, 0.02 eq), (±)-BINAP (9.5 mg, 0.015 mmol, 
0.04 eq) and sodium tert-butoxide (50.0 mg, 0.520 mmol, 1.42 eq) and the brown 
reaction mixture was stirred at 71 °C for 15 hr. Some more acetal 220 (16.2 mg, 
0.071 mmol, 0.19 eq), Pd2(dba)3 (6.5 mg, 0.007 mmol, 0.02 eq), (±)-BINAP (12.0 mg, 
0.019 mmol, 0.05 eq) and sodium tert-butoxide (99.5 mg, 1.03 mmol, 2.83 eq) were 
added and the reaction was stirred at 71 °C for another 16 hr. It was allowed to cool 
down, diluted with ether, filtered over celite and the celite washed with ether. 
Concentration in vacuo yielded a dark orange oil which was purified by flash column 
chromatography on silica gel (hexane/ether 10:1, 8:2; 1:1) to yield 26.7 mg (25%) of 
the product as a bright yellow oil: Rf 0.25 [hexane/ether 8:2]; Vmax  (DCM film)/cm-1  
3020, 1691, 1646, 1265, 738; SH (CDCI3) 9.76 (1H, s, CHO), 7.80-7.75 (2H, d, J 9.0, 
H2), 7.39-7.35 (2H, m, H3"), 7.30-7.28 (3H, m, H2", H4"), 6.63-6.61 (2H, d, J 9.0, H3), 
3.87-3.82 (1H, dd, J 7.5, J 2.0, H2'), 3.67-3.61 (1H, m, H5'), 3.59-3.52 (2H, m, H5', 
H3'), 3.48-3.44 (1H, m, H2'), 2.52-2.45 (1H, m, H4'), 2.25-2.16 (1H, m, H4'); Sc 
(CDCI3) 190.27 (CHO), 151.69 (C, C4), 141.42 (C, Cl"), 132.19 (CH, 2xC2), 128.75 
(CH, 2xC3"), 127.01 (CH, 2xC2", C4"), 125.23 (C, C1), 111.20 (CH, 2xC3), 54.28 
(CH2, C2'), 47.66 (CH2,C5'), 43.94 (CH, C3'), 32.94 (CH2, C4'); m/z (El+) 251 ([M]+, 
100), 147 ([M-benzaldehyde]+, 71), 119 (85), 91 (47); found [M+H]+, 251.1303, 
Ci7Hi7NO requires [M+H]+, 251.1310; A = -2.8 ppm. 
(Z)-ethyl 2-ethoxy-3-(4-(3-phenylpyrrolidin-1-AphenyOacrylate 223 and (E)-ethyl 2-
ethoxy-3-(4-(3-phenylpyrrolidin-1-AphenyOacrylate 224 
To a milky suspension of sodium hydride, 60% in oil (10.6 mg, 0.265 mmol, 2.47 eq) 
and molecular sieves 4A in anhydrous THF (0.400 ml) at 0 °C, under a constant flow 
of N2, was added dropwise, via syringe pump, phosphonoacetate 129 (56.5 mg, 
0.211 mmol, 1.96 eq) in THF (0.500 ml) over 7 min. The suspension was stirred at 
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0 °C for 1 hr before the dropwise addition of aldehyde 222 (27.0 mg, 0.107 mmol, 
1.00 eq) in dry THE (0.900 ml) via syringe pump over 31 min. The solution which had 
turned bright yellowish orange was left stirring in the ice bath over 45 hr. The RM was 
concentrated in vacuo, next re-dissolved in EtOAc (25.0 ml) and washed with water 
(25.0 ml). An emulsion was observed, thus some NaCl was added. The aqueous 
phase was extracted with EtOAc (4x25.0 ml). After drying the organic extracts over 
MgSO4, concentration in vacuo of the organic phase gave a yellow oil which was 
purified by flash column chromatography on silica gel (hexane/ether 12:1, 10:1) to 
yield 36.0 mg (92%) of the product. Ratio Z:E = 63:37. 
Z isomer: very pale yellow oil Rf 0.25 [hexane/ether 8:2]; Vmax  (DCM film)/cm-1  1747, 
1706, 1604, 1178, 738; OH (CDCI3) 7.76-7.72 (2H, d, J 8.8, 2xH5), 7.38-7.33 (2H, m, 
2xH8'), 7.30-7.24 (3H, m, 2xH7', H9'), 7.00 (1H, s, H3), 6.60-6.56 (2H, d, J 9.0, 
2xH6), 4.32-4.26 (2H, q, J 14.5, J 7.0, 2xH3"), 4.01-3.95 (2H, q, J 14.0, J 7.0, 2xH1"), 
3.81-3.76 (1H, dd, J 7.5, J 1.5, 1xH2'), 3.61-3.38 (4H, m, 2xH5', H3', 1xH2'), 2.49-
2.41 (1H, m, 1xH4'), 2.21-2.12 (1H, m, 1xH4'), 1.41-1.35 (6H, m, 3xH4", 3xH2"); toc 
(CDCI3) 165.37 (C, Cl), 147.82 (C, C7), 142.14, 141.09 (2xC), 131.90 (2xC6), 128.64 
(2xCH), 127.06 (2xCH), 126.77 (CH), 125.62 (CH, C3), 121.25 (C, C4), 111.35 
(2xCH, 2xC7), 67.26 (CH2, Cl"), 60.68 (CH2, C3"), 54.21 (CH2, C2'), 47.46 (CH2, 
C5'), 44.02 (CH, C3'), 33.12 (CH2, C4), 15.55 (CH3), 14.38 (CH3); nn/z (ES1+) 366 
([M+H]
+, 100); found [M+H]+, 366.2069, C23H28NO3 requires [M+H]+, 366.2069; 
Found: C, 75.6; H, 7.4; N, 3.8. Required: C, 75.6; H, 7.5; N, 3.7; A = 0.0 ppm. 
E isomer: pale yellow oil Rf 0.20 [hexane/ether 8:2]; Vmax (DCM film)/cm-1  1743, 1706, 
1531, 1265, 1053, 740; 6H (CDCI3) 7.38-7.32 (2H, m, 2xH8'), 7.30-7.24 (3H, m, 2xH7', 
H9'), 7.20-7.16 (2H, d, J 8.5, 2xH5), 6.54-6.50 (2H, d, J 8.5, 2xH6), 6.17 (1H, s, H3), 
4.26-4.21 (2H, q, J 14.5, J 7.0, 2xH3"), 3.95-3.90 (2H, q, J 14.0, J 7.0, 2xH1"), 3.76-
3.72 (1H, dd, J 7.5, J 1.0, 1xH2'), 3.61-3.36 (4H, m, 2xH5', H3', 1xH2'), 2.49-2.40 
(1H, m, 1xH4'), 2.21-2.10 (1H, m, 1xH4'), 1.42-1.38 (3H, t, J 7.0, 3xH2"), 1.25-1.21 
(3H, t, J 7.0, 3xH4"); Oc (CDCI3) 165.11 (C, C1), 146.68 (C, C7), 144.52, 142.49 
(2xC), 129.85 (2xCH, 2xC5), 128.58 (2xCH), 127.05 (2xCH), 126.66 (CH), 125.61 
(CH), 121.57 (C, C4), 113.07 (CH, C3), 111.11 (2xCH, 2xC6), 64.94 (CH2, Cl"), 
60.99 (CH2, C3"), 54.40 (CH2, C2'), 47.54 (CH2, C5'), 44.06 (CH, C3'), 33.18 (CH2, 
C4), 14.63 (CH3), 13.96 (CH3); m/z (ESI+) 366 ([M+Hr, 100); found [M+H]
+, 
366.2063, C23H28NO3 requires [M+H]+, 366.2069; Found: C, 75.6; H, 7.4; N, 3.8. 
Required: C, 75.6; H, 7.5; N, 3.7; A = -1.6 ppm. 
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Methyl 2-ethoxy-3-(4-(3-phenylpyrrolidin-1-yl)phenyl)propanoate 225 
9' 
To a mixture of the starting materials 223 and 224 (30.0 mg, 0.082 mmol, 1.00 eq) 
and the magnesium turnings (52.0 mg, 2.14 mmol, 26.1 eq) at RT, under a constant 
flow of N2, was added the anhydrous methanol (1.50 ml). The colourless solution 
turned into a milky white suspension, it was stirred for 20 hr before being poured onto 
water (20.0 ml) and 1M HCI (0.500 ml). The 2 phases were separated and the 
aqueous phase was extracted with DCM (4x25.0 ml). After drying over MgSO4, 
concentration in vacuo gave a colourless oil which was purified by flash column 
chromatography on silica gel (hexane/ether 10:1, 9:1) to yield 20.0 mg (68%) of the 
product as a colourless oil: Rf 0.45 [hexane/ether 1:1]; vmax (DCM film)/cm-1  1743, 
1620, 1523, 1369, 1117, 737; 6H (CDCI3) 7.37-7.24 (5H, m, 2xH8', H9', 2xH7'), 7.14-
7.12 (2H, d, J 8.5, 2xH6), 6.55-6.53 (2H, d, J 8.5, 2xH5), 4.03-3.99 (1H, t, J 6.5, H2), 
3.75-3.70 (1H, m, 1xH2'), 3.73 (3H, s, 3xH3"), 3.65-3.58 (1H, m, 1xH1"), 3.57-3.43 
(3H, m, 2xH5', 1xH3'), 3.41-3.34 (2H, m, 1xH1", 1xH2'), 2.95-2.94 (2H, d, J 6.5, 
2xH3), 2.46-2.39 (1H, m, 1xH4'), 2.19-2.09 (1H, m, 1xH4'), 1.22-1.18 (3H, t, J 7.0, 
3xH2"); be (CDCI3) 173.22 (C, C1), 146.40 (C, C7), 142.68 (C), 130.11 (2xCH, 2xC6), 
128.56 (2xCH), 127.12 (2xCH), 126.61 (CH), 123.95 (C), 111.47 (2xCH, 2xC5), 80.79 
(CH, C2), 66.18 (CH2, Cl"), 54.58 (CH2, C2'), 51.75 (CH3, C3"), 47.69 (CH2, C5'), 
44.11 (CH, C3'), 38.52 (CH2, C3), 33.24 (CH2, C4'), 15.09 (CH3, C2"); m/z (ESI+) 354 
([M-Mr, 100); found [M+H]+, 354.2071, C22H28NO3 requires [M+H]+, 354.2069; A = -
0.6 ppm. 
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2-Ethoxy-3-(4-(3-phenylpyrrolidin-7-Aphenyl)propanoic acid 44 
OH 
9' 
The starting material 225 (14.6 mg, 0.041 mmol, 1.00 eq) was refluxed with 
potassium hydroxide pellets (13.0 mg, 0.232 mmol, 5.66 eq) in a mixture of 
ethanol/water 1:1 (1.00 ml) at 81 °C for 8 hr. The clear colourless solution was 
allowed to cool down to RT, then concentrated in vacuo. With vigorous stirring in ice, 
was added dropwise, 1M HCI (-8 drops) until a pH of 1 was reached. The desired 
acid crashed out as a white ppt. DCM was added and the 2 phases were separated. 
The aqueous phase was extracted with DCM (4x25 ml). After drying over MgSO4, 
concentration in vacuo gave 12.3 mg (88%) of the product as a colourless oil: Rf 0.50 
[solvent B]; vmax (DCM film)/cm-1  2921, 1730, 1647, 1517, 1115, 743; 5H (CDC13) 7.36-
7.24 (5H, m, 2xH8', H9', 2xH7'), 7.15-7.13 (2H, d, J 8.5, 2xH6), 6.56-6.54 (2H, d, J 
8.0, 2xH5), 4.08-4.05 (1H, dd, J 7.5, J 4.0, H2), 3.74-3.70 (1H, t, J 8.0, 1xH2'), 3.65-
3.41 (5H, m, 2xH1", 2xH5', 1xH3'), 3.38-3.34 (1H, t, 1xH2'), 3.09-3.05 (1H, dd, J 14.0, 
J 4.0, 1xH3), 2.97-2.92 (1H, dd, J 14.0, J 7.5, 1xH3), 2.46-2.39 (1H, m, 1xH4'), 2.20-
2.09 (1H, m, 1xH41), 1.23-1.20 (3H, t, J 7.0, 3xH2"); 5c (CDCI3) 174.62 (C, C1), 
146.50 (C, C7), 142.58 (C), 130.31 (2xCH, 2xC6), 128.59 (2xCH), 127.13 (2xCH), 
126.66 (CH), 123.95 (C), 111.60 (2xCH, 2xC5), 80.11 (CH, C2), 66.83 (CH2, Cl"), 
54.69 (CH2, C2'), 47.77 (CH2, C5'), 44.12 (CH, C3'), 37.72 (CH2, C3), 33.23 (CH2, 
C4'), 15.11 (CH3, C2"); m/z (ES1+) 340 ([M+H]+, 100); found [M+H]+, 340.1917, 
C211-126NO3 requires [M+H]+, 340.1913; Found: C, 74.2; H, 7.6; N, 4.1. Required: C, 
74.3; H, 7.4; N, 4.1; A = 1.2 ppm. 
6.3 Biological methods 
6.3.1 Preparation of the samples for the PPAR activation assay 
Lipids: 25 mM solutions of lyso TTA-PC 34 and TTA-PG 36 were prepared in 0.1 M 
NaOH by heating to ca. 80 °C until complete dissolution, next they were slowly added 
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to pre-heated Foetal Bovine serum (Gibco Invitrogen, catalog no 10106169) at 37 °C. 
The final concentration of the lipids in serum was 0.74 mM. The solution of the lipids 
in serum was added to serum-free medium to the desired concentrations (1 to 75 
PM), and pure serum was added to get a total of 10% serum (v/v) in the medium. 
lndoles: The indole leads 38 to 43 were dissolved in DMSO, 0.1% (v/v). DMSO 
concentration was kept constant in all samples. 
6.3.2 Transfection procedure 
Human MCF-7 breast cancer cells were seeded at a density of 85,000 cells per well 
of a 12-well pate. The following day, they were transiently transfected by the 
SuperFect transfection procedure according to the manufacturer's protocol (Qiagen), 
using 0.9 pg PPREx3-LUC reporter plasmid and 0.15 pg of the plasmid vector, 
pcDNA3.1 humanPPARa/y/S. The total amount of plasmid was kept constant at 2.65 
erg by compensating with promoterCMV-5. 24 hours after transfection, the cells were 
treated with the compounds to be tested or the PPAR specific agonists. 48 hours 
after transfection, the cells were washed once with PBS, lysed in 80 pL lysis buffer 
containing 25 mM TAE, 2 mM DTT, 10% (v/v) Glycerol, 1% (v/v) Triton X-100 and 
de-ionised water. 35 pL of the cell extracts were used for luciferase determination on 
a LUCY-1 luminometer (Anthos, Austria). The luciferase assay was performed in 
accordance with the protocol of the Luciferase Assay Kit (B10 Thema AB, Sweden). 
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Appendix 1 Crystal structure data for 2-benzylcyano indole 
194 
Crystal data and structure refinement for indole 194 
Identification code 	 ADM0701 
Empirical formula C22H16N1202S 
Formula weight 	 372.43 
Temperature 173 (2) K 
Diffractometer, wavelength 	OD Xcalibur 3, 0.71073 A 
Crystal system, space group 	Monoclinic, P2(1)/n 
Unit cell dimensions 	 a = 10.8591(3) A 	a = 90° 
b = 10.0425(3) A 	p= 100.888(3)° 
c = 17.0542(4) A 	y= 90° 
Volume, Z 	 1826.32(9) A3, 4 
Density (calculated) 	 1.354 Mg/m3 
Absorption coefficient 0.197 mm-1  
F(000) 	 776 
Crystal colour / morphology 	Colourless blocks 
Crystal size 	 0.11 x 0.08 x 0.08 mm3 
0 range for data collection 	3.79 to 28.96° 
Index ranges 	 -14<=h<=14, -10<=k<=13, -22<=I<=22 
RefIns collected / unique 	12993 / 4231 [R(int) = 0.0606] 
Reins observed [F>4o(F)] 	2710 
Absorption correction 	 Analytical 
Max. and min. transmission 	0.988 and 0.976 
Refinement method 	 Full-matrix least-squares on F2 
Data / restraints / parameters 	4231 / 7 / 245 
Goodness-of-fit on F2 	 1.040 
Final R indices [F>40-(F)] R1 = 0.0438, wR2 = 0.1012 
R indices (all data) R1 = 0.0808, wR2 = 0.1155 
Largest diff, peak, hole 0.248, -0.307 eA-3 
Mean and maximum shift/error 0.000 and 0.000 
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Bond lengths (Al and angles 171 for indole 194 
N(1)-C(9) 	 1.411 	(2) 
N(1)-C(2) 1.426 	(2) 
N(1)-S(10) 	 1.6757 	(14) 
C(2)-C(3) 1.339 	(3) 
C(2)-C(19) 	 1.499 	(2) 
C(3)-C(4) 1.419 	(2) 
C(4)-C(5) 	 1.388 	(3) 
C(4)-C(9) 1.411 	(2) 
C(5)-C(6) 	 1.375 	(3) 
C(6)-C(7) 1.406 	(3) 
C(6)-C(26) 	 1.442 	(3) 
C(7)-C(8) 1.372 	(2) 
C(8)-C(9) 	 1.390 	(2) 
S(10)-O(11) 1.4175 	(14) 
S(10)-O(12) 	 1.4217 	(13) 
S(10)-C(13) 1.7187 	(15) 
S(10)-C(13') 	 1.774 	(4) 
C(13)-C(14) 1.3900 
C(13)-C(18) 	 1.3900 
C(14)-C(15) 1.3900 
C(15)-C(16) 	 1.3900 
C(16)-C(17) 1.3900 
C(17)-C(18) 	 1.3900 
C(13')-C(14') 1.3900 
C(13')-C(18') 	 1.3900 
C(14')-C(15') 1.3900 
C(15')-C(16') 	 1.3900 
C(16')-C(17') 1.3900 
C(17')-C(18') 	 1.3900 
C(19)-C(20) 1.518 	(2) 
C(20)-C(21) 	 1.383 	(2) 
C(20)-C(25) 1.385 	(2) 
C(21)-C(22) 	 1.380 	(2) 
C(22)-C(23) 1.376 	(3) 
C(23)-C(24) 	 1.362 	(3) 
C(24)-C(25) 1.389 	(3) 
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C(26)-N(26) 	 1.137 	(3) 
C(9)-N(1)-C(2) 	 107.88 	(14) 
C(9)-N(1)-S(10) 124.08 	(11) 
C(2)-N(1)-S(10) 	 128.00 	(12) 
C(3)-C(2)-N(1) 108.35 	(15) 
C(3)-C(2)-C(19) 	 126.30 	(16) 
N(1)-C(2)-C(19) 125.32 	(16) 
C(2)-C(3)-C(4) 	 109.55 	(16) 
C(5)-C(4)-C(9) 119.48 	(16) 
C(5)-C(4)-C(3) 	 133.01 	(17) 
C(9)-C(4)-C(3) 107.50 	(16) 
C(6)-C(5)-C(4) 	 118.96 	(17) 
C(5)-C(6)-C(7) 121.00 	(18) 
C(5)-C(6)-C(26) 	 119.20 	(19) 
C(7)-C(6)-C(26) 119.79 	(18) 
C(8)-C(7)-C(6) 	 121.05 	(17) 
C(7)-C(8)-C(9) 117.94 	(17) 
C(8)-C(9)-C(4) 	 121.56 	(17) 
C(8)-C(9)-N(1) 131.74 	(16) 
C(4)-C(9)-N(1) 	 106.68 	(15) 
O(11)-S(10)-O(12) 120.25 	(9) 
O(11)-S(10)-N(1) 	 106.64 	(8) 
O(12)-S(10)-N(1) 105.70 	(7) 
0(11)-S(10)-C(13) 	 106.10 	(13) 
0(12)-S(10)-C(13) 110.72 	(13) 
N(1)-S(10)-C(13) 	 106.66 	(12) 
0(11)-S(10)-C(13') 115.1 	(2) 
0(12)-S(10)-C(13') 	 103.9 	(2) 
N(1)-S(10)-C(13') 103.7 	(3) 
C(13)-S(10)-C(13') 	 9.0 (2) 
C(14)-C(13)-C(18) 120.0 
C(14)-C(13)-S(10) 	 119.80 	(13) 
C(18)-C(13)-S(10) 120.19 	(13) 
C(15)-C(14)-C(13) 	 120.0 
C(14)-C(15)-C(16) 120.0 
C(17)-C(16)-C(15) 	 120.0 
C(16)-C(17)-C(18) 120.0 
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C(17)-C(18)-C(13) 	 120.0 
C(14')-C(13')-C(18') 120.0 
C(14')-C(13')-S(10) 	 118.8 	(3) 
C(18')-C(13')-S(10) 121.1 	(3) 
C(13')-C(14')-C(15') 	 120.0 
C(16')-C(15')-C(14') 120.0 
C(17')-C(16')-C(15') 	 120.0 
C(18')-C(17')-C(16') 120.0 
C(17')-C(18')-C(13') 	 120.0 
C(2)-C(19)-C(20) 115.51 	(14) 
C(21)-C(20)-C(25) 	 118.04 	(16) 
C(21)-C(20)-C(19) 122.17 	(16) 
C(25)-C(20)-C(19) 	 119.76 	(16) 
C(22)-C(21)-C(20) 120.82 	(17) 
C(23)-C(22)-C(21) 	 120.37 	(18) 
C(24)-C(23)-C(22) 119.70 	(17) 
C(23)-C(24)-C(25) 	 120.15 	(17) 
C(20)-C(25)-C(24) 120.89 	(18) 
N(26)-C(26)-C(6) 	 179.8 	(3) 
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Appendix 2 Crystal structure data for 2-naphthylmethylcyano 
indole 195 
Crystal data and structure refinement for indole 195 
Identification code 
Empirical formula 
Formula weight 
Temperature 
Diffractometer, wavelength 
Crystal system, space group 
Unit cell dimensions 
Volume, Z 
Density (calculated) 
Absorption coefficient 
F(000) 
Crystal colour / morphology 
Crystal size 
0 range for data collection 
Index ranges 
Reflns collected I unique 
Reflns observed [F>4cr (F)] 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2  
Final R indices [F>40-(F)] 
R indices (all data) 
Largest diff. peak, hole 
Mean and maximum shift/error  
ADM0702 
C26H18N202 S 
422.48 
173(2) K 
OD Xcalibur PX Ultra, 1.54248 A 
Monoclinic, P2(1)/n 
a = 18.0309 (4) A 	a = 90° 
b = 5.88641 (15) A 	,8 = 98.636 (2)° 
c = 19.5220 (4) A 
	
y= 90° 
2048.52(19) A3, 4 
1.370 Mg/m3  
1.615 mrril 
880 
Colourless needles 
0.23 x 0.03 x 0.01 mm3  
3.11 to 63.12° 
-20<=h<=20, -6<=k<=6, -22<=I<=22 
8932 / 3230 [R(int) = 0.0501] 
1894 
Semi-empirical from equivalents 
1.00000 and 0.81707 
Full-matrix least-squares on F2  
3230 / 0 / 280 
0.867 
R1 = 0.0404, wR2 = 0.0764 
R1 = 0.0879, wR2 = 0.0869 
0.152, -0.256 eA-3  
0.000 and 0.000 
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Bond lengths [A] and angles r] for indole 195 
N(1)-C(9) 1.415 (3) 
N(1)-C(2) 1.434 (3) 
N(1)-S(10) 1.6708 (19) 
C(2)-C(3) 1.343 (3) 
C(2)-C(19) 1.505 (3) 
C(3)-C(4) 1.434 (3) 
C(4)-C(5) 1.391 (3) 
C(4)-C(9) 1.403 (3) 
C(5)-C(6) 1.388 (3) 
C(6)-C(7) 1.397 (3)  
C(6)-C(30) 1.434 (4)  
C(7)-C(8) 1.377 (3) 
C(8)-C(9) 1.390 (3) 
S(10)-O(11) 1.4261 (18) 
S(10)-O(12) 1.4314 (15) 
S(10)-C(13) 1.763 (3) 
C(13)-C(18) 1.378 (3)  
C(13)-C(14) 1.393 (4)  
C(14)-C(15) 1.381 (4) 
C(15)-C(16) 1.371 (4) 
C(16)-C(17) 1.366 (4) 
C(17)-C(18) 1.403 (4) 
C(19)-C(20) 1.527 (3) 
C(20)-C(21) 1.361 (3) 
C(20)-C(29) 1.414 (3) 
C(21)-C(22) 1.425 (3) 
C(22)-C(23) 1.412 (3) 
C(22)-C(27) 1.412 (3) 
C(23)-C(24) 1.372 (3) 
C(24)-C(25) 1.397 (3) 
C(25)-C(26) 1.362 (3) 
C(26)-C(27) 1.423 (3) 
C(27)-C(28) 1.409 (3) 
C(28)-C(29) 1.370 (3) 
C(30)-N(30) 1.153 (3) 
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C(9)-N(1)-C(2) 107.78 (19) 
C(9)-N(1)-S(10) 122.41 (15)  
C(2)-N(1)-S(10) 126.61 (16)  
C(3)-C(2)-N(1) 107.9 (2) 
C(3)-C(2)-C(19) 127.1 (2) 
N(1)-C(2)-C(19) 124.8 (2) 
C(2)-C(3)-C(4) 109.9 (2) 
C(5)-C(4)-C(9) 119.7 (2) 
C(5)-C(4)-C(3) 133.3 (2) 
C(9)-C(4)-C(3) 107.0 (2) 
C(6)-C(5)-C(4) 118.3 (2)  
C(5)-C(6)-C(7) 120.9 (3)  
C(5)-C(6)-C(30) 119.5 (2) 
C(7)-C(6)-C(30) 119.6 (2) 
C(8)-C(7)-C(6) 121.9 (2) 
C(7)-C(8)-C(9) 116.7 (2) 
C(8)-C(9)-C(4) 122.5 (2) 
C(8)-C(9)-N(1) 130.0 (2) 
C(4)-C(9)-N(1) 107.45 (19) 
O(11)-S(10)-O(12) 120.96 (11) 
O(11)-S(10)-N(1) 106.20 (10) 
O(12)-S(10)-N(1) 105.73 (10) 
O(11)-S(10)-C(13) 109.86 (13) 
O(12)-S(10)-C(13) 107.80 (12) 
N(1)-S(10)-C(13) 105.14 (11) 
C(18)-C(13)-C(14) 120.8 (3) 
C(18)-C(13)-S(10) 119.3 (3) 
C(14)-C(13)-S(10) 119.8 (2)  
C(15)-C(14)-C(13) 119.3 (3)  
C(16)-C(15)-C(14) 120.2 (3) 
C(17)-C(16)-C(15) 120.7 (3) 
C(16)-C(17)-C(18) 120.3 (3) 
C(13)-C(18)-C(17) 118.6 (3) 
C(2)-C(19)-C(20) 114.8 (2) 
C(21)-C(20)-C(29) 119.5 (2) 
C(21)-C(20)-C(19) 121.5 (2) 
C(29)-C(20)-C(19) 118.9 (2) 
C(20)-C(21)-C(22) 121.5 (2) 
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C(23)-C(22)-C(27) 119.0 (2) 
C(23)-C(22)-C(21) 122.3 (2) 
C(27)-C(22)-C(21) 118.7 (2) 
C(24)-C(23)-C(22) 120.6 (2)  
C(23)-C(24)-C(25) 120.6 (3)  
C(26)-C(25)-C(24) 120.2 (2) 
C(25)-C(26)-C(27) 120.9 (2) 
C(28)-C(27)-C(22) 118.7 (2) 
C(28)-C(27)-C(26) 122.7 (2) 
C(22)-C(27)-C(26) 118.6 (2) 
C(29)-C(28)-C(27) 121.5 (2) 
C(28)-C(29)-C(20) 120.1 (2)  
N(30)-C(30)-C(6) 179.7 (3)  
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